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Abstract
Up to 30% of patients who undergo colonic resection for colorectal cancer
have spread of their disease, to the liver, at the time of operation. In 50% of
these patients the metastases are so small that they cannot be detected either
by preoperative ultrasonography or by visualisation and palpation of the liver
at the time of surgery. Patients who have hepatic metastases have a poor
prognosis.
Hepatic resection for colorectal metastases offers a survival advantage of 25%
at five years. At present about half of the patients with hepatic metastases are
picked-up during follow-up by which time only a small percentage have
resectable disease.
This thesis proposes that IOUSS and IOE scanning may be effective in the
detection of small metastases at the time of primary colon resection, and that
IOE scanning in the follow up period will detect new metastases as they
develop. Patients who have metastases detected in this way will be suitable
for hepatic resection and have an improved 5 year survival. The detailed
staging of patients with regard to hepatic metastases has been used to clarify
the relationship between the presence of hepatic metastases, and elevation in
the level of serum CEA.
Iodised oil enhanced CT (IOE) scanning, intra-operative ultrasonography
(IOUSS) and dynamic bolus enhanced CT scanning are used to detect hepatic
malignancy prior to hepatic resection. The accuracy of each technique is
calculated. IOE scanning is shown to be the most accurate preoperative
investigation to determine resectability in patients with hepatic malignancy.
The serum level of carcinoembryonic antigen is also related to the presence of
hepatic metastases from colorectal cancers at the time of hepatic resection.
IOUSS is shown to be as accurate as IOE scanning in the detection of patients
with metastases at the time of operation and detects more patients with
metastases than IOE scanning, although this difference does not reach
statistical significance.
IOE scanning can detect the appearance and growth of metastases in patients
following colonic resection, however, it cannot be used as a routine form of
follow-up as patients are reluctant to undergo repeated scans over a two year
period.
IOE scanning and IOUSS are able to detect very small hepatic metastases in
patients following colonic surgery. Two patients with small metastases went
on to have a hepatic resection. Unfortunately both of these patients died
within 2 years of hepatic surgery. Early detection of metastases by IOE and
IOUSS scanning did not therefore improve patients' survival. The results of
IOE scanning and IOUSS have been used to define levels of serum CEA
which are likely to be related to the presence of hepatic metastases both at the
time of colonic resection and during follow up.
In conclusion IOUSS is shown to be a sensitive and accurate method of
detecting hepatic metastases from colorectal cancer and should be undertaken
at the time of resection of primary colorectal cancers. The information gained
improves staging and estimation of prognosis.
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Chapter I History of staging and surgery 1
Chapter I
History of staging and surgery for colorectal cancer
I.A. Introduction
I.A.I. Hepatic metastases
Colonic cancer often spreads to the liver as the first site of extra lymphatic
disease (Hogg IL, 1956) and may represent the only site of spread in up to 32%
of patients following apparently curative resection of their primary cancer
(Russell AH, 1984). The presence of hepatic metastases is the single most
powerful prognostic indicator following apparently curative colonic resection.
Up to 90% of patients with hepatic metastases succumb in the 24 months
following surgery (Bengmark S, 1969; Wagner JS, 1984; Arnaud JP, 1984).
Current surgical practice relies on pre-operative ultrasonography and palpation
at the time of operation to detect hepatic metastases. Both of these methods
have been shown to be insensitive and inaccurate (Gunven P, 1985; Finlay
IG, 1986).
Intraoperative ultrasonography (IOUSS) is a sensitive and accurate method of
detecting intrahepatic tumours ( Sheu J-C, 1985; Rifkin MD, 1987; Parker GA,
1989; Clarke MP, 1989; Olsen AK, 1990; Charnley RM, 1991; Machi J,
1991). It is possible that this technique may be used to improve the detection
of hepatic metastases at the time of operation, reducing the number of
metastases that remain occult. Early detection of otherwise occult metastases
may improve staging, better define prognosis and increase the detection of
patients with resectible hepatic metastases. Early resection may in turn lead to
an improvement in survival. The overall survival of patients with colorectal
cancer has not changed in the last 50 years (Scottish Cancer Registry 1990).
I.A.I.a. Why the liver?
Malignant tumours shed cells into their venous drainage. Colorectal cancers
drain via the portal venous system which, except in very special circumstances,
drains solely to the liver. Turnbull has shown that during tumour manipulation
portal blood contains viable tumour cells singly and in clumps (Turnbull RB
(Jr), 1967) which pass into the hepatic capillary bed (Wiggers T, 1988; 1990).
Not all of these tumour cells successfully implant. Weiss has proposed a
theory of metastatic inefficiency (Weiss L, 1990) in that the rate of tumour cell
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delivery to the liver is at least 1,000 times greater than the number of metastases
that appear. At a late stage in their development, liver metastases shed viable
tumour cells into the hepatic veins and via the vena cava into the pulmonary
capillary bed. Only 1:1,000 or less of the malignant cells delivered to the lungs
successfully implant (Sugarbaker PH, 1990).
The portal route of spread applies to nearly all colorectal cancers; only in very
low rectal cancers is there any direct access to the systemic venous circulation
by tumour cells. The majority of tumour cells delivered to the liver do not
survive; however the mechanism of their destruction is not understood. Only
a very few cells successfully implant (Plate 1. ) and form a detectable
metastases (Plate 2.).
Plate 1. A micro metastasis from a colon cancer: found in the resected specimen
from a patient with an apparently solitary metastasis in the right hetni liver.
Implantation and growth are not a random events, the population of cells shed
into the circulation exhibit various levels of ability to form metastases. It has
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been shown that cloned sub populations of cells from a metastasis will form a
larger number of new metastases (when reintroduced to immunologically nude
mice) than cells cloned at random from the parent tumour (Poste G, 1980).
Individual cell lines cloned from the parent tumour will also show variation in
their ability metastasise. Once a single cell line has been cloned then its level of
successful implantation remains constant.
Plate 2. A large, solitary metastases detected by ultrasound, CT scanning and
palpation prior to resection.
The site of implantation is not random either, rather it is a function of the
number of cells (seeds) delivered to the target organ (soil) and the ability of that
'soil' to support the growth of the 'seeds'. The 'seed and soil' hypothesis is
by no means new (Paget S, 1889) and has been supported by more recent
research (Hart IR, 1981). Although the latter refers to experimental sarcoma
cell lines, it has shown that the metastases show organ-specific implantation
even when the tissue of the target organ is placed in a heterotopic site.
Further evidence against the hypothesis of metastatic implantation being merely
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a function of the number of 'seeds' being delivered to a 'soil' may be derived
from patients with malignant ascites. Peritoneal-venous shunts, allow patients
with malignant ascites have their ascitic fluid drained internally to the great veins
(Laveen shunts). This method of drainage delivers large numbers of tumour
cells to the pulmonary capillary beds. Despite this there is not a marked
increase in the number of pulmonary metastases associated with the use of these
shunts (Tarin D, 1984). This suggests that the pulmonary capillary bed is not a
fertile soil for malignant cells contained in the peritoneal fluid in these cases.
I.A. 1 .b. Detection and growth of metastases
A number of investigations have been directed towards the physical detection of
hepatic metastases, the serological markers they produce, their specific cell
surface antigens and the physiological and anatomical changes caused by their
presence. Detection of the actual metastases at laparotomy, by visualisation
and palpation, was until recently the "gold standard", despite strong evidence
that palpation was insensitive (Schreve RH, 1984; Hogg L, 1955). Up to 29%
of metastases present at the time of operation are not detected by palpation
(Finlay IG, 1982). Longitudinal studies have shown that metastases missed by
palpation will appear during follow-up, being detected by computerised axial
tomography (CT) scanning (Finlay IG, 1982; Machi J, 1991).
Hepatic metastases may be of different sizes and appear at different times during
follow-up (Plate 3.). If we assume that metastases from a single tumour all
grow at approximately the same rate ( Finlay IG, 1988), then the implication is
that at the time of surgery the liver contains metastases at all stages of
development. This also assumes that the establishment of one metastasis does
not prejudice the development of another in the same organ. Also that
metastatic tumours shed cells on numerous occasions or perhaps constantly and
not as a single event.
Plate 3. Multiple metastases in the resected right hemi liver, from a primary
colorectal cancer. The small solitary nodule in the bottom left ofthe photograph
is 1.2 cm in diameter and spherical inform.
Solitary metastases are rare and occur in only 10%-14% of patients (Blumgart
L, 1982; Scheele J, 1991) with colorectal cancer. The finding of a truly
solitary metastasis implies that only one cell or clump of cells successfully
implanted and evaded destruction by the host immune system. However,
apparently solitary metastases may actually be the only detectable metastases in
a liver which harbours a number of other occult lesions. If the apparently
solitary metastases is resected and the patient survives, without hepatic
recurrence, then either it really was the only lesion, or the patient continues to
harbour occult, hepatic, metastatic disease. This may become apparent,
remain dormant or be completely eradicated by the host immune response.
Between 70% and 75% of patients die following hepatic resection for
metastases: in these patients micro metastases, occult at the time of resection,
continue to grow, becoming clinically apparent within five years.
Resection of solitary or small numbers of hepatic metastases confers a survival
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benefit of 25% - 30 % at five years ( Adson MA, 1987). The finding of a
resectable lesion occurs in 2-5% of patients and may suggests a level of immune
competence towards the primary tumour in these patients. This presence of an
active host defence may in itself confer a survival advantage.
It is not possible to predict who will survive after curative hepatic resection and
who will not. It is recognised however, that the presence of residual disease:
either as multiple micro metastases in the resected specimen or tumour at the
resection margin, indicates a poor prognosis.
I.A.2. Magnitude of problem
I.A.2.a. Number of patients in Scotland and in Great Britain
There has been a progressive rise in the registration of colorectal cancer in
Scotland from 2,594 in 1975 to 2,860 in 1986. This trend is similar for the
rest of the country with 27,000 new cases registered annually in Great Britain.
In Scotland the mortality rate for colorectal cancer has remained relatively
constant at 35 per 100,000 population per annum. In Lothian, 426 patients
underwent primary surgery for colorectal cancer in 1987 (Lothian Surgical
Audit). Colorectal cancer was the registered cause of death for 253 patients in
the same year ( WHO Mortality statistics 1987).
The crude 5 year survival rates for patients undergoing potentially curative
resection of colonic cancer is 47-69% (Wield U, 1985; Murray D, 1975;
Turnbull RB(Jr), 1967). Between 15% and 35% of patients have hepatic
metastases present at the time of their primary surgery of which 8% to 24% are
occult (Olsen AK, 1990; Finlay IG, 1983). More than 70% of patients who
die with colorectal cancer have liver metastases present at the time of death
(Pestana C, 1964). Patients with hepatic metastases have a 0% to 20% 3 year
survival, and negligible 5 year survival (Wagner JS, 1984; Arnaud JP, 1984;
Cady B, 1970).
Population and incidence data suggest that, in Scotland, 57 to 142 patients per
annum will have resectable metastases.
I.A.2.b. Mortality
There has been a decrease in the peri-operative mortality associated with
colorectal cancer surgery over the past 50 years. Prior to the Second World
War, peri-operative mortality was in the region of 11% to 31% with 41% to
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50% operability rates (Allen AW, 1947; McKittrick LS, 1948; Grinnell RS,
1953; Morgan CN, 1957; Smiddy FG, 1957). This has improved with a
decrease in peri-operative mortality to between 5% and 7% and an operability
rate of 90% (Pihl E, 1980; Turunen MJ, 1983). Furthermore advances in
anaesthetic and intensive care techniques plus the development of more effective
antibiotics have led to a larger number of older and sicker patients being offered
and surviving surgery. Although the 30 day post-operative mortality following
colorectal surgery has improved, the long-term survival of patients is no better
now than it was before the First World War. There has been no change in the
death rates from the disease itself in over forty years (Wield U, 1985).
I.A.2.C. Change in the population in the same period
As the mean age of the population has risen so has the annual registration of
patients with colorectal cancer. Over and above this there is a rise in the
incidence of the colorectal cancer exceeding that expected from the increasing
age of the population. That is, the number of cases of colon cancer per
100,000 patients over 70 years of age is increasing annually. There are also an
increases in the number of right sided cancers (Green FL, 1983) and cancers in
women (which may be related to the increase in smoking in women). It is not
known how these changes will affect survival or the incidence of metastases in
the next decade.
I.A.2.d. Variation with ethnic groups and environment
There is a marked difference in the incidence of colorectal cancer related to the
ethnic origin of a community and the environment in which that group is placed.
The incidence of colon cancer in Nigeria is around 2.5 : 100,000 compared to
around 32 : 100,000 in Scotland (Waterhouse JAH, 1976). This difference is
probably due to enviromental factors. There are also genetic factors within a
population which affect the incidence of cancer (Lynch HT, 1981; Lovett E,
1976). Both environmental and genetic factors are disrupted by ethnic mixing
and population movements. There are no published data examining the
relationship of hepatic metastases to ethnic group or environment.
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I.B. The history of surgery
I.B.I. Early surgery
Early rectal surgery was largely limited to the local resection of tumours
described by Volkman in 1878. At the turn of the century Herbert Allingham
performed local excision of rectal tumours by splitting the rectum and working
from inside the lumen. The operation was by its design contaminating and the
results were poor. Patients having these operations were left incontinent and
tumour commonly recurred locally after a few months (Lockhart-Mummery JP,
1926). Kraskes' operation of trans-sacral resection of tumour and rectum left
the patient with either a sacral anus or a re-anastomosis and was little better
(Lockhart-Mummery JP, 1926). Attempts at re-anastomosis were generally
poor; the inverting stitch described by Lambert in 1826 was first used
successfully by Diffenbach in 1836 to re-anastomose bowel in dogs. The same
technique was used in the colon following resection for cancer eight years later
by Reybard of Lyon.
I.B.I.a. Colostomy
While the first description of a lumbar colostomy was published by Amussat in
1839 the operation was actually first performed in 1836. This was followed
by an anterior abdominal wall colostomy described by Maydl in 1888.
Although both of these procedures reduced post-operative deaths, mortality
remained high. The double-barrel colostomy was independently described by
Paul of Liverpool in 1895 and Von Mikulicz of Breslaw in 1903 and became
popular. The procedure was, however, first described by Bloch in 1894
(Williams NS, 1993).
l.B.l.b. Abdominoperineal resection
A major advance in the surgery for rectal cancer came in 1908 with the
description by Miles of the operation of abdominoperineal resection for rectal
carcinoma (Miles EW, 1925). This operation along with description of the
perineal excision of the rectum by Lockhart-Mummery in 1905 (Lockhart-
Mummery JP, 1926) marked the beginning of modern surgery for carcinoma of
the rectum. Until this time little attention had been paid to the staging of rectal
cancers, the mortality of the surgery having been so high that there were very
few patients who survived past 30 days to be studied. It is likely that the
mortality from other illnesses prevalent at the turn of the century would also
have had a considerable independent effect on survival.
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In the Post War period there have been innumerable advances in both surgical
and anaesthetic techniques and the general health of the population has
improved. As more patients have survived the curative operative procedures
for the treatment of colorectal cancer, their long-term outcome has been related
to the extent of their disease at presentation and its amenity to treatment.
I.C. Staging
I.C.I. Why stage ?
It is possible to place patients into survival groups defined by the extent and the
nature (stage) of their primary tumour. This staging aids: the clinician in the
planning of treatment, gives some indication of prognosis, assists in the
evaluation of treatment, facilitates the exchange of information between
treatment centres and contributes to the continuing investigation of human
cancers (Hermanek P, 1987).
I.C.I .a. History
As peri-operative mortality began to fall it became apparent that the extent of the
tumour and the integrity of the resection could prejudice the survival of the
patient. Lockhart-Mummery published the results of his first 200 cases of
perineal resection in which he noted that prognosis was related to the depth of
penetration of the tumour into or through the rectal wall. Survival for the first
year was significantly higher in those patients in whom the tumour had not
penetrated the muscularis mucosa (in this study he made no reference to hepatic
spread of tumour) (1926). Rankin (Rankin FW, 1928) described the value of
the grade of tumour as an indicator of prognosis. He found that as the degree
of differentiation increased so did survival, with poorly differentiated (high
grade) tumours having the worst prognosis.
Dukes emphasised the value of recording the local extent of tumours of the
rectum in predicting outcome for rectal carcinoma (Dukes CE, 1932).
Tumours were staged as : A, Disease confined to the rectal wall; B, Direct
extension into extra rectal tissue (no lymphatic involvement); C, Extension with
involvement of regional lymph nodes.
This classification did not take account of more distant, extra rectal spread.
I.C. 1 .b. Hepatic metastases
In 1928 F.W. Rankin wrote "Nowhere is there any dissension from the dictum
that metastases to the liver rules out radical resection except as a palliative
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measure." (Rankin FW, 1928). He had noted that patients with hepatic
metastases, without exception, did not enjoy long-term survival. Dukes
(1958) modified his classification to take account of the presence of tumour in
the most proximal lymph node of the resected specimen, Dukes C2. A further
addition, Dukes D, indicating distant spread of tumour outwith the resected
specimen is now in common use.
The Dukes classification remains a standard method of reporting used by many
pathologists. It is also generally accepted by colorectal surgeons as a practical
and useful system of reporting for patients with colon and rectal cancer. The
Dukes classification of rectal cancers and similar staging systems do not rely on
any form of pre-operative data to aid in the prediction of long-term outcome.
There are, however, a number of investigations that may be undertaken prior
to surgery to indicate prognosis.
I.C.2. Current practice in staging of colorectal cancer
I.C.2.a. Accuracy of staging in applying prognostic groups to patients.
Dukes staging is used to place patients into groups of expected survival.
Patients with Dukes A disease will have a 97% five year survival; Dukes B
77.6% , Dukes CI 40.9% , Dukes C2 13.6%.( Age sex corrected five year
survival Dukes HE, 1958). These figures represent the mean survival for a
patient placed in the group. Other features of the resected specimen may be
used to try to give a more accurate estimation of outcome and these are
considered below.




more than 10 2.1
Fig 1. The number of lymph nodes involved is a negative prognostic indicator
(Dukes HE, 1958)
The number of lymph nodes containing metastases is of significance, survival
decreases as the number of lymph node metastases increases (Fig /.). The site
of lymphatic metastases in the resected specimen is also of importance.
Tumours were originally staged as Dukes C if there was evidence of lymphatic
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involvement. However, it is recognised that the involvement of the lymph
node nearest to the ligature on the vascular pedicle (the apical node) of the
resection specimen is a negative prognostic indicator. Dukes original stage "C"
is refined to take account of this and is redefined as Dukes CI and C2 if the
apical node is involved.




Fig 2. Grade of tumour related to five year survival. ( Dukes CE, 1958)
Involvement of the apical node (C2) gives a five year survival of 13.6% while
sparing (CI) gives a figure of 40.9%. The overall survival for stage "C"
patients is 32%. The degree of differentiation of the tumour is also significant
and can be related to prognosis (Fig 2.). The grade of malignancy allows
patients to be grouped in a similar manner to the extent of spread of tumour.
Grade of malignancy is closely related to the degree of local invasion but gives
additional information in terms of prognosis. It should also be noted that grade
of tumour is related to age of patients, with significantly more high grade
tumours occurring in younger rather than in older patients. This association is
slightly stronger in women than men. These data relate to a specific method of
treatment of the resected specimen and could not be immediately related to all
surgical specimens. Also these data deal only with rectal cancer and not with












Fig 3. Jass score from 0 to 5 indicates prognosis for colorectal cancer ( Jass
JR, 1987).
There have been subsequent systems suggested for the staging of colorectal
cancer: one of the more significant is from Jass et al (1987). Recognising the
importance of being able to place patients accurately in prognostic groups Jass
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et al. have attempted to improve upon the Dukes system. By reviewing the
resection specimens from 379 operations performed between 1960 and 1965,
pathological findings were related to known, actual survival. A number of
discrete pathological variables were identified, each of which independently
predicted survival. These variables were scored and weighted to give the best
fit to the known outcome ("Jass" score).
This system gave a lowest possible score of 0 and a highest of 5 (Fig 3.). The
scores were then grouped into stages: Stage I, score 0-1, Stage II, score 2,
Stage III, score 3, Stage IV, score 4-5. Five year survival was then predicted
for a group of 710 patients using the new system (Fig 4.). This scoring
system placed 47% of patients in either very good I, or very poor IV,
prognostic groups. Dukes staging of the same patients placed only 20.5% of
patients into Dukes A, or C2. The "Jass" system gave a significant
improvement in accuracy of prediction.
The "Jass" system relies on a subjective assessment of the infiltrating margin of
the tumour and the degree of lymphocytic infiltration at the margin. In a
separate study the investigators found little inter-operator variation when
making these assessments (Jass JR, 1987). The counting of lymph nodes
remains a labour intensive procedure but is included because of its additional
independent value in this scoring system.





Fig 4. Jass score related to patients surviving 5 years. The score can he used to
place 47% ofpatients into either very good or very poor prognostic groups ( I
or IV)
Michelassi et al have also described a 16 point staging system which is
significantly more accurate than Dukes staging. It and others are not in
common use because of their complexity ( Michelassi F, 1991; Wolmark N,
1986; 1983; Whittaker M, 1976).
I.C.2.b. Change in recurrence rates with time over the past 50 years
There has been no evidence to suggest that the pattern of recurrence of
colorectal cancer has changed over the past 50 years, despite changes in the
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number and type of operations performed and in the suture materials used.
I.C.2.C. Limitations of pathological staging
The accuracy of the pathological staging systems is limited because they infer
the extent of systemic disease from the evidence presented in the resected
specimen. This leads to a number of errors; the piece of tumour which is fixed
and stained is only a very small part of the whole;, even if many sections are
taken they still amount to a minute fraction of the entire mass of the tumour;
only a very small fraction of the number of lymph nodes present will be
detected; there may be microscopic foci of tumour spread outwith the resected
specimen which are not seen and finally the tumour may not behave as its
phenotype would suggest. It is unlikely that the current methods of assessment
of tumour by its physical appearance will improve in their accuracy of
determining outcome. Studies of the molecular biology of the tumours and
their genetic makeup are more likely to give an accurate indication of which
tumour could produce viable metastases and which could not. Until this
technology is in place the only prospect of an improvement in the accuracy of
staging is to detect a larger percentage of the metastases that are present at the
time of operation.
The largest error in assessment of outcome for patients with colorectal cancer is
the failure to detect hepatic metastases present at the time of operation (Finlay
IG, 1982). The negative effect of the presence of hepatic metastases on
survival is independent of local stage of disease. This powerful independent
factor accounts for much of the inaccuracy of pathological staging systems in
placing patients into a high survival group. It also confuses the outcome of
trials of adjuvant treatment applied to patients who have had an apparently
curative resection of their tumour. Up to 15% of these patients will in fact have
hepatic disease. Such patients are unlikely to respond to adjuvant therapy




The importance of detection of hepatic metastases has increased because of their
amenity to treatment. Successful resection of hepatic metastases increases
expected survival from zero to 25% at 5 years (Adson MA, 1984,1987; Coppa
GF, 1985; Blumgart LH, 1982; Fortner JG, 1984). Other treatments including
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alcohol sclerotherapy, chemo-embolisation with cytotoxic drugs, cryotherapy
and laser ablation have all been used to improve the quality of life by reducing
rate of growth or reducing the size of tumours but have not shown any
improvement in patient survival (Kemeny NM, 1985; Blumgart LH, 1982;
RavikumarTS, 1987; Charnley RM, 1990; Balch CM, 1987; Zhou X-D, 1988;
Moffat FL, 1985; Goldberg JA, 1990). Chemo-embolisation has also been
shown to reduce the levels of circulating carcinoembryonic antigen (CEA) in
some patients (Yoshikawa C, 1987) and to reduce the symptoms in patients
with metastases from carcinoid tumours. However, resection remains the only
treatment to have shown a survival benefit.
I.C.3.b. Pulmonary metastases
There are very few data relating to the resection of pulmonary metastases from
colorectal cancers. Resection confers a 21% chance of survival at 5 years with
long-term survival related to the disease-free period prior to presentation (Kelm
C, 1988). Pulmonary metastases occur late in the disease and are commonly
associated with other dissemination, particularly hepatic metastases. There
have been a number of cases where patients with resectable hepatic metastases
and a single pulmonary metastasis have had both areas of disease resected.
This is very uncommon (Brister SJ, 1988; Sugerbaker PH, 1990).
I.D. Pre-operative investigation of colorectal cancer patients
I.D.I. Introduction
Colorectal cancers present with alteration of bowel habit, blood in the stool,
pain and weight loss. Pain, distension and obstruction may occur in advanced
disease. None of these symptoms has been directly related to the presence or
absence of hepatic metastases.
I.D. 2. History
I.D.2.a. Personal history and presentation
The presenting history of colon cancer relates in the main to the presence of the
primary tumour. It is uncommon to find a patient who presents with
symptoms relating to the presence of hepatic metastases.
I.D.2.b. Family history
Although the genetic basis of colorectal cancer is currently the centre of much
research there are no data linking early metastatic spread to any particular gene
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addition / deletion. Nor has there been any familial link to the suceptability of
an individual to hepatic metastases.
I.D.2.C. Signs
The signs relating to the presence of hepatic metastases occur late in the disease.
The presence of a palpable malignant liver invariably means that the disease is
beyond curative resection and may be beyond any form of treatment. Jaundice
is also a late event in the course of hepatic metastases (McGarrity TJ, 1987).
I.E. Pre-operative investigation
I.E.I. Introduction
I.E.I .a. Pre-operative staging
Pre-operative assessment is undertaken prior to colonic surgery to ensure the
eventual surgical intervention is to the patients best advantage. Between 4.5%
and 9% of patients will have synchronous colonic tumours and up to 29% will
have synchronous colonic polyps (Tate JJT, 1988) at the time of resection for
their primary colorectal cancer. The investigation of patients presenting with
colorectal cancer should include: barium enema, colonoscopy /
sigmoidoscopy, postero-anterior chest radiograph, abdominal ultrasound scan
of the liver, full blood count, serum urea and electrolytes, liver function tests
(bilirubin, glutamine oxalic acid transaminase, glutamine pyruvic acid
transaminase, lactate dehydrogenase, gamma-glutamyl transpeptidase,
alkaline phosphatase) and blood estimation of the tumour marker
Carcinoembryonic antigen (Wood CB, 1979; Schreve RH, 1984).
The most important findings are: the presence of more than one primary colonic
tumour or the presence of a tumour and a number of polyps and the presence of
metastatic tumour in liver, lung, bone or brain.
I.E. l.b. Barium enema
Barium enema examination has a sensitivity of 89% to 92% for colonic tumours
and 72% for rectal cancers (Reiertsen O, 1987; Bolin S, 1988; Tate JJT, 1988).
I.E.I.e. Rigid sigmoidoscopy
Between 50% and 70% of colon and rectal cancers will be visualised by this
means. The number of patients presenting with carcinomas that can be reached
Chapter I History of staging and surgery 16
by the sigmoidoscope is falling and the frequency of more proximal cancers is
rising (Ghahremani G, 1989; Snyder DN, 1977; Rhodes JB, 1977; Maglinte
DDT, 1983; Beart RW, 1983; Abrams JS, 1979; Greene FL, 1983).
I.E.l.d. Endoscopic sigmoidoscopy
The diagnostic accuracy of flexible endoscopy in the left side of the colon is
high (90%) in the detection of polyps and cancers (Reiertsen O, 1987; Jensen J,
1990). The morbidity and mortality associated with the examination are low
and are principally related to perforation of the colon and to hypoxia and
hypotension related to the use of sedation.
I.E. I.e. Colonoscopy
Colonoscopy detects 90% of all cancers present at the time of the investigation
if the investigation has been complete (Reiertsen O, 1987). In 30 % of cases the
investigation is incomplete because of: inadequate preparation of the colon,
failure to fully advance the instrument and operator error in failure to recognise
incomplete advancement. The overall morbidity for colonoscopy is about
0.05% following polypectomy (Williams NS, 1993).
I.E. 1 .f. Chest radiography
It has been shown that pulmonary metastases are rare at the time of presentation
(Sugarbaker PH, 1990) The plain postero-anterior chest radiograph will
demonstrate these lesions. The detection rate is improved by the concomitant
lateral views being taken. This investigation has a high resolution for
metastases from colon cancer which can only be improved upon by thoracic CT
scanning, which is not routinely used in the United Kingdom (Kelm C, 1988).
I.E.I.2. Ultrasonography of primary colorectal cancers
Trans-abdominal and endo-anal ultrasound may be used to stage not only the
tumour but also local lymph nodes in the pelvis. Large carcinomas of greater
than two centimetres diameter lying in an advantageous position in the colon
may be detectable by 3.5Mhz trans-abdominal ultrasonography.
Ultrasonography, however, lacks the sensitivity and specificity to be used as a
diagnostic tool in the detection of impalpable primary colonic tumours. Endo-
anal ultrasonography may be used to detect the depth of penetration of rectal
cancers and the presence of pelvic lymph node involvement (Holdsworth PJ,
1988).
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I.E.l.h. • Computerised axial Tomography (CT)
CT of the pelvis may provide useful information as to the stage of known rectal
and pelvic colonic cancers. CT scanning provides accurate information as to
the local infiltration of the tumour in relation to the bony and vascular structures
of the pelvis. CT scanning does not give sufficient detail of the rectal wall to
be able to provide information regarding the depth of penetration of a cancer in
relation to the muscularis propria and the muscularis mucosae. CT may detect
local lymph node involvement and involvement of other pelvic organs. Pelvic
CT scanning can be enhanced by the use of a dilute barium enema to increase
the attenuation afforded by the rectal mucosa, and a vaginal tampon to indicate
the position of the vaginal vault. Intravenous urography may be performed at
the same time to increase the attenuation of the ureters and the urinary bladder.
With this enhancement of the urinary tract it is possible to identify invasion or
compression of the urinary tract (Freeney PC, 1986; Holdsworth PJ, 1988;
Thompson WM, 1986).
I.E.l.i. Rectal examination
Attempts have been made to locally stage rectal cancers pre-operatively. Digital
examination noting the size of the tumour and its fixity combined with
sigmoidoscopic biopsy are related to outcome. The advent of endoluminal
ultrasonography has improved the accuracy of local staging, particularly with
regard to depth of penetration. High frequency (7.5Mhz) 360 degree probes
and linear array (5-7.5Mhz) probes give visualisation of the muscle layers of the
rectal wall. Tumour penetration can be related to these layers, the boundaries
between the mucosa, muscularis and the adjacent fat giving strong echo
reflections. Adjacent lymph nodes can be assessed, characteristic changes in
the attenuation occurring as the node approaches 1cm in diameter and the degree
of replacement by tumour approaches 50% (Holdsworth PJ, 1988).
I.F. Summary
There has been no change in the long-term outcome for patients with colorectal
cancer in the last 50 years, although there has been an improvement in the peri¬
operative mortality associated with the primary surgery for colorectal cancer.
There have been a number of attempts to improve upon Dukes staging, to put
more patients into either 'very good' or 'very poor' prognostic groups. The
Jass classification is better than Dukes in this regard but has not yet been widely
accepted. It also fails to take account of the presence or absence of hepatic
metastases.
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Pre-operative investigation of patients with colorectal cancer now routinely
involves visualisation of the entire colon to detect synchronous lesions and a
chest X-ray to detect pulmonary metastases. Liver ultrasonography may also
be undertaken. Following surgical resection, the specimen will be examined
by a pathologist to confirm the diagnosis of colorectal cancer and to calculate the
stage of the disease. This staging is then used to inform the patient of their
prognosis, decide on further treatments, follow-up protocols, and to group
patients with similar prognosis for research purposes.
Although there have been improvements in the pre-operative investigations to
image the liver and an increasing awareness of the importance of the presence of
hepatic metastases, little has been done to improve their peri-operative
detection: 15% of patients still have occult hepatic metastases following their
primary surgery. These patients have a mean survival of 18 months. Failure
to take into account the presence of occult hepatic metastases introduces a
random factor which radically affects outcome. Occult hepatic metastases may
be the single most important determinant of outcome in patients undergoing
curative primary resection of colorectal cancer.
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Chapter II
Ultrasonography and the detection of hepatic metastases
.A. The history of ultrasonography
II.A.1. Introduction
Discovery of the scientific basis of ultrasound precedes the discovery of X-
rays. In 1880, fifteen years before the first X-ray plates were produced,
Jacques and Pierre Curie (later to marry Marie Sklodow) discovered the
piezoelectric effect. They found that when certain naturally occurring
crystals were physically deformed, an electrical voltage was produced.
Similarly if a voltage was passed across the crystal, a small change in its
physical shape would occur. The application of an alternating current would
allow sound waves to be produced at the frequency of the alternating current.
This effect allowed ultra high frequency sound waves - outside the range of
the human ear - to be produced. No further development of the possible
applications of ultrasound took place until the first World War when Pierre
Langevin developed a system to detect submarines by their reflection of
pulsed sound waves in water. Sound Navigation and Ranging (SONAR)
allowed the Royal Navy to detect and sink a great many of the German
submarine fleet.
The second World War saw the further development of SONAR in the
tracking of submarines and the development of smaller ultrasonic devices for
industrial use. The need to detect flaws within mass produced steel, for the
shipbuilding industry, led to the development of ultrasonic "flaw detectors".
These devices beamed ultrasound waves through the steel and recorded their
reflections off internal fissures, thus revealing otherwise unseen defects.
II.A.1.a. Medical ultrasonography
Following preliminary laboratory and animal work (Wild JJ, 1950; French
LA, 1951) the first medical application of ultrasonography was in 1950
(French LA, 1950). A simple single crystal transducer was used to look at
living tissues in an attempt to define structure (Wild JJ, 1952). These early
images were unclear and difficult to interpret and further development of the
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technique was delayed by the lack of appropriate technology. The advent of
semiconductors and subsequently "micro chips " accelerated the development
of ultrasonography.
II.A.2. Developments
Major developments in extra-corporal ultrasonography have been; M-mode
and then B-mode scanning (Donald I, 1958), articulated arms and latterly
sectoral scanners or linear array transducers to produce a sectional picture of
the body's anatomy and the production of images from black to white in a
number of graduations of grey. Each of these developments have improved
the quality of the images obtained with a corresponding increase in the
accuracy of the investigation. The most recent innovation in hepatic
ultrasonography has been the introduction of probes that can be placed on the










OOO Cathode Ray Tube
Fig 1. Cathode ray tube with incident and reflected signal. This represents
the simplest form ofultrasound scanning. The time between the incident pulse
and the returning signal is proportional to the distance from the transducer to
the reflecting interface.
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The earliest ultrasonographic images were the simple representation on a
cathode ray tube (CRT) of the incident ultrasound signal and the returning
signal as upward deflections of the baseline (Fig 1.), with the baseline sweep
of the CRT being triggered by the incident pulse.
II.B.2. M-mode scanning
During M-mode scanning, the incident and reflected signals are represented
as points of brightness along a vertical line. The incident signal appears at
the top of screen and the reflected signal at a lower point. The distance
between the points on the line is proportional to the distance of the point of
reflection from the ultrasound probe. The early bi-stable machines gave
images in black and white (Fig 2.) with no grey shades. The level at which a
reflected signal was strong enough to produce an image could be varied by
increasing or decreasing the sensitivity of the signal amplifier. This made
very high contrast images which were difficult to interpret and unintelligible




0 0 0 Cathode Ray Tube
Fig 2. M-mode in vertical orientation, this output can he applied to a
thermal printer to provide a permanent record ofheart valve movement.
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II.B.3. Real time B-mode scanning
M-mode ultrasound scanning allows the detection of movement but the
images produced are not immediately recognisable as anatomical structures.
However if the vertical line of the M-mode scan is made to pan through the
tissues by either electronic or mechanical means, a true "picture" can be
produced. A very large number of "M-mode" images are then displayed side
by side giving a composite picture of the planes of reflection in the tissues
under interrogation (Fig 3). The ultrasound images are acquired rapidly and
refreshed at a rate of more than 15 times per second. The successive images
appear to create a moving picture when in fact there is just a sequence of
single frames. Flicker is virtually eliminated by having the previous line
remain until it is overwritten by the subsequent line, unlike Cinema film
where each entire image is seen and then replaced. This creates a smooth
image and is an important factor in the reduction of operator fatigue.
Scan lines
Ipa1mm- p°ints °f bpm8| reflections111!
Echo camera
Fig 3. Multiple "M-mode" images side by side create an anatomically
recognisable picture: a B-mode scan.
The returning ultrasound signal can be processed so that the intensity of the
image on the screen is proportional to the intensity of the returning signal.
Each strength of returning signal being represented as a shade of grey, the
stronger the signal the lighter the shade. This creates a grey scale from which
the image is constructed. Grey scale images in B-mode give true anatomical
representations of the internal structures of the body in real time, with
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moverrient. This is the type of system used for most general applications in
ultrasound.
,C. Physical principles of ultrasound
II.C.l. The piezoelectric effect
Ultrasound scanning relies on the physical properties of piezoelectric crystals.
When an electric current is passed across the crystal it deforms. This change
in shape is almost instantaneous and if the crystal is embedded in sound
transmitting medium, then the change in shape of the crystal is transmitted to
that medium as a pressure (sound) wave. Similarly if a physical force is
applied to a piezoelectric crystal, an electric current is generated. The power
generated is proportional to the extent of the deformity of the crystal.
When an alternating current is passed across the crystal, it will vibrate with
the same frequency as, and with an amplitude proportional to, the voltage of
the current. This vibration creates the sound. Once generated, the sound
waves (areas of compression and rarefaction in the medium) are governed by
the laws of wave physics. Ultrasound waves have the following properties;
a. They can be focused: refraction occurs as sound travels through
materials of different densities. The speed of propagation of the waves
increases in proportion to the density of the material. Thus a lens can be
formed from a dense material to focus the waves.
b. They can be reflected: at any interface between two materials of
different density a proportion of the incident sound wave will be reflected
from the interface. Reflection is dependent on the degree of difference in the
densities of the two materials creating the interface, their smoothness and the
angle of incidence of the wave front to the interface. The direction of the
reflection is dependent on the angle of the incident wave front to the interface.
If the interface is irregular, then the wave front will be reflected in a great
many directions (scattered). The most severe form of scatter is the reflection
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of sound from a large number of points within a medium, such as red blood
corpuscles within a blood vessel.
c. Sound waves undergo diffraction and interference. Diffraction occurs
at the point of origin of the wave and after interaction with any obstacle in the
wave path. The edge of the wave front is propagated more slowly than the
centre and so the wave front becomes divergent. This phenomenon causes
the sound wave to fill in the space behind obstacles. If two ultrasound beams
cross each other they may interfere. This can occur between the incident and
reflected part of the same beam. Interference occurs when an area of
rarefaction and compression meet and cancel each other out. This can cause
both the degradation of the image and the appearance of phantom images.
d. A proportion of the ultrasound beam is absorbed as it passes through
tissues. The degree of absorption is dependent on a number of physical
properties of the material but primarily on its coefficient of elasticity. The
more elastic a material is, the less efficient is its transmission of sound.
Efficiency of transmission is also related to density. As the density of the
medium increases so does its efficiency of transmission of sound.
e. Attenuation is a summation of all factors which reduce the power of
the ultrasound wave as it passes through a material. These factors are:
absorption, reflection, scattering, refraction and wave front divergence. The
more homogeneous a material is the less scatter, the fewer interfaces and the
less reflection and refraction will be evident. Absorption is dependent on the
coefficient of elasticity, density of the material and the frequency of the
ultrasound beam. Taking all of these factors into account, pure fluids and
solids give high levels of signal transmission, whereas gases and
heterogeneous fluids give lower levels.
Chapter II Ultrasonography and hepatic metastases 25
II.C.2. Intensity
In order to discuss attenuation of an ultrasound signal, the strength of the
signal must be quantified. The intensity of the ultrasound beam may be
defined as the rate of flow of energy through a unit of area perpendicular to
the direction of the beam. There are a number of formulae which can be used
to calculate the intensity of the beam. One of these is
Where I is the intensity of the signal, p is the density of the medium, / is the
frequency of the ultrasound signal and yo is the particle displacement
amplitude in the medium.
The total power of a scanner (W) may be expressed as the ultrasonic intensity
(I) multiplied by the cross sectional area of the scanning field (cm2).
I = l/2pc ilnf) 2 yo2
Attenuation
Io
ly = Io e fx
X Distance
Fig 4 Intensity ofan ultrasound signal I is attenuated as the distance X from
the source increases where p is the coefficient ofattenuation (McDicken WN,
1991).
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II.C.2.a. Coefficient of attenuation (u)
The coefficient of attenuation (p) can be calculated for any material by
detecting the reduction in intensity of an ultrasound beam in the material.
When Io is the intensity of the ultrasound beam at its origin, 1% is the intensity
of the beam at distance x from the origin and p is the coefficient of attenuation
(Fig 4).
The coefficient of attenuation, p, is the fraction of energy removed from a
plane wave by attenuation in a unit path length and may be expressed in the
following manner:
'■HJ)
This expression gives the coefficient of attenuation in dB/cm.
The attenuation coefficients for biological tissues have been calculated and
tabulated (Table 1 ), these values are for a 1 MHz probe.







Soft tissue (average) 0.7
Table 1. Attenuation coefficients for biological tissues (McDieken WiV,
1991) . The attenuation coefficient of muscle is high, the abdominal
musculature causes significant attenuation during abdominal
ultrasonography.
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II.C.2.b. Time gain compensation
To minimise the effect of attenuation on the final image (Fig 5), the returning
signals from distant interfaces are amplified to a greater degree than those in
the near field.
Fig 5. The returning signal strength in dB has a negative, linear relationship
to the distance from the point of reflection. The slope is dependent on the
attenuation coefficient of the tissues.
As the distance travelled is proportional to the time taken, the level of
amplification is related to the time for the signal to return. There are a
number of terms which relate to the enhancement of an ultrasound signal with
time. Some of these are: swept-gain, depth-gain compensation, time-gain
control and near- and far-gain control. All of these terms refer to the
increasing amplification, with time, of the current produced by the returning
ultrasound waves. The attenuation of a signal is calculated as 2d/t when d is
the distance from the ultrasound probe to the point of reflection and p is the
coefficient of attenuation. The time for the signal to return is related to the
distance it has travelled. The speed of sound in soft tissue can be
approximated as 1540m/s, and so the time for the signal to return from any
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point can be calculated. Increasing amplification of the returning signal with
time maintains a near constant image intensity on the screen. The level and
delay of the gain can be altered to produce the best image in any given
circumstance (Fig 6) .
Fig 6 The gain applied to the returning signal is increased with time until a
pre-set maximum gain is reached. The time is measured in milliseconds (ms)
,D. Biological images
II.D.1. Tissue differentiation
In early experiments, (French LA, 1951) showed that pulsed ultrasound
waves at a power and frequency sufficient to produce an image did not
produce harmful effects on the tissues. These images could be used to
differentiate between tissues, the reflected signal being displayed as a peak on
a CRT. In the same year Howry showed that tumours could be of sufficiently
different acoustic impedance so as to produce a detectable reflection of
ultrasonic waves at the interface of tumour and normal tissue (Howry DH,
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1951).' Later this effect was used to produce bi-phasic pictures of intra¬
abdominal masses (Donald I, 1958). The first images produced were on an
oscilloscope showing the incident ultrasonic pulse and the delay in
milliseconds to the reception of a reflection, a simple A-mode scan. By
calibration and by a knowledge of the speed of sound in the soft tissue being
investigated, it was possible to calculate the distance from the probe to the
interface. Donald used pulsed beams of 2.5 MHz and 5 MHz. As the
frequency of the pulsed beam was increased, the attenuation of the beam
increased and so the range decreased. Reid and Wild had also noted the
attenuation of the beam with distance and introduced time varied sensitivity
(Time Gain Compensation, TGC) to enhance the returning signal (Wild JJ,
1952).
A-mode presentation was used to investigate the movements of the right
atrium, the representation of the amplitude of the returning wave form being
the brilliance of a point on the CRT. The scanning of that image across the
screen gave the earliest M-mode scans (Donald I, 1958). Using a mechanical
arm to link the time-base sweep of the oscilloscope to the movement of the
probe, it was possible to build up composite pictures of a target (B-mode
images). Donald was somewhat sceptical of the ability of the then currently
available systems to differentiate between malignant and non malignant
tissues as had been suggested by Wild (1952).
II.D.2. Key developments
In the decades since the early discovery of ultrasonography there have been a
number of key developments. The general improvement in the fidelity of
electronic components has led to an increase in the clarity of the images that
can be produced. A decrease in the physical size of the machines has been
brought about by the use of solid state components and the boom in micro
computing has allowed the incorporation of more features into smaller and
cheaper machines. It is now common to have probes which function at a
spread of frequencies within a narrow band, allowing an improvement in near
field resolution whilst maintaining depth penetration. A number of machines
have dynamic focusing which allows the focal length of the beam to be altered
during the scan to improve the definition of targets in either the near or far
field. Waterproof probes which can be sterilised have been developed for
intraoperative use. These are available in a number of formats from various
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manufacturers. All of these probes have the advantage of small size and the
ability to be introduced into the abdominal cavity.
Doppler shift scanners, incorporating both a standard and a Doppler image
have been developed. The Doppler image is produced by detecting a shift in
the frequency of a reflected ultrasound beam. The shift is caused by
movement of the reflecting interface towards or away from the probes surface.
The frequency shift is usually represented in colour on the screen and by an
audio signal. A colour image is overlaid electronically on the standard
display. By manipulation of the colour assigned to each frequency shift it is
possible to differentiate both the direction and velocity of flow in a vessel. It
is also possible to estimate the volume of flow in a vessel by measuring its
cross sectional area and the velocity of the flow. Improvements in the fidelity
of electrical components, electronic enhancement of the picture and better
beam focusing have made ultrasound images easier to interpret. Component
size has been reduced, allowing the construction of small linear arrays which
may be mounted on endo-anal probes or laparoscopic probes. Intraoperative
scanning heads are now of a convenient size for routine use.
,E. Intraoperative ultrasound scanning (IOUSS)
II.E.l. Contact hepatic ultrasonography
Intraoperative hepatic ultrasound scanning removes the limitations of
attenuation and access. As there is no tissue interposed between the scanning
head and the capsule of the liver, the ultrasound signal is not attenuated or
diffused and so image intensity and clarity are maintained. Access to the
surface of the liver is practically unlimited: by dividing the triangular and
coronary ligaments, the probe can be placed anywhere on the upper or lower
surface of the liver (Plate 1). The reduction in attenuation allows the use of
higher frequency probes which have lower penetration but better definition.
These probes may also be placed directly onto the surface of the pancreas,
biliary tree, kidneys, bladder and uterus. The most common use of
intraoperative ultrasonography has been in the detection of hepatic tumours,
pancreatic tumours and biliary calculi.
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Plate 1. A composite intraoperative ultrasound scan of the portal confluence
and a large tumour in the right liver.
II.E.l.a. Reduction in attenuation
Contact ultrasonography involves the use of a special ultrasound probe, for
the direct examination of an organ or area of the body, during an operation.
The probe is usually brought into direct contact with the organ to be
examined, though in some cases an echo-lucent "stand off" may be used to
reduce near field loss (see below). The organ may be viewed through a pool
of sterile saline introduced into the body cavity. Direct contact or sono-lucent
linkage between the scanning probe and the tissue to be imaged eliminates
attenuation of the ultrasound signal by interposed structures. In particular,
the sometimes thick layers of fat and muscle which lie between the surface of
the skin and the target organ are avoided.
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Fat has an acoustic attenuation coefficient of 0.6 dB/cm at 1MHz nearly equal
to that of the liver (0.7 dB/cm), the attenuation by muscle is twice as great at
1.5 dB/cm. Scanning the liver through the anterior abdominal wall with 2 cm
of subcutaneous fat and 2 cm of muscle reduces the effective depth of signal
penetration into the liver by 6 cm i.e. 50% of the thickness of the organ. The
signal has to travel the same path on its return and attenuation also applies.
So interposition of 4 cm of subcutaneous tissue reduces the effective depth of
visualisation of the liver by 12 cm. The attenuation coefficient gives a
numerical value to the reduction in power of the ultrasound signal but does not
quantify the loss of image clarity which also occurs. At each interface
between tissue planes not only is the power of the signal reduced but also the
integrity of the wave front. The effect is similar to looking through a series of
plates of frosted glass. The focus of the beam is disrupted and the clarity of
the reflected signal is lost. This loss of clarity does not have a numerical
value.
Access to the liver is limited during preoperative ultrasonography. Because
the liver is in contact with the diaphragm only a small part of its surface can
be "seen" by a probe on the anterior abdominal wall, the remainder is hidden
from view by the interposed, air-filled lung. It is sometimes possible to "see"
the liver by scanning between the lower ribs through the acoustic window
provided by the lower intercostal spaces, but again access is severely limited.
This means that some areas of the liver always remain at a distance from the
scanning head, in particular the posterior part of the right lobe, segments VII
and VIII.
II.E.l.b. Loss of near field image
With all ultrasound probes there is an area of tissue immediately adjacent to
the surface of the probe from which no image can be obtained. This occurs
because of the design limitations of using the same crystals to both generate
and detect the ultrasound waves. A 5 MHz probe produces sound waves in
intermittent bursts at a rate of 20 - 30 Hz, this is referred to as the frame rate.
Each of these pulses lasts for 0.025 to 0.016 of a second. The period of
emission is greater than the time taken for the reflected signal from the tissues
nearest to the probe face to return. As signals from the very near field cannot
be received until emission has ceased, they are lost. The depth of tissue
affected by this phenomenon depends largely on the design of the equipment
and the duration of the pulse. In the case of the 5Mhz probe used in the study
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the depth of loss has been measured at 4 mm by experiment (Fig 7). This
loss of the near field can be overcome by placing a piece of acoustically
transparent material, of greater thickness than the depth of near field loss,
between the probe and the surface of the organ to be scanned. This is called
a stand-off, and in practice a sterile condom filled with water is often used.
The stand-off causes a marginal reduction in penetration.
Loss of near field
Scanning head
4mm loss of near field
Metastases
Liver
Fig 7 There may he no image from the near field because of interference
between the emitted and received signal and because the transducer cannot
receive the returning signal while it is still transmitting.
II. E. I.e. Development
Intraoperative ultrasonography has been used to detect biliary calculi (Hill MJ,
1961). Using a 2.5 MHz probe, experiments were performed in saline tanks,
or with saline in the abdominal cavity to provide acoustic coupling. With
stones of differing composition and size ( from 3 to 30 mm ). Hill et al were
able to detect 3 mm stones in the test tank and 6 mm stones in the bile duct of
patients. Similar research had shown that IOUSS could detect renal calculi
(Schlegel JU, 1961). Research continued in the early 60's, using a 2.5 MHz
industrial flaw detector modified for intraoperative use, which was able to
detect 1 mm biliary calculi in water at a distance of 10 cm (Knight PR, 1963).
Two stones could be differentiated if they were separated by 1 mm or more.
The image was unaffected by the composition of the stones, however the
angle of the probe to the face of the stone greatly affected the amplitude of the
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reflected signal. During clinical trials, the probe detected stones in the
common bile ducts in 3 out of 8 patients. The presence of stones was
confirmed in these 3 patients by exploration and refuted, by cholangiography,
in the remaining 5. This gave 100% accuracy for the scanner in the
determination of stones in the common bile duct. Stones in the gallbladder
were also detected, with ease, when present. All of these scans were
performed in A-Mode and without "Kocherisation" of the duodenum.
In a larger series of 46 patients, Eiseman reported the use of two types of
probe, the first a 2.25 MHz probe previously used to measure intra-cranial
shift, the second a custom made miniature 7.5 MHz scanning head mounted
on the end of a malleable common duct probe (Eiseman B, 1965). The 7.5
MHz probe was designed to be introduced directly into the common bile duct
to look for stones during duct exploration. In 38 cases the large probe alone
was used: there was 100% concordance in the detection of stones in the
gallbladder by ultrasonography and the findings after its surgical removal. In
26 patients there were no stones in the common duct by operative
cholangiography. This was confirmed in 24 patients by the small ultrasound
probe. In the remaining two the small probe gave a false positive result, the
first was the detection of a calcified lymph node behind the bile duct which
was reported as a stone, and the second, calcification in the head of the
pancreas was reported as a stone in the duct. Eighteen patients had stones in
the common duct, 16 of these were detected by the larger 2.25 MHz probe.
Eight patients, known to have stones in the duct, all had positive results when
examined using the small probe. The authors felt that the accuracy of the
investigation was dependent on the experience of the investigator.
II.E. l.d. Cholelithiasis
IOUSS has not become a popular method of assessing the presence of
gallstones in the biliary tree, and its use by the general surgeon has never been
high. Although IOUSS may be as accurate as intraoperative cholangiography
(Sigel B, 1983; Lane RJ, 1982), cholangiography has the advantage of being
simple to perform with little training needed to interpret the images. The
same is not true of IOUSS. The capital costs of IOUSS are also high and may
be prohibitive
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II.E. I.e. • Hepatic scanning
Early reports suggested that IOUSS could demonstrate small (5mm diameter)
tumours within the liver (Plainfosse MC, 1983). With development in
France and America, IOUSS has become a routine procedure during hepatic
surgery. Hepatic resection is guided by the intrahepatic vascular anatomy
(Bismuth H, 1987). The need for accurate'information regarding the
presence of vascular anomalies, coupled to a need for accurate information
regarding the exact extent and vascular relationships of a tumour, have led to
the rapid development of IOUSS by hepatic surgeons. The common
intrahepatic ultrasonographic patterns of vascular anatomy (Castaing D,
1985) have been published, and provide a "map" for the operator. Hepatic
resection for tumour is now a common operation and is guided in most cases
by the use of IOUSS (Sheu J-C, 1984; 1985; Gozzetti G, 1986; Igawa S,
1985; Sugarbaker PH, 1990). IOUSS alters the course of the operation in up
to 49% of cases (Rifkin MD, 1987; Parker GA, 1989) and may be used to
direct the extent of resection during the operation.
It has been suggested that IOUSS of the liver is 99% sensitive in the detection
of hepatomas (Makuuchi M, 1987). Boldrini has shown that IOUSS can be
used at the time of resection of primary colorectal cancers to detect hepatic
metastases with greater sensitivity than preoperative CT scanning, detecting
tumour in 21 out of 86 patients compared to 16 out of 86 by CT scanning
(Boldrini G, 1987). When used to detect hepatic metastases from colon
cancer in 189 patients IOUSS has a reported sensitivity (at the time of
operation) of 93.3%, specificity of 94%, a positive predictive value of
92.4%, a negative predictive value of 95% and an overall accuracy of 94.1%
(Machi J, 1991). After follow-up of more than 18 months in all patients
lesions missed by IOUSS became apparent and the results were re-evaluated
(Table 2 and 3 ). Olsen in a series of 213 patients compared IOUSS to
palpation and inspection at the time of operation. Sixty three patients were
found to have metastases, 42 detected by preoperative ultrasonography or
palpation at operation. The remaining 21 were detected by IOUSS, giving a
sensitivity of 66.1% for palpation and 98.3% for IOUSS (Olsen AK, 1990).
In a series of 54 patients being assessed prior to hepatic resection for
neoplasm, compared IOUSS with CT, preoperative ultrasonography (USS)
and angiography. IOUSS detected 167 lesions in 54 patients, preoperative
USS detected 127 of these (76% accuracy) CT scanning in 48 patients
detected 91 of 150 lesions present on IOUSS (60.6% accuracy) ( Clarke MP,
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1989).- IOUSS is therefore a sensitive and accurate investigation in the
detection of intrahepatic malignancy.
Preop USS CT Palpation IOUSS p-value
True positive 43 49 69 97
True negative 147 143 136 144
False positive 5 9 16 8
False negative 61 55 35 7
Sensitivity (%) 41.3 47.1 66.3 93.3 p<0.0001
Specificity 96.7 94.1 89.5 94.7
PPV 89.6 84.5 81.2 92.4 p<0.05
NPV 70.7 72.2 79.5 95.4 p<0.0001
Accuracy 74.2 75.0 80.1 94.1 p<0.0001
Table 2. Comparison of IOUSS, palpation, CT scanning and preoperative
ultrasonography in the detection of hepatic metastases form colorectal
cancer. The p value for the PPV represents IOUSS compared to palpation,
the other p values are compared to all of the other investigations. Chi sq
analysis was used (from Machi J, 1991).
Preop USS CI Palpation IOUSS p-value
True positive 43 48 68 93
True negative 141 136 129 134
False positive 5 10 17 12
False negative 70 65 45 20
Sensitivity (%) 38.1 42.8 60.2 82.3 p<0.0005
Specificity 96.6 93.2 88.4 91.8
PPV 89.6 82.8 80.0 88.6
NPV 66.8 67.7 74.1 87.0 p<0.005
Accuracy 71.0 71.0 76.1 87.6 pcO.001
Table 3. After 18 months follow-up by CT and ultrasonography 188 patients
were re-evaluated. Thirteen of 144 patients who had no evidence of
metastases at the time of operation developed metastases in follow-up. On
the basis of this information the results were recalculated (from Machi J,
1991).
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.F. Comparison of the methods of detection of hepatic tumours
II.F.l. Pre-operative assessment
II.F.l.a. Introduction
Whilst the intraoperative detection of hepatic tumours may be facilitated by
ultrasonography, most patients with intra-hepatic malignancy will never
undergo laparotomy. The majority of tumours are detected and delineated by
pre-operative investigations. Each of these investigations has a recognised
lower limit of resolution and overall accuracy. This must be taken into
account when interpreting the results of the investigations.
The detection of the actual metastasis or tumour relies on there being a
demonstrable difference between its composition and that of the surrounding
liver. The physical presence of a tumour may be implied by a detectable
displacement of other structures. Imaging techniques rely on these factors to
identify tumours. The routine investigations in use at present are: hepatic
scintigraphy, hepatic ultrasound, hepatic CT and hepatic arteriography.
II.F.2. Hepatic scintigraphy
Scintigraphy is the least specific and the least sensitive imaging technique
(Schreve RH, 1984; Smith TJ, 1982, Alderson PO, 1983). The lower limit
of resolution for scintigraphy is of the order of 2 cm depending on the site of
the tumour. This poses difficulty in the assessment of the liver since up to
30% of hepatic metastases are smaller than 2 cm in diameter at presentation
(Ozarda A, 1962).
Scintigraphy relies on the differential distribution of radioactive sulphur
colloid, technetium 99m, within the liver. The colloid is scavenged from the
circulation by Kupffer cells and held within these cells for a period of time.
The photon emission of the colloid can then be detected by a gamma camera.
The definition of a scintigram can be improved by attempting to label the
tumour with a different isotope and then digitally subtracting the image of the
tumour from that of the liver. External subtraction imaging using sheep IgG
(radio labelled with 1131) raised to carcinoembryonic antigen, with 99mTc-
pertechnate and 99mTc-human serum albumin to identify tissue spaces, was
used by Dykes. In 13 patients, 4 of 5 primary tumours and 8 of 11 secondary
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sites of tumour were identified. One very large liver metastasis was not
imaged and the size of the other tumours that were successfully imaged is not
given. The anti-serum used was purified by immunoadsorption and produced
fever in only one patient. Because of sensitisation of the patients to the
serum, the examination could not be repeated. The IgG was raised against a
CEA producing liver metastasis which may explain why the sheep IgG did not
all bind to the free CEA in the circulation. A fall in, the circulating CEA was
noted in some patients and may have represented a proportion of the sheep
IgG binding to free CEA. This type of subtraction scintigraphy is not
currently in clinical use because the potential risk of patients becoming
sensitised to the sheep IgG (Dykes PW,1980).
II.F.2.a. Scintigraphy, CT scanning and ultrasonography
A prospective comparison of scintigraphy, CT scanning and pre-operative
ultrasonography (USS) in a group of 189 patients with breast or colon cancer,
(Alderson PO, 1983) showed that, in patients who had all three
investigations (n=122), CT scanning had a sensitivity of 93%, compared to
86% for scintigraphy and 82% for ultrasonography. The specificities for each
of three investigations were not statistically different, although overall, CT
scanning was the most accurate investigation. In comparing CT scanning
and USS scanning Alderson showed little difference in the detection rate for
each technique. In 25 patients, the final diagnosis of hepatic metastases was
made on the basis of hepatic imaging, supported by the presence of extra
hepatic lesions. These 25 patients did not have laparotomy to confirm the
presence of hepatic lesions. There was no significant difference in the overall
accuracy of the different investigations and there was no significant difference
in the results for the patients who had operative confirmation of metastases
and those who did not.
A study using bi-manual palpation at the time of surgery as the gold standard,
found that scintigraphy at 15 minutes after injection of 185MBq of 99m Tc-
Sn-colloid using four views gave an accuracy of 79% when compared to the
operative findings (Schreve RH, 1984). This was not significantly different
from pre-operative ultrasonography using a 3.5 MHz probe taking two views;
supine and left lateral, or CT scanning with a Philips 300 scanner using a
slice thickness of 1.2 cm at 1 cm intervals. The CT scans were enhanced
using 500 ml of oral 3% iothalamate (380 mg I/ml) and 60 ml of intravenous
iothalamate in all cases, except those with unequivocal liver involvement.
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Scintigraphy was insensitive in the detection of small metastases and
identified only 2:10 of those which were less than 2 cm in diameter. CT
scanning detected 5:10 metastases of the same size. This study included
patients with metastases from a number of different primary tumours (37
oesophagus, 27 gastric, 3 duodenum, 20 pancreatic or peri-pancreatic, and
26 colon). It is impossible to tell from the data if metastases from one
primary site were more or less easy to detect than .metastases from another
primary site. The detection rate for scintigraphy in this study is high. As
palpation at operation was used as the gold standard it is likely that a number
of metastases present at operation were not detected. Scintigraphy detected
79% of palpable metastases as opposed to 79% of all metastases present.
II.F.2.b. Radioimmunoguided surgery
Scintigraphy has fallen behind CT scanning and ultrasonography as the
investigation of choice in the detection of hepatic metastases. There has,
however, been increasing interest in the use of radio-labelled antibodies to
improve the performance of scintigraphy in the detection of metastases at
operation (Abdel-Nabi HH, 1990). This study used indium-111-labelled
antimucin murine antibody (MoAb) CCR086 in 17 patients with known
metastases from colorectal carcinoma. A dose of 203.5 MBq of In-111 bound
to 1 mg of CCR086 was co-infused with either 4 mg or 19 mg of unlabelled
CCR086. All of the patients had histological confirmation of colorectal
cancer and of at least one metastasis of 1 cm diameter. All had been
discontinued from chemo- or immunotherapy for at least a week before the
scan. Five of the patients also had a routine sulphur-colloid liver spleen scan
performed. The results of the In-111 CCR086 scans were read with full
knowledge of all other scans and the operative findings. The MoAb was
shown to accumulate in 17 of 25 known lesions. The smallest identifiable
liver lesion was 1.5 cm in diameter. A further 4 areas of uptake not
previously suspected as being metastases were found but only 2 of these were
confirmed on CT scanning. Of 12 patients with liver metastases, only 4 had
hot spots in the liver on In-111 CCR086 scanning, a further 4 patients had
mixed areas of uptake in metastases and the remainder had no uptake in the
metastases.
A refinement of the use of radio labelled antibodies is radioimmunoguided
surgery (RIGS) ( Sardi A, 1989). The radio-labelled antibodies used were
MoAbs B72.3 and 17-1A prepared by hybridoma technology. A hand-held
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intraoperative gamma detection probe (GDP) ( Neoprobe, Colombus, Ohio)
was used to detect areas of localisation of the labelled antibody.
II.F.3. Preoperative ultrasonography and preoperative CT scanning of the
liver
Ultrasonography is the mainstay clinical examination of the liver for the
presence of metastases from colorectal cancer. With the advance of
technology, the accuracy and sensitivity of ultrasonography has increased.
Schreve found ultrasonography to be as accurate as CT in the detection of
hepatic metastases with a sensitivity of 85 % (Schreve RH, 1984). In a
prospective audit of pre-operative investigations in patients with known
hepatic metastases, Gunven was also able to demonstrate the comparative
accuracy of CT scanning and ultrasonography. In 31 patients, 19 of whom
had hepatic metastases from colorectal cancer, 26 had CT scans and 26 had
ultrasonography performed. All of these patients went on to have laparotomy
and IOUSS performed. Preoperative ultrasonography was performed using a
3.5 MHz linear array probe and a B-mode grey scale echo camera. A total of
113 metastases were detected by intraoperative scanning palpation and
pathological sectioning . In this study the anatomical site of a metastasis did
not appear to affect its likelihood of being detected by CT scanning.
Preoperative ultrasonography was significantly less sensitive (p < 0.05) than
CT scanning in the detection of lesions in the posterior part of the right lobe,
missing 3 out of 5 lesions greater then 2 cm in diameter. Overall, of the
metastases exposed to pre-operative ultrasound scanning, 75% were detected
and 60% were correctly sited. Broken down by size, pre-operative
ultrasonography detected only 9% of lesions smaller than 1 cm, 40% of
lesions 1-2 cm in diameter and 89% of lesions greater than 2 cm. In this
study, ultrasonography was less sensitive in the detection of metastases than
CT scanning but of equal accuracy in the anatomical siting of the lesions
detected (Gunven P, 1985).
A retrospective study of 108 patients, 63 of whom had hepatic malignant
disease (McGarrity TJ, 1987), failed to support these findings. Only patients
with a positive histological diagnosis were included and all ultrasonographic
examinations were carried out with 2.5, 3.5, 5, or 7.5 MHz probes and real
time B-mode grey scale echo cameras. The ultrasonographic scans of 61
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patients were included in the analysis and compared to their histological
findings. Ultrasonography had a sensitivity of 73% compared to 81% for CT
scanning with a specificity of 94% compared to 83% and an accuracy of 84%
compared to 82%. In conclusion, this study found that a negative
ultrasonogram combined with a normal level of serum alkaline phosphatase
was 100% specific for the absence of malignant disease, although this
combination of results was only present in 11 (10%) of the patients studied.
In a prospective evaluation of CT scanning angiography and ultrasonography
in 54 patients, Clarke found that ultrasonography detected more lesions than
CT scanning (Clarke MP, 1989). All of the patients went on to have IOUSS
which was used as the gold standard. Preoperative ultrasonography was
performed on all patients and detected 76% of the total number of metastases.
CT scanning in 48 of the 54 patients detected 61% of the lesions present and
angiography in 35 patients detected 52% of the lesions present. In a segment
by segment analysis, ultrasonography detected more lesions in the left lobe
than CT scanning. CT scanning failed to detect 70% of the metastases
present in segments 2 and 3 whilst ultrasonography failed in 23%.
Ultrasonography also had a greater sensitivity for metastases of less than 2
cm in diameter. The results of ultrasonography and CT scanning, in this
series were complimentary and had a combined accuracy of 81% for the right
lobe and 76% in the left. Other studies however, have failed to show a
significant advantage to CT scanning over USS (Smith TJ, 1982)
Il.F.3.a. Enhancement of preoperative ultrasonography
Attempts have been made to improve the sensitivity, specificity and accuracy
of preoperative ultrasonography by altering the relative acoustic impedance of
the tumour deposits to the surrounding liver. Injection of microbubbles of
carbon dioxide into the hepatic arterial circulation has been used to produce
this effect (Matsuda Y, 1986). Forty three patients with histological
confirmation of hepatic malignancy underwent enhanced ultrasonography.
Carbon dioxide microbubbles were introduced via an angiogram catheter into
the coeliac, common hepatic or superior mesenteric artery. Different effects
were seen with different pathologies and different patients. The effects noted
were hyper-echoic change, iso-echoic change, hypo-echoic change with a
hyper-echoic rim, marginal spotty hyper-echoic change and internal spotty
hyper-echoic change. Hepatocellular carcinomas predominantly showed
hyper-echoic change while metastatic tumours tended to show hypo-echoic
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change with a rim sign. Contrast enhancement lasted for between 3.5 and 4
minutes. Enhancement improved the detection of small (less than 2 cm)
hepatocellular carcinomas by 19 % and also allowed some differentiation of
the nature of the tumour by its pattern of enhancement.
II.F.4. Computerised axial tomography in the preoperative assessment of
hepatic metastases
There are few papers describing the use of CT scanning in the preoperative
staging of the liver in patients with colorectal cancer. In clinical practice the
use of this investigation has been limited by cost, a lack of perceived benefit
and availability. Finlay (1982) showed that CT scanning of patients
following curative resection for colorectal cancer would detect hepatic
metastases which were otherwise occult, of 35 patients having curative
resection of primary colorectal cancer, immediate post-operative CT
scanning detected occult metastases in 11, these metastases being confirmed
on subsequent sequential CT scanning. Follow-up showed a 30 month
survival of 9% for those with metastases compared to 88% for those without.
Smith (1982) prospectivly compared both unenhanced and water-soluble
contrast (Iotholamate Meglumine Injection USP 60%) enhanced CT (EMI
5005 or General Electric 8800 body scanner) scans to preoperative
ultrasonographic examination and hepatic scintigraphy in 80 patients. Forty
seven of the patients had normal livers on palpation and visualisation at
surgery. Smith found that CT scanning detected only 12 of 49 lesions, 2 cm
or smaller in diameter, that had been detected by surgical exploration. It is
likely that a number of smaller lesions were missed by both techniques
(Ozarda A, 1962)
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II.G. Iodised oil emulsion enhancement of CT scans
II.G.l. Introduction
Routine CT scans are enhanced by the injection of a water soluble contrast
agent prior to and during the scan sequence, this is called dynamic bolus
enhancement (DBCT). The contrast injected prior fo the scan is distributed
throughout the extra cellular component of the total body water. The contrast
injected during the scan remains in the circulation while the images are being
obtained.
Iodised oil emulsion (IOE) enhancement of CT scans is a technique that has
been developed in Edinburgh (Miller AM, 1990) which improves the
detection of primary and metastatic malignancy in the liver by increasing the
radio density of normal liver without effecting that of tumour deposits. A
similar technique has been reported in the American literature using an agent
called EOE-13 ( Grimes G, 1979; Reed WP, 1986; Miller DL, 1984; Lewis
E, 1982; Ward BA, 1989). The technique involves the peripheral infusion
of an iodinated oil as a stable emulsion in a measured dose.
Peripheral Injection of I.O.E.
Fig 8. The peripheral injection of IOE (over a period of45 minutes) is taken
up by the liver and spleen after a further 45 minutes. Patients are
premedicated with lOOmg ofhydrocortisone to prevent reactions to the IOE.
The particle size of the emulsion is controlled at preparation to remain
between 2 to 4 pm. These particles are able to pass from the venous
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circulation to arterial circulation without becoming entrapped in the
pulmonary or splanchnic capillary beds. The oil micro droplets are removed
from the circulation by cells of the reticuloendothelial system within the liver
and spleen (Fig 8.).
Fig 9. Uptake of the IOE hy the Kupffer cells and its vacuolisation within
the cells.
In the liver, Kupffer cells fill with the iodinated oil (Fig 9.) and become radio
dense. This causes an increase in radio density of all areas of normal
parenchyma within the liver.
Areas of abnormal liver, not containing functioning Kupffer cells have no
increase in density. On subsequent CT scanning, normal areas of the liver
and spleen have a high radio density and so higher attenuation of the X-ray
signal. Areas that do not contain active Kupffer cells (such as tumours)
show no change in density (Fig 10.).
Uptake of IOE by Kupffer cells
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IOE scan enhancement
Liver post-enhancement
Fig 10 Post IOE injection enhancement ofthe liver scan
Infusion of emulsions of iodinated oil have been shown to increase the radio
density of both the liver and spleen on plain radiography, but the dose
required to cause sufficient enhancement of a plain radiograph was found to
be too toxic. Subsequent development of the technique using a lower dose
and CT scanning instead of plain radiography showed improved delineation of
tumour and reduced side effects (Grimes G, 1979). The more recent
publications using EOE-13 advocated the use of a pre-infusion injection of
hydrocortisone to reduce the unwanted side effects. This does not affect the
quality of image-enhancement (Ward BA, 1989). EOE-13 enhanced CT
scanning in this study was as sensitive and more accurate than either arterial
portography or nuclear magnetic resonance imaging. Because of the initial
problems of toxicity, EOE-13 has not found favour as method of investigation
in the United States of America where it was initially developed. The
Department of Radiology of the University of Edinburgh has continued
research and development of this technique as IOE scanning. The technique
is now a fully established service in the Department of Radiology of the RIE
and the Hepato-Biliary unit of the RIE.
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II.G.2. ' Conclusion
There are two principle factors that will continue to confound the accuracy of
pre-operative hepatic ultrasonography. Firstly, as demonstrated by
McGarrity (1987), the anatomical site of the tumour may preclude its
detection: significantly fewer small tumours are detected in the posterior part
of the right lobe than in the rest of the liver. This finding is supported by
Clarke (1989). The morphology of the patient may also have considerable
relevance as thick layers of subcutaneous fat and muscle may reduce the
quality of a preoperative ultrasonographic scan (McDicken WN, 1991).
These factors can be overcome at operation by placing the ultrasound probe in
direct contact with the liver. Signal attenuation caused by interposed tissue is
eliminated and access to the posterior portion of the right lobe and the whole
of the left lobe of the liver is improved. By its very nature, IOUSS includes
palpation of the liver and this contributes to the detection of small subcapsular
lesions. These major advantages, plus the ability to biopsy any lesion that
may be identified, have led to an increase in the use of intraoperative
ultrasonography at the time of operation for known hepatic metastases.
Intraoperative ultrasonography represents the gold standard for the imaging of
known hepatic malignancies and has been used in a large scale trial of hepatic
evaluation in patients undergoing curative resection of colorectal cancers
(Machi J, 1991). There are a number of potential benefits to IOUSS:
immediate accurate hepatic imaging, targeted biopsy of any suspicious
lesions seen and very low cost.
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II.H. Aim
This thesis will evaluate the use IOUSS and IOE scanning in the detection of
occult hepatic metastases in patients undergoing curative resection for
colorectal cancer.
To confirm that IOE scanning is superior to DBCT in the detection and
definition of hepatic tumour, both of these investigations have been
performed on a group of patients known to have hepatic malignancy. The
results of these investigations have been compared with regard to the volume
of liver involved and the accuracy of the investigation in determining if the
tumour was resectable or not. The results of the preoperative investigations
have been compared to the operative findings including intraoperative
ultrasonography.
To show that IOUSS can detect all occult hepatic metastases, IOUSS has
been compared to IOE scanning at the time of operation and to IOE scanning
at 6 monthly intervals for 4 consecutive scans. This will confirm that IOUSS
is the investigation of choice for the detection of occult hepatic metastases at
the time of surgery for colorectal cancer.
Furthermore, to show that the presence of occult hepatic metastases has a
powerful effect on outcome, the survival of patients with and without hepatic
metastases is calculated and compared.
The superior staging and follow-up of patients in these series will be used to
further clarify the relationship of CEA to the presence of hepatic metatases
both at presentation and during follow-up.
Finally, this thesis will show that the information obtained by the use of
intraoperative ultrasonography may be used to successfully select patients
with hepatic metastaes for hepatic resection.
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Chapter III
Methods of imaging investigations
III.A. Technical description of methods
llI.A.l. Introduction
A number of investigative techniques have been used in the evaluation of
patients involved in the studies that comprise this thesis. The method of each
investigation is described here and referred to in subsequent chapters. The
method of laparoscopic ultrasonography and of data storage and analysis form
separate chapters.
III.A.2. Investigations undertaken
The following investigative techniques were used to evaluate patients: chest
radiography (X-ray), abdominal ultrasonography (USS), thoracic and
abdominal computed axial tomography scanning with water soluble contrast
enhancement (DBCT), selective and highly selective angiography, iodised oil
emulsion enhanced CT scanning (IOE), intraoperative and laparoscopic
intraoperative ultrasonography and biopsy (IOUSS).
III.A.2.a. Chest radiograph.
All chest X-ray films (a single view postero-anterior film) were taken in the
main X-ray department of the Royal Infirmary of Edinburgh (RIE) or in the
X-ray department of the Eastern General Hospital (EGH). All of the films
were viewed and reported by a consultant radiologist.
III.A.2.b. Ultrasonography
In the evaluation of patients with known metastases, ultrasonography was
undertaken as part of the pre-operative staging and was performed by one of the
radiologists of the RIE Department of Radiology. The reports were checked by
a consultant member of staff and experienced hepatic ultrasonographer. All
scans were performed using a 3.5 MHz sectoral scanning probe (Acuson).
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A standard investigation was performed with the patient in the supine position
following a 6 hour fast. Contact gel was used to improve ultrasonic coupling
and the images were stored on photographic film. Patients were also scanned
sitting up and in the left lateral position to improve the visualisation of the
postero-superior portion of the right lobe of the liver ( segments VII and VIII).
III.A.2.C. Thoracic CT scanning
All thoracic and abdominal CT scans were performed at the RIE. The patients
were fasted prior to the CT scan which was performed without contrast
enhancement. The scans were obtained in 10 mm slices at 10 mm intervals
with breath holding. Dynamic interpretation was undertaken and the images
transferred to photographic plates for storage.
III.A.2.d. Abdominal CT scanning
All abdominal DBCT scans in the series were obtained with dynamic bolus
contrast enhancement. Intravenous access was obtained via a butterfly needle
in the dorsum of the hand or by intravenous canula. The scans were
undertaken in three phases.
Scout views
A longitudinal antero posterior image of the patient to map the level of the most
superior and the most inferior parts of the liver was obtained. In patients with
known or suspected pelvic tumour the scout view included the pelvis.
Plain scans
A scan sequence was obtained with slice thickness of 15 mm and a slice interval
of 15 mm without contrast enhancement in patients who had a contraindication
to iodine-based contrast agents. Unenhanced scans were also performed in
patients who had a lesion suspected of being a haemangioma.
Dynamic bolus enhancement
Prior to commencement of each run, a single intravenous injection of 50 ml
Niopam 300 (E. Merck Pharmaceuticals) was given via an indwelling canula.
A further 50 ml of Niopam 300 was infused during the first half of the scan
sequence giving a total dose of 100 ml (30 grams of Iodine). Patients with
gastric, pancreatic or biliary lesions were given an oral meal of dilute barium
immediately prior to scanning. The scans were undertaken with a slice
thickness of 10 mm and a slice interval of 10 mm. Ten to 12 images were
obtained depending on the size of the liver. The patients were asked to hold
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their breath during the acquisition of each image. Following each run the
images were viewed to ensure the technical adequacy of the scan. Magnified
images were obtained of areas of interest. If the scans were not of satisfactory
quality the run was repeated on a separate occasion (Plate 1.).
Plate 1. DBCT scan of the right lobe of the liver in a patient wtih suspected
hepatic metastases from a colorectal cancer.
III.B. Iodised oil emulsion enhanced CT scanning
III.B. 1. Preparation of iodised oil emulsion
The iodised Oil Emulsion was prepared in a standard manner. Using a 2K
Standard Short Sealed Unit Laboratory Mixer (Silveron Machines), the
detachable head and emulsifier screen are sterilised by autoclaving. All
glassware is sterilised by hot air and all instruments and glassware are rinsed in
Sterile Water for Injection BP or particle-free ethanol, prior to use. A mixture
of 25g of Soya lecithin (INC. Biochemical) and 100 ml of Dehydrated Alcohol
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BP are'stirred for 20 minutes. The ethanolic extract of lecithin is then obtained
by vacuum filtration of the liquid phase through a 5 pim PTFE filter (Mitex,
Millipore). All further preparation is undertaken in a laminar flow cabinet
under aseptic conditions. Iodised Oil Fluid Injection BP( Lipidol Ultra Fluid,
May and Baker) 200 ml is placed in a 500 ml conical flask. The ethanolic
extract of lecithin, 50 ml is filtered through a 220nm millex FG filter
(Millipore) and placed into the flask, covered and placed in a water bath at 60
degrees centigrade along with a similar, covered, 500 ml flask containing
Water For Injection BP 250ml. The water for injection is then transferred to a
500ml beaker and placed beneath the homogeniser. With the homogeniser
running at full speed the lecithin/iodised oil mixture is added in 50 ml aliquots,
with two minutes of homogenisation between each addition. The final
preparation is then aliquoted into 10 ml rubber capped multi-dose vials for
subsequent use.
Using this technique, a stable emulsion is created with a mean particle diameter
of 3 ]A.m. The emulsion is stable over time with no appreciable change in the
distribution of particle size over a three month period. The emulsion is also
stable on dilution to more than five times its original volume with Glucose
Intravenous Infusion 5% BP.
III.B.l.a. Administration
The dose is calculated at 0.2 ml of the emulsion per kg body weight and diluted
to 45 ml total volume with 0.5% dextrose infusion BP on the morning of the
scan. This diluted mixture is then infused into a peripheral vein over a period
of 45-60 minutes. Prior to the infusion the patients are given a single dose of
hydrocortisone 100 mg BP. The patients, vital signs are monitored at 15
minute intervals during the infusion and at half hourly intervals thereafter for a
further three hours. A delay of 40 to 60 minutes is allowed between the end of
the infusion and the start of the scan to allow all of the emulsion to be removed
from the circulation by the reticuloendothelial system.
III.B.l.b. Scanning
Following the infusion of the IOE, patients are transferred to the CT scanner.
Scout views are obtained to identify the level of the superior surface of the liver
and its most inferior point. Serial scans are then taken at 10mm intervals with
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a slice'thickness of 10 mm. The patients are required to breath hold for the
image acquisition time of the scanner (8 seconds). Following the acquisition
the images are reviewed and any areas of interest interrogated further. Final
evaulation is made from the X-ray plates of the scan, the images being stored
as hard copy and on laser disc. The patients return to the ward following the
scan and are monitored for a further 3 hours by recording their pulse, blood
pressure and temperature at 30 minute intervals.
III.B.l.c. Reporting
The IOE scans were reported by one of two consultant radiologists (LT, PA),
blind to the results of other investigations. Each image of the scanning
sequence was dynamically interrogated to produce the maximum differentiation
between the enhanced liver parenchyma and the unenhanced tumour deposits.
Plate 2. IOE scan of the same patient as plate I revealing a small (1.4 cm )
metastasis lying between segments V and VIII.
The hepatic vascular anatomy was identified by the continuation of vessels from
one image to another though the sequence of the scans. Metastases were
identified as areas of low attenuation not corresponding to a vessel (Plate 2.).
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The site of each metastases was recorded using hepatic segmental anatomy
(Bismuth H, 1982) (Plate 3.).
Plate 3. The segmental anatomy of the liver after Castaing, the segments are
separated by the intra-heptic branches ofthe hepatic veins (black) and supplied
by the branches of the portal vein (white). There are eight segments, four on
the left andfour on the right.
III.B.2. Appearances of lesions on IOE scanning
A number of normal and abnormal appearances were seen on IOE scanning,
not all of which could be easily differentiated from tumour or metastases. The
overall increase in attenuation of the liver parenchyma was directly related to the
ability of the reticuloendothelial system to successfully remove the emulsion
from the circulation.
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III.B.2.a. • Normal liver.
Scan images are identical in format to a standard DBCT scan in that the
sequential scans are recorded as digital images on a computer disc and recalled
as required. Normal liver appears as an amorphous grey of similar attenuation
to the spleen and of higher attenuation than the kidneys or pancreas
Major intrahepatic vessels appear in cross or tangential section and are seen as
either circles or ellipses of low attenuation; this is in contrast to DBCT where
they are of higher attenuation. Vessels are recognised by their anatomical site
and by their appearance on more than one slice at a site contiguous with areas of
similar attenuation and position on the previous and subsequent slices of the
series. The gallbladder is identified by its position and the presence within the
lumen of low attenuation bile and, in some cases, gallstones. The
intrahepatic portion of the inferior vena cava is also identified by its low
attenuation and its anatomical position. Bile canniliculae, intrahepatic radicals
of the biliary tree and the right and left hepatic ducts are not normally seen on
IOE images of the liver. The intrahepatic radicals of the hepatic artery are not
seen by IOE scanning.
III.B.2.b. Benign lesions seen on IOE scanning.
Any area of the liver parenchyma that has a reduced number of Kupffer cells in
it will appear as an area of reduced attenuation on IOE scanning. Reduced
attenuation will also occur in areas of the liver that have a relatively reduced
blood supply from either the hepatic arterial or portal venous circulation.
III.B.2.C. Benign liver cysts
Liver cysts are the most common benign abnormal finding on IOE scanning
and appear as areas of very low attenuation with smooth outline and near
spherical form. Cysts were also the most common benign lesion to be
confused with tumours on IOE scan images.
III.B.2.d. Haemangiomas
Small haemangiomas may also be detected by IOE scanning and mimic small
metastases or malignant tumours. Differentiation of these two findings is not
possible from a single IOE scan. However haemangiomas may be recognised
by their increase in attenuation on administration of water-soluble contrast
during a DBCT scan and so, in this regard, the information from these two
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investigations is complementary.
IIl.B.2.e. Fibronodular hyperplasia
Areas of fibro nodular hyperplasia within a normal liver may have exactly the
same appearance as a tumour or a metastasis on IOE scan. It is impossible to
differentiate between these lesions and tumour by IOE scan.
III.B.2.f. Malignant lesions on IOE scanning
A lesion seen on IOE scanning may have a number of features that suggest
malignancy. Highly suspicious features are;
- Low attenuation and irregular outline in a larger lesion.
- A lesion of mixed attenuation.
- A small area of low attenuation which does not correspond to the expected
site of a vessel and is not present on sequential images of a run.
- An area of low attenuation surrounded by one or more smaller satellite areas
of low attenuation.
- An area of low attenuation associated with a segmental perfusion defect: this
is suggestive of carcinoma with involvement of the portal vein and hepatic
arterial supply causing an area of non-functioning liver.
- A centrally placed area of low attenuation with evidence of peripheral
intrahepatic biliary dilation.
- Peripherally placed areas of low attenuation which demonstrate invasion into
adjacent anatomical structures.
III.B.2.g. Hepatocellular carcinomas
The appearance of hepatocellular carcinomas is essentially the same as on
DBCT scanning. The increase in the difference in attenuation between normal
liver and tumour afforded by IOE scanning reveals more of the small daughter
nodules which may be present (Plate 4 and 5). IOE scanning does not improve
the detection of intra-vascular spread of tumour.
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Plate 4. DBCT ofa hepatocellular carcinoma of the liver occupying segment
IV with daughter nodules in segments V and VI.
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Plate 5. IOE scan of the same lesion showing increased attenuation of the
normal liver more clearly revealing the daughter nodules in the right lohe.
III.B.2.h. Cholangiocarcinomas.
Whilst intra-hepatic cholangiocarcinomas are rare, the effects of extra-hepatic
lesions may be seen. Metastases from cholangiocarcinomas are also
uncommon; when present they appear as low attenuation lesions on the IOE
scan.
III.B.2.i. Metastases from colorectal cancers.
Metastases from colorectal cancers may present with a number of features.
They vary in size from so small as to be undetectable to single lesions
occupying an entire lobe of the liver. They are generally more radio dense than
unenhanced blood vessels and less dense than the enhanced liver. They may
have a smooth outline and be of regular shape or they may be irregular and
spiculated. Large lesions may be of irregular density and, if necrotic in the
centre, may be of particularly low attenuation. Colorectal metastases which
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have originated by transcoelomic spread may form subcapsular lesions which,
if small, are difficult to detect because of the adjacent structures. Metastases
from mucinous tumours may form complex cysts, the internal septa of which
are apparent on both IOE scanning and on DBCT. The appearances of
metastases on IOE and DBCT scanning are essentially similar but the contrast
between metastases and normal liver is increased by IOE enhancement ( Plates
6,7,8,9).
Plate 6. DBCTofa malignant hepaic cyst from a mucinous adenocarcinoma of
the colon.
Plate 7. IOE scan ofthe same patients showing increased definition ofthe cyst
and the presence of internal septa.
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Plate 8. DBCTofsegments V and VI in the same patient.
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Plate 9. IOE scan ofsegments V and VI in the same patient revealing a further
small malignant cyst not seen on DBCT scanning.
There are no special features of colorectal metastases which allow confident
diagnosis of the primary from the IOE appearances of the hepatic metastases
alone. It is not possible to determine the site of a primary cancer by the IOE
appearance of the metastases in patients who have occult primary disease.
III.B.2.j. Recording
Each lesion was recorded by its site and its size. The site is described with
reference to the segmental liver anatomy described by Bismuth. Size was
measured as the maximum recordable diameter on the scan image. In the
series of patients being assessed for resection of liver tumours, the scans have
been reported in terms of the maximum number of hepatic segments involved
rather then just the number of metastases present, as this gave a better
representation of the anatomical resectability of tumours as well as the number
of metastases involved.
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III.C. Intra-operative Ultrasonography
11I.C.I. Introduction
Intra-operative ultrasonography was performed by placing a sterilised linear
array 5 MHz "T" shaped ultrasound probe directly onto the surface of the liver.
Direct access to the surface of the liver increased the volume of liver which
could be visualised compared to pre-operative ultrasonography. The reduction
in attenuation of the ultrasound beam allowed the use of a 5 MHz probe as
opposed to the 3.5 MHz probe thus giving improved definition. Increased
definition allied to the improved access to the liver afforded by laparotomy
allowed the interrogation of structures within the liver from a number of
different viewpoints with great clarity.
III.C. 1.a. Equipment
The Aloka SSD 210 II with a 5Mhz T' shaped ultrasound probe was used for
the investigations except for a short period of time when due to failure of the T'
probe a finger shaped probe was used (Plate 10). A 7.5 MHz endo-anal probe
was used for the laparoscopic ultrasonography .
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Plate 10. Aloka 5 Mhz "T" probe usedfor the intraoperative hepatic scanning
ofpatients undergoing curative resection ofcolorectal cancers.
Ill.C.l.b. Technical details
The Aloka SSD 210 II is a portable ultrasound camera capable of supporting a
number of compatible ultrasound probes. Scanning is by electronic linear
scanning with 40 piezoelectric crystals in the scanning head. The scan obtained
has a width of 56 mm and a depth of 147 mm. This machine has a maximum
frame rate of 30 frames /second. The fixed focus is obtained by transmission
/reception electronic focusing plus an acoustic lens. Time biased gain is
variable: near field-80 to-10 dB, far field 0 to+5dB. The final image is
displayed on a 13.75 cm video screen and may be transferred to a video printer
for permanent record.
III.C.l.c. Method
Prior to laparotomy, the ultrasound probe (Aloka UST-5810T-5) is sterilised
by immersion for 15 minutes in gluteraldehyde solution (Cydex). Only the
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scanning head and cable are immersed as the multipoint connector to the Echo-
camera is not waterproof. Following Cydex immersion and in the sterile field,
the cable and head are rinsed by immersion in 1L of Sterile Water BP for 1
minute and then dried. The multi connector is held out of the sterile field and
connected to the Echo-camera and the cable fixed to the operating drapes to
prevent it from contaminating the operating field. Following standard skin
preparation and draping, laparotomy is performed usually via a bilateral
subcostal incision in patients for hepatic resection and either a midline,
paramedian, or lower transverse incision for colonic resections. Bimanual
palpation of the liver is then undertaken. In patients who were being assessed
for resection of hepatic tumour, the liver is mobilised by division of the
falciform ligament and the triangular ligaments to allow complete examination of
the surface segments II, VII and VIII. Firstly, light palpation is undertaken to
examine the surface of the liver for studding by transcoelomic metastases.
Deep palpation is then undertaken with one hand on the upper surface of the
lobe and one beneath. Firm pressure is applied between the fingertips and
with a rubbing motion the substance of the liver examined. Large metastases
within the substance of the liver are detected in this manner and their
approximate site noted.
In patients having primary resection of colorectal cancer any non anatomical
adhesions to the liver are divided but no other mobilisation of the liver is
undertaken. Particular attention is paid to light palpation of the surface of the
liver to detect subcapsular metastases in these patients because of the near field
loss of image. A stand off was not used in these patients as it was found to be
impractical to perform the examination in this way. Following palpation the
liver is systematically examined using the ultrasound probe (Plate 11).
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Plate 11. A 5Mhz probe on the surface of the liver.
The examination is guided by the intra-hepatic vascular anatomy and by this
means the entire internal volume of the liver can be visualised. All of the initial
scanning was undertaken with the probe head in a sagittal plane with the
scanning array in contact with the anterior surface of the liver and directed
posteriorly.
III.C. 1 .d. Identification of the major vascular structures.
With the probe on the surface of segment IV, the inferior vena cava is identified
and followed superiorily to the level of its junction with the hepatic veins.
Further superior movement of the probe is prevented by the right triangular
ligament (Fig 1, Plate 12 ).
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Starting Position
Fig 1 initial position of scanning head to identify the major intra-hepatic
vessels, RHV- Right Hepatic Vein , MHV- Middle Hepatic Vein, LHV-Left
Hepatic Vein, JVC - Inferior Vena Cava. The 5 MHz prohe is placed on the
anterior surface ofthe liver and angledposteriorly .
Plate 12. Position I showing the right, middle and left hepaic veins and the
inferior vena cava.
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To visualise the most superior part of the liver, the plane of the probe head is
angled superiorily until the inferior aspect of the heart comes into view. From
this point ( Fig 2 the most superior aspect ofsegment IV) the probe is angled
inferiorly until the plane of scan is vertical.
Fig 2 Most superior position ofscanning head. Ifthe scanning head is angled
superiorilyfollowing the IVC , the lowerportion of the right atrium and right
ventricle come into the plane of the scan.
The probe is then moved inferiorly across the surface of the liver imaging the
volume of liver anterior to the inferior vena cava. As the probe is drawn
across the liver the angle of the head is varied superiorily and inferiorly, by a
few degrees, in a sweeping fashion. This manoeuvre greatly increases the
differentiation of spherical or near spherical structures from vessels. This
plane of scanning visualises the following structures: the inferior vena cava, the
right, middle and left hepatic veins, the hilar plate and the intra-hepatic
confluence of the right and left branches of the portal vein (Fig 3), the hepatic
artery, the right and left hepatic ducts including the primary confluence of the
right hepatic ducts and portal vessels, and the branches of the same to segments
I, II, and III. The extra hepatic biliary tree, portal vein and hepatic artery are
visualised posterior to the inferior portion of segment IV. This completes the
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Confluence intra-hepatic portal vein
Scanning head
Fig 3. Showing the intrahepatic confluence of the portal vein (PV) and the
branches ofthe portal vein to segments II and IV.
The probe is repositioned on the anterior surface of the liver superiorily abutting
the right triangular ligament overlying the medial superior aspect of segment






Fig 4 .To the right of the IVC visualising the right anterior (RAPP) and right
posterior (RPPP) portal pedicle and the right hepatic vein.
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Plate 13. Starting position 2, with the probe head angled slightly to better
show the right hepatic vein, the anterior portal pedicle has divided into the
segment V and VIII branches and the posterior pedicle branches to segmentsVI
and VII are bisected by a branch of the hepatic vein.
Again the position of the probe is confirmed in relation to the intrahepatic
vascular anatomy. The left hand side of the scanning plane being in line with
the right hand side of the inferior vena cava. With the probe in this starting
position the head is angled superiorly until the plane of scan passes out with the
substance of the liver superiorily. The plane of the scan is then returned to the
vertical and the probe moved in an inferior direction across the anterior surface
of the liver in a similar manner to the previous sweep. The anatomical
structures visualised are: the middle and right hepatic veins, the anterior and
posterior pedicals of the right portal tracts splitting into their segmental
branches, the gallbladder and the right kidney posteriorly. The portal
structures are seen again but from a slightly different viewpoint. The probe is
then moved superiorily and to the right so that the left hand edge of the plane of
scan is in line with the superior and inferior division of the anterior portal
pedical. As the probe head passes more laterally with each scan so the natural
curvature of the anterior surface of the liver becomes more pronounced. With
the probe on the anterior surface of the liver in this position the plane of the scan
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passes-posteromedially instead of posteriorly as in the two previous sweeps.
With the probe on the anterior surface of segment VII the head is angled
superiorily and posteromedially and drawn inferiorly across the surface of
segments VII and VI (Fig 5 ).
Starting position 3
Fig 5 As the prohe moves round the liver, the plane of the scan becomes more
horizontal. This gives a constantly changing view of the portal structures and
allows areas of interest to he viewedfrom more than one angle.
The structures seen are the lateral extension of the middle and right hepatic veins
and the right kidney. The probe is then moved laterally and superiorily to lie
over the posterior superior portion of segment VII. This puts the probe on the
right lateral aspect of the liver with the plane of the scan almost horizontal. The
head is again moved and angled as superiorily as possible and then returned to
what is now a sagittal plane. The probe is drawn inferiorly as before,
visualising the inferior vena cava, the middle and right hepatic veins, the
anterior and posterior portal pedicles and the porta hepatis. In this way, all of
the internal volume of the right lobe of the liver can be visualised from at least
two different viewpoints. Any areas of interest can be further interrogated by
moving the probe over the surface of the liver whilst keeping the area of interest
in the field of the scan. This gives an opportunity to view the area of interest
"from all sides" and assists in differentiating between subtle areas of acoustic
shadowing caused by the normal intrahepatic structures and true areas of
alteration of acoustic attenuation that might indicate diffuse malignant change.
The left lobe of the liver is scanned in a similar manner with the scan head being
moved to the left on each subsequent pass across the anterior surface of the
lobe. The first superior to inferior pass identifies the superior portion of the
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inferior vena cava, the middle and left hepatic veins and hepatic vein branches
to segments IV, II (Plate 14) and III (Plate 15) in that order, the intrahepatic
portion of the edge of the lesser omentum, the round ligament as it fuses with
the left branch of the portal vein at its bifurcation into segment III and IV





Plate 14. The segment 2 duct seen in relation to the left hepatic vein.
If the left lobe is small, a second pass more laterally over the lobe may visualise
the remainder of segments II and III in some patients. When the lobe is large
two further passes may be required.






Plate 15. The segment III duct seen in relation to the edge of the lesser
omentum.
Any lesions identified are recorded with regard to the segment of the liver in
which they lie and to their size. It is possible to target lesions for Trucut'
biopsy by identifying the lesion on ultrasound and then guiding the needle into
the lesion by direct visualisation.
IH.C.l.e. Postoperative sterilisation
After use, the ultrasound probe is washed under running cold water and
sterilised for 15 minutes in a Cydex bath. The probe is then rinsed and stored
non-sterile for future use.
111.C.2. Lesion identification on intra-operative ultrasound
scanning.
Tumours in the liver are recognised by a number of features all or some of
which may be present in any one tumour. A small percentage of tumours have
an echogenic profile so close to that of normal liver that they cannot be
recognised by their echo signature. These tumours may be detected by their
volume effect, causing displacement of the normal intrahepatic anatomy .
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Tumours less than 5 mm present such a small image that they are difficult to
detect even if they are echogenic. Tumour recognition is dependent on both
the echogenic profile of the tumour, its size and its position. Tumours must
also be differentiated from benign lesions within the liver and from variations of
normal liver tissue.
IH.C.2.a. Benign lesions
Hepatic cysts are the most common benign lesion seen on examination of the
normal liver. They appear as spherical or near spherical areas of very low
echogenicity, and may be present in any part of the liver. Most cysts contain
serous fluid or bile which has an acoustic impedance close to that of blood and
so may be compared to the blood vessels. Cysts however do not contain any
movement artefact, which is often seen in blood vessels. Another feature is
an enhancement of the image of the furthest wall of the cyst as compared to the
nearest. Enhancement is caused by the relative reduction of the attenuation of
the ultrasound signal as it crosses the fluid filled cavity of the cyst. Resulting
in a relatively brighter reflection from the posterior wall of the cyst and also
enhancement of the reflections from all structures posterior to the cyst. The
effect of posterior enhancement increases with the size of the cyst.
III.C.2.b. Haemangiomas.
Haemangiomas are congenital areas of abnormal vascular development. They
may occur at any site in the liver and may range in size from a few millimetres
to many centimetres. Simple haemangiomas appear as areas of mixed
increased echogenicity, signal reflection may be so great as to cast an acoustic
shadow behind the lesion. Haemangiomas have a well defined margin and do
not normally exhibit a hypoechoic halo. However, the appearance of a small
haemangioma may exactly imitate that of a small tumour so as to be
indistinguishable by routine ultrasonic examination alone. Haemangiomas
may be defined by the use of an ultrasonic contrast agent such as carbon dioxide
microbubbles; this technique is not in current clinical practice.
II1.C.2.C. Nodular hyperplasia
Nodular hyperplasia is an area of abnormal growth within a normal liver.
These areas of hyperplasia may have an ultrasonic appearance that can exactly
mimic a hepatic tumour or a hepatic metastasis and so cannot be differentiated
from tumour on the basis of ultrasonographic appearance alone. Nodular
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hyperplasia is uncommon in the Scottish population.
HI.C.2.d. Nodular regeneration in cirrhosis
Regenerating nodules in a macronodular cirrhosis may also give an ultrasonic
appearance that is similar to an area of tumour or metastasis. The nodularity of
micronodular cirrhosis is so fine as to be below the resolution of the ultrasound
scanner but causes a generalised increase in the atteriuation and reflectivity of
the liver. The image of the liver appears brighter than the adjacent solid
organs, particularly the right kidney.
III.C.3. Malignant lesions in the liver
A number of features when seen in relation to a lesion within the liver indicate
malignant origin.
III.C.3.a. Hepatocellular carcinomas
When small, hepatocellular carcinomas tend to present as areas of decreased
echogenicity. As they increase in size the core of the tumour becomes
avascular and necrotic, the echogenic profile then changes. A hypoechoic rim
appears associated with a central area of mixed echogenicity, some of which
may be greater than the surrounding liver. When the central portion is of
increased echogenicity there may also be some degree of posterior shadowing.
Hepatocellular carcinomas tend to metastasise early via the intrahepatic portal
circulation, producing a number of small daughter nodules. These may be
seen in the portion of the liver supplied by one branch of the portal vein.
Portal vein branches may be directly involved by the tumour and intra-vascular
extensions of tumour thrombus are common and easily visualised. These two
features seen together are characteristic of hepatocellular carcinoma. When
very large, it may be difficult to compare the tumour to normal liver
parenchyma. This problem can be overcome by using the split screen facility
of the ultrasound camera to store a view of the normal liver against which the
tumour can be compared ( see chapter II Plate 1.).
III.C.3 .b. Cholangiocarcinoma
Intrahepatic cholangiocarcinoma is uncommon, a more common occurrence is
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the intrahepatic spread of cholangiocarcinoma from tumours occurring at the
porta hepatis. These tumours are generally hyper-echoic and involve the extra
hepatic portion of the biliary tree, arising from the bile ducts They are often
diagnosed following a period of biliary obstruction. If this is the case there
may be associated dilatation of the intrahepatic biliary tree.
III.C.3.C. Hepatic metastases from colon cancer
The appearance of these metastases is very varied and is to some degree
dependent on their size. Features associated with colonic metastases are
described here;
- Bull's-eye lesions are the most common appearance of hepatic metastases.
They have a hypo-echoic rim and an iso-echoic or hyper-echoic centre.
Lesions of this type tend to be 1 cm or larger in diameter and may occur at any
position in the liver. They are near spherical in form until large, when they
may take on a multi-lobulated appearance. They may be indented by an





Plate 16. Three small hulVs-eye metastases from a colon cancer related to the
gallbladder bed.
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Plate 17. Solitary "Bull's-eye" metastases from colorectal cancer (centre of the
plate). A second lesion is present at the top left hand edge of the plate. Roth
of these lesions are about I cm in diameter.
- Small hypo-echoic lesions which are spherical in form. These lesions are
of a lower echogenicity than the liver but not as low as the intrahepatic vessels
or cysts. They are uniform in echogenicity and may occur in any position in
the liver (Plate 18).





Plate 18. Two hypoechoic metastases lying anterior to the inferior vena cava.
- Iso-echoic diffuse involvement of the liver can occur when the metastasis has
no clear margin. This type of metastasis can be very difficult to detect and if
detected may be very difficult to delineate. The metastasis is of very similar
echogenicity to the liver and has no outline, but can be recognised by very
subtle changes in the parenchymal echo pattern or by a disturbance of the
normal hepatic architecture. There may be an absence of small portal vein
branches or the vascular anatomy may be distorted by the tumour. In some
patients the only evidence of tumour is a change in the granular appearance of
the liver parenchyma. These changes may be so subtle as to go unnoticed and
may only be recognised in retrospect (Plate 19).
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Plate 19. A near iso-echoic metastasis distorting the lateralportion of the right
hepatic vein.
Complex cysts with thickened irregular walls and internal septa may
represent metastases from mucous producing colonic cancers. These cysts
may be seen in association with bull's-eye lesions in the same patient. Cystic
degeneration may occur in very large metastases and appears as a hyper-echoic
lesion with a markedly hypo-echoic centre (Plate 20).
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Plate 20. A complex cyst lying in segment IV. This scan is from the same
patients as Plates 6, 7, 8, and 9. The scan shows the internal debris and
septa.
III.C.3.d. Biopsy procedure.
A number of techniques are used in patients having resection of known hepatic
metastases and in patients who are having resection of primary colon cancer.
In patients with known hepatic cancer biopsy is undertaken one of three ways;
Excision biopsy: after mobilisation of the liver and identification of the main
tumour, if any other surface lesions of uncertain origin are seen they are
excised in total. These samples are sent for immediate pathological
identification by frozen section preparation.
Trucut biopsy: the needle tip is scratched with a scalpel to improve its
echogenicity. It is then guided by the ultrasound image into the centre of the
tumour and the needle closed. Ultrasonic guidance ensures that the biopsy
actually comes from the lesion in question.
Fine needle aspiration cytology: this gives the smallest sample of cells to the
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pathologist for diagnosis of the presence of malignancy. This technique is
only used when either of the other techniques cannot be employed. Using a
22 gauge needle mounted on a 5 ml syringe, the tip of the needle is cross
hatched by scratching with a scalpel blade and guided to lie within the lesion by
ultrasonography. The plunger of the syringe is then withdrawn to create a
negative pressure in the syringe and the tip of the needle moved back and forth
in the lesion. The resultant small cores of tissue, are smeared on to glass
slides, air dried and fixed in alcohol.
The techniques used in patients with colorectal cancer were the same. In the
majority of patients it was not possible to obtain either excision biopsy or Tru-
cut biopsy within the confines of the study protocol which did not allow
mobilisation of the liver or extension of the abdominal wound. In those cases
where limited access was available, fine needle aspiration was the most
commonly performed technique.
III.D. Selective Angiography
Selective angiography was performed on patients with potentially resectable
liver metastases in order to delineate the internal arterial and portal anatomy of
the liver and to identify the vascular anatomy of the tumours. In selected
patients who had been found to have irresectable hepatic tumour therapeutic
angiography with highly selective chemo-embolisation was performed.
III.D. 1. Method
With the patient on the arteriography table, vascular access is obtained via a
peripheral vein. The patient is sedated with 5-10 mg of midazolam. Using
aseptic technique, arterial access is obtained in the right groin via the right
common femoral artery using an arteriography sheath. The arteriography
catheter is then inserted under fluoroscopic control. By intermittent injection
of small aliquots of Niopam 300, to identify the arterial anatomy, the tip of the
arteriography catheter is placed, via the coeliac axis and the common hepatic
arteries, into the right or left hepatic artery. As the origin of the right hepatic
artery may be from the superior mesenteric artery and the left lobe of the liver
may less frequently derive part of its blood supply from the left gastric artery
these vascular trees are defined by selective angiography of each vessel in turn.
With the catheter in position, infusion is made via a computer controlled
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syringe driver. The sequence of injection and exposure of the plates is
computer controlled. Multiple sequences are obtained with contrast in the
hepatic arterial tree.
Water-soluble contrast is injected at a rate high enough to cause an increase in
the radio density of the arterial blood flow. Relatively high infusion pressures
are required to overcome the internal resistance of the small bore arterial
catheters and provide sufficient delivery of contrast to give an increase in
density of the smaller branches of the arterial tree. At the end of the
examination the access sheath is removed from the groin and the patient
confined to bed rest with a pressure dressing applied for 24 hours.
This dynamic technique requires specialised equipment, considerable expertise
in the performance of the investigation and in the interpretation of the resultant
X-ray plates.
ril.D.l.a. Contraindications
Arteriography was not performed in patients receiving anticoagulant therapy.
Special care was exercised in patients with known peripheral arteriosclerosis as
friable portions of intimal plaques within the arteries may be dislodged and
cause distal embolisation. Patients with impalpable groin pulses were not
suitable for angiography.
III.D.l.b. Reporting
The angiography fdms were all reported by a single consultant radiologist who
performed all of the investigation in full knowledge of the findings of any other
investigations that had been performed. Arteriography was not used as an
investigation to detect new tumour but rather to detect the anatomical
relationships of known tumours to the intrahepatic vascular tree and assess their
resectability.
All of the investigations were carried out with the written informed consent of
the patients.
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Chapter IV
A comparison of preoperative ultrasonography, DBCT




Prior to hepatic resection, the extent of intrahepatic tumour deposits and the
presence of extra hepatic disease must be defined. The primary considerations
in this regard are: the exact extent of the intrahepatic disease, the presence of
local metastatic spread (transcoelomic, transhepatic), the presence of local
recurrence of non hepatic, primary cancers and the presence of distant
metastases (Baer HU, 1989; Eckberg H, 1987; Adson MA, 1987; Reinig JW,
1987; Nelson RC 1990). Although DBCT can be employed to stage intra¬
abdominal spread of disease, IOE scanning may improve the detection of intra¬
hepatic tumour. This chapter investigates the use of these two investigations in
patients with known hepatic malignancy to establish whether IOE scanning can
be used for the quantification and determination of resectability of intrahepatic
malignancy.
IV.B. Aim
To compare DBCT and IOE scanning in the determination of resectability of
hepatic malignancy by answering the following questions;
- Can DBCT alone be used to assess patients prior to hepatic resection ?
- Does IOE scanning detect more tumour than DBCT and if so how does this
effect assessment of resectablilty ?
- Is IOE scanning as accurate as IOUSS in the determination of resectablilty of
hepatic malignancy ?
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IV.C. Patients
The series consists of patients referred to the Hepatobiliary Unit of the Royal
Infirmary of Edinburgh over a 34 month period from January 1989. All of
these patients had potentially resectable hepatic malignancies from a variety of
primary tumours including primary hepatic cancers. Assessment was
undertaken with a view to curative resection of the hepatic disease in all cases.
The data were collected in a prospective manner onto a computerised database to
enable comparison of the investigations. In those patients who underwent
surgery, the results of the operative findings were compared with the
preoperative staging investigations. There were 140 patients, 87 of whom
were male with a median age of 59 years ( range 52 to 82 years). The median
age of the women was 61 years ( range 25 to 84 years),
The underlying primary pathology in these patients is detailed in Table 1.
Site of origin Number of patients
Colorectal 60
Primary hepatic malignancy 40











Table I. Primary pathologies in 140 patients presenting with hepatic
metastases being stagedprior to hepatic resection.
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Of the 60 patients (38 male and 22 female), with colorectal cancer the median
age was 60 (range 28-84 years). The stage of the primary tumour at
presentation was Dukes "A" in 2, "B" in 17, "C" in 25 and "D" in 2. In 12
patients, the Dukes stage of the original tumour was not available. The mean
time from primary operation to presentation was 652 days (4-6843). The
longest disease free period of 18 years and 273 days occurred in a 56 yr. old
man who had a sigmoid colon resection for a cancer of unspecified stage.
IV.D. Method
Patients were admitted to the Hepatobiliary Unit of the Royal Infirmary of
Edinburgh. On admission a full history and examination was undertaken
paying particular attention to signs of extra-hepatic malignancy. In a number
of cases, preoperative abdominal ultrasound investigations performed in other
hospitals were not repeated. All other investigations were undertaken at the
Royal Infirmary of Edinburgh. Routine full blood count, urea and
electrolytes, liver function tests and clotting screen were performed and a
serum sample obtained for analysis of carcinoembryonic antigen and other
tumour markers.
Each patient had a series of investigations performed to assess the extent and
potential resectability of their hepatic tumour (Fig /.). Not all of the
investigations were performed in every case and the investigation algorithm was
not always performed in this particular order.

















Fig 1. Sequence of investigation ofpatients with hepatic malignancy prior to
operation
IV.D.l. Reporting of preoperative investigations
The investigations were reported in the following manner: the anatomical site of
any metastases was described after Bismuth (1982). If a segment was in any
way involved by tumour, it was recorded as positive. If a single metastases
was reported as involving two or more segments then each of these segments
was regarded as being positive for tumour. This method was adopted to give
an accurate indication of the volume of liver involved by tumour and hence the
volume of liver that would have to be resected to achieve a surgical cure.
Patients have been considered to have inoperable disease by the following
criteria;
- More than five contiguous segments of the liver involved by tumour.
- Tumour involving both the left (segments I-IV) and the right (segments V-
VIII) hemi livers.
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- Encasement of the inferior vena cava or the proximal hepatic veins at the vena
cava.
- Tumour encasement of the confluence of the right and left portal tracts at the
porta hepatis.
- Any evidence of extra-hepatic tumour.
IV.D. 1 .a. Operable disease
A tumour(s) was considered resectable, by extended right or left hemi
hepatectomy, if it involved up to 5 segments in either the left (segments I-IV)
or the right side of the liver (segments IV-VIII) with no evidence of tumour at
any site outwith the liver. Multiple metastases were considered operable if they
lay in 5 or less segments, in one side of the liver, or consisted of a single or
less than four large metastases surrounded by multiple smaller daughter
nodules.
IV.D.l.b. Inoperable disease.
Metastases were considered irresectable if they involved the porta hepatis and
could not be removed without resection of; the primary biliary confluence or the
primary bifurcation of the portal vein. If metastases involved the inferior vena
cava and could not be resected with a 1cm clearance of normal liver they were
not considered suitable for resection. Patients with primary hepatocellular
carcinoma were considered irresectable if there was evidence of tumour
thrombus extending into the portal vein. Patients who had evidence of any
metastases outwith the liver were not considered for resection.
IV.D.2. Decision to operate
Following each investigation the results were reported and a decision made by
the consultant surgeon (OJG), on resectability. If resection was feasible then a
decision was made either to further investigate the patient, or proceed to
laparotomy. At each stage, all of the information from previous investigations
was re-evaluated and the decision to proceed made after its consideration.
Angiography was used selectively in an attempt to more accurately define the
operability of tumours in patients who had resectable disease on their other
investigations. Patients who were considered to have resectable disease and
were fit for general anaesthesia were subjected to either a laparotomy or
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laparoscopy and hepatic ultrasonography. Contact hepatic ultrasonography
undertaken at laparotomy and the these findings were considered to be the
"standard" against which the preoperative investigations were assessed.
IV.D.3. At operation
At operation, laparotomy was undertaken by a bilateral subcostal incision. If
obvious irresectable disease was present, no further hepatic mobilisation was
undertaken. Laparotomy included visualisation and palpation of the primary
site of the tumour, if this was intra-abdominal, followed by visualisation and
palpation (as far as possible) of all of the peritoneal surfaces. If the initial
laparotomy was clear then the liver was mobilised by division of the triangular
and coronary ligaments. Bi-manual palpation and intra-operative
ultrasonography was undertaken as previously described (Chapter III). In
those patients who had laparoscopy performed with laparoscopic
ultrasonography, the examination was undertaken in a similar fashion except
palpation was not performed. All of the intraoperative / laparoscopic
ultrasonography was performed by one surgeon (OJG). If patients went on to
hepatic resection IOUSS was used to monitor the progress of the resection. If
local palliation was required this was undertaken and the wound closed.
IV.D.3.a. Resection
Resection was undertaken with the CUSA ultrasonic hepatic dissector. The
liver capsule was divided by coagulating diathermy current and then dissection
was undertaken. During the dissection, progress was monitored using intra¬
operative ultrasonography. At the end of the procedure the specimen was sent
fresh for pathological examination and photography by JP, University of
Edinburgh Dept of Pathology.
IV.D.4. Analysis
The results of the preoperative investigations have been analysed with regard to
the results found at laparotomy, excluding those patients who did not undergo
laparotomy, and including all patients using the agreed stage of disease after all
of the investigations had been reviewed. The outcome for patients who have
remained in the Edinburgh area has been documented through follow up as an
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outpatient. For patients living outside this area, follow up data has been
collected from the referring consultant.
All of the paired, comparative, non-parametric data has been analysed using
the 'Wilcoxon signed-rank test'. The actual calculation has been performed
with the aid of 'Statview™ SE + Graphics v 1.03' (Abacus Concepts inc.,
1984 Bonita Ave, Berkley, California 94704), Comparison of discrete
variables in a series has been performed using the Chi sq. test and Four fold
tables with 1 degree of freedom. These calculations have been performed by a
program written for dBase III plus and published tables (Fisher and Yates).
IV.F.l.a. Morbidity
There was no physical morbidity associated with preoperative ultrasonography
or preoperative DBCT scanning. The morbidity associated with IOE scanning
has been investigated further and is analysed in chapter V. There were no
complications related to intraoperative ultrasonography.
IV.E. Results
IV.E.I. Investigations performed




Thoracic CT scan 60
Abdominal (DBCT) scan 118 60 (23)
Abdominal ultrasonography 112 60(16)
Selective hepatic angiography 71 30 (25)
Iodised Oil Emulsion enhanced CT scan 74 36 (22)
Laparotomy / laparoscopy and IOUSS 64 64(28)
Total number of investigations 600
Table 2. The investigations performedprior to laparotomy in 140 patients with
hepatic malignancy, the number ofpatients having each investigation, the
number reported as operable, (the numberfinally resected)
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IV.E.2. Preoperative hepatic ultrasonography
Preoperative hepatic ultrasonography (USS) was performed on 112 patients,
the presence of tumour was confirmed in 101, of whom 60 were reported as
having resectable disease. Of these 101, 30 patients went on to laparotomy for
hepatic resection, 25 with an USS report of resectable disease and 5 with an
USS report of irresectable disease. The presence of operable tumour was
confirmed in 16 of the 25 patients and refuted in 9. Of the 5 with a report of
irresectable disease, 4 had a successful hepatic resection, in-operability was
confirmed in 1 (Fig 2 ). Of the 11 patients who did not have tumour on their
preoperative USS, 10 were found to have tumour by other investigations. The
remaining patient, who had been referred from another hospital was found to
have a simple cyst. In 32 patients the USS report defined inoperability in terms
of the criteria detailed above .
Resection
16
Patients having had USS and















Fig 2. Algorithm for the investigation and treatment of patients who had
preoperative ultrasonography and went on to laparotomy with the intention of
performing hepatic resection
The results of USS in assessing operability of disease in the 30 patients who
finally had a laparotomy are displayed in Table 3




Positive predictive value 64%
Negative predictive value 20%
Accuracy of 56%.
Table 3. Accuracy of preoperative ultrasonography in determining the
resectablilty ofhepatic metastases in 30 patients who underwent laparotomy.
Analysis can be made of these data considering all patients who had USS
performed and their final outcome. There were 101 in whom USS confirmed
the presence of tumour. The scan suggested operable disease in 60 patients
and inoperable disease in 41 patients (the patient with a cyst has been excluded)
{Fig 3. ). Ultrasonography failed to detect intrahepatic tumour in 11 patients.
Of the 60 patients with apparently operable disease, only 16 went on to
























Fig 3 Algorithm for the outcome of all patients who had a preoperative
ultrasound scan ofthe liver.
The overall results for specificity etc. of preoperative ultrasonography in
detecting the presence of resectable disease are as follows ( Table 4 ).




Positive predictive value 27%
Negative predictive value 90%
Accuracy 52%.
Table 4. The overall results ofpreoperative USS in determining resectability.
IV.E.3. Upper abdominal DBCT scanning
IV.E.3.a. Patients
One hundred and sixteen patients had DBCT scans performed the average age
of the patients was 60 years (range 22-82 years). There were 73 men and 43
women. One hundred and eleven scans confirmed tumour within the liver.
The primary tumours in the five patients who had undetectable metastases were:
colon in 2 and one each from liver, biliary and lung. The primary sites of
tumour in the patients with positive scans are listed below ( Table 5).











Table 5 Primary sites of tumour in patients having a positive DBCT scan as a
staging investigation prior to resection ofhepatic malignancy.
Sixty patients had operable disease on DBCT scanning, 23 of whom
underwent successful hepatic resection. Of the remaining 51 patients who had
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inoperable disease on DBCT scanning, none went on to successful hepatic
resection. There were 2 patients who had no evidence of metastases on DBCT
scan who had resectable tumour detected by other investigations.
Negative DBCT -









Operable DBCT Inoperable DBCT
60






Successful No resection Successful No resection
23 14 0 4
Fig 4. Outcome of 116 patients undergoing DBCTand being considered for
hepatic resection.
DBCT scanning correctly predicted inoperability in all patients who had a
laparotomy (and had inoperable disease on DBCT scan). There were 60
patients who had operable disease on their DBCT scans, of whom 3 7
underwent laparotomy and 23 had successful resection. Of 5 patients who had
no evidence of tumour on DBCT scanning, 2 had successful resection of
tumours ( Fig 4). The overall results of DBCT in determining resectability of
hepatic metastases in patients who had evidence of hepatic tumour on their
DBCT scans are displayed in Table 6 .




Positive predictive value 38%
Negative predictive value 100%
Accuracy , 67%
Table 6. Results of DBCT scanning in 111 patients with evidence of
metastases on their CT scan. The 5 patients with no evidence of hepatic
metastases have been excluded as resectability could not be determinedfrom the
negative scans.
IV.E.4. Iodised Oil Emulsion Enhanced CT Scans
IV.E.4.a. Patients
Seventy four patients had an IOE scan performed. Their average age was 58
years (range 22-78 years), 50 were male and 24 female. Forty one of these











Table 7 Site ofprimary tumour in 74 patients who had an IOE scan.
Of the 74 scans, 70 confirmed the presence of tumour, with 35 showing
operable disease. Twenty two patients with operable scans went on to
Chapter IV Ultrasonography CT and IOE scanning 94
successful resection. None of the 35 patients who had an inoperable scan
went on to a successful resection. There were 4 patients in whom the IOE scan
failed to detect any hepatic tumour, two of these went on to have successful
resection of hepatic lesions (Fig 5 ). One of these two also had a negative
DBCT scan. These four patients are detailed below.
Patient 1. 74 year old man with a previous history of resection of a Dukes B
adenocarcinoma of the colon 6 months before the appearance of a hepatic
metastasis on ultrasonography. CEA was moderately raised at 109 u/1. The
metastasis was 1.8 cm in diameter lying in segment II. Curative left lobectomy
was undertaken. This tumour was not seen by either DBCT or by IOE
Patient 2. 47 year old man with a previous history of resection of a Dukes C
adenocarcinoma of the colon had a small centrally placed lesion detected by
intra-operative ultrasonography. IOE scans, following chemotherapy, failed
to detect the centrally placed lesion. Staging laparoscopy and laparoscopic
ultrasonography were undertaken and the lesion was detected. Curative right
hemi-hepatectomy was undertaken. Subsequent pathological examination
revealed the lesion to be an area of nodular hyperplasia. The patient died with
recurrent local, peritoneal and hepatic disease within 24 months of resection.
Patient 3. A 74 year old man presented with primary carcinoma of the
gallbladder. CT scan failed to demonstrate any hepatic involvement, however
intra-operative ultrasonography revealed the presence of tumour in segments IV
and VIII. Curative right hemi-hepatectomy was undertaken with
hepaticojejunostomy and roux-en-'Y' anastomosis.
Patient 4. In a 64 year old man with pancreatic carcinoma. DBCT scan
performed at the referring hospital had revealed intrahepatic metastases, which
were confirmed on arteriography as lying in segment II. The Arteriogram also
showed involvement of the superior mesenteric vein and splenic vein by the
primary tumour. The hepatic tumour was not seen on IOE scanning.
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Fig 5. Outcome of 74 patients undergoing IOE scan and benig consideredfor
hepatic resection.
The overall results for IOE scanning in determining resectability of hepatic




Positive predictive value 62%
Negative predictive value 100%
Accuracy 83%
Table 7. Results of IOE scanning in 70 patients with evidence ofmetastases
on their scan. The 4 patients with no evidence ofhepatic metastases have been
excluded as resectability could not be determinedfrom the negative scans.
The details and the reasons for hepatic resection not being performed in the 7
patients with apparently operable IOE scans were as follows:
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Patient 1: A 57 year old man with a previous resection of a Dukes B carcinoma
of the colon. IOE scan suggested resectable metastases limited to segments II
and III. These findings were confirmed at laparotomy but extensive coeliac
nodal involvement by metastatic adenocarcinoma precluded resection.
Patient 2: A 71 year old man with a primary hepatoma in segment III, IV and
V on IOE scanning. Found at laparotomy to have involvement of the falciform
ligament and the anterior abdominal wall.
Patient 3: A 62 year old woman with prior resection of a Dukes B carcinoma of
the colon. IOE scan suggested resectable metastases in segments V, VII and
VIII. She was found to have multiple bilateral hepatic metastases at operation.
Patient 4: A 56 year old woman with prior resection of a Dukes C carcinoma of
the colon. IOE scan suggested resectable disease in segments IV, VI, VII and
VIII. At operation more extensive disease found in the right lobe involving the
I.V.C. and the porta hepatis.
Patient 5: A 66 year old man with previous resection of a Dukes A carcinoma
of the colon. The extent of intrahepatic disease found by IOE scanning was
confirmed at operation. The peritoneal surfaces were, however, studded with
adenocarcinoma and there were portal lymph node metastases.
Patient 6: A 55 year old woman with a hepatic metastasis from a
lieomyosarcoma of the colon. IOE scanning failed to detect direct extension of
the hepatic metastasis into the anterior abdominal wall.
Patient 7: A 59 year old man with a hepatoma in the right lobe of the liver.
IOE scanning failed to delineate a large metastasis in the right adrenal gland.
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IV.E.4.b.
, Pulmonary metastases
There were 16 patients with pulmonary tumour in this series. One hundred and
one patients had a chest X-ray (CXR) performed and 60 patients had a CT scan
of the thorax. Seven tumours were detected in the 101 patients by CXR.
Twelve tumours were detected in 60 patients by CT of the thorax. In 50
patients who had both investigations, CXR detected only 3 of 11 tumours
present on CT (Chi sq. = 5.32 ldf, p <0.05) There were no false positive
investigations.
Although the specificity and accuracy of CXR in the detection of pulmonary
metastases were high (100% and 84% respectivly) its sensitivity was poor
(27%) CT scanning of the thorax detected all of the thoracic tumours which
were known to be present. It should be noted that these results have not been
validated by any other investigation, however, no patient has presented
pulmonary metastases during the follow up period. .
IV.E.5. Angiography
Arteriography was performed in 71 patients with a mean age of 60 years; the
series contained 48 men. The examination revealed operable disease in 30
patients, 20 of whom eventually underwent successful hepatic resection.
Forty four patients had both an IOE scan and arteriography performed, 28 of
whom had operable disease on their IOE scan. Arteriography correctly
predicted resectability in 17 and IOE correctly predicted resectability in 19 of the
20 patients who had a successful resection. Of the 24 who did not undergo
successful resection, irresectable disease was predicted in 19 by arteriography
and in 15 by 10E scanning. In the 44 patients who had both arteriography and
IOE scanning, arteriography had a sensitivity of 85%, specificity of 79%,
positive predictive value of 77%, negative predictive value of 86% and an
overall accuracy of 82% compared with 95%, 62%, 68%, 94%, and 77%
respectively for IOE scanning. The arteriograms were reported with full
knowledge of the IOE scan results and did not significantly improve the
accuracy of the investigation (Chi sq = 0.3 ldf p > 0.5).
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IV.F. Comparison of DBCT and IOE by detection of
involved segments.
A direct comparison has been made between IOE and DBCT scanning in the
number of hepatic segments found to be involved by tumour by each
investigation. All of the DBCT and IOE scans were reported with regard to the
number of liver segments involved by tumour rather than the number of
metastases present. There were 66 patients who had both investigations
performed (Table 8).
Segments detected
Patient group numbers IOE DBCT Significance
All patients 66 200 139 p = 0.0001
Colorectal cancer 33 96 66 p = 0.0002
Primary Hepatic cancer 16 55 35 p = 0.0006
Other cancers 17 49 38 p = 0.0067
Table 8. Comparison of the number of segments detected by DBCT and IOE
scans in patients having both investigations. Statistical analysis by Wilcoxon
signed rank.
Overall DBCT detected 94 involved segments in the right hemi liver ( segments
V, VI, VII, VIII) and 45 in the left hemi liver side ( segments I, II, III, IV),
IOE detected 123 involved segments in the right and 77 in the left. Patients
with metastatic disease were more likely to have tumour in the right liver than
the left compared to those with primary hepatic malignancy. In the 33 patients
with metastatic colorectal cancer, DBCT identified 54 segments in the right
liver and 12 in the left (p = 0.0001). IOE detected 67 segments in the right
liver and 28 in the left (p = 0.002). In the 16 patients with primary liver
tumours DBCT detected 18 involved segments in the right and 17 in the left (p
= 0.5) where as IOE detected 28 segments on the right side and 27 in the left
hemi- liver (p = 0.7).
In the 66 patients assessed by both DBCT and IOE the hepatic lesions were
deemed to be resectable by DBCT in 41 patients; 18 (44%) of these underwent
successful resections. Nineteen (66%) of the 31 patients shown by IOE to
have resectable disease went on to successful resection. The false positive rate
for resectablilty was 34 % for DBCT and 18 % for IOE.
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ThirtyTfour patients underwent operative assessment of the liver either at
laparotomy or at laparoscopy. In these patients there was 90% concordance in
the number of segments involved per patient, intraoperative ultrasonography
detecting 84 involved segments, 76 of which had been detected by IOE.
DBCT detected only 63 segments in the same patients. There was no
significant difference in the number of involved segments among the three
investigations in these patients.
IV.F.l. Comparison of USS. DBCT and IOE
All three preoperative investigations, USS, DBCT and IOE were performed
and detected the metastases in 49 patients. The accuracy has been calculated for
each investigation in determining the resectability of these metastases (Table 9).
Results USS DBCT IOE
True positive 12 16 16
True negative 11 18 25
False positive 22 15 8
False negative 4 0 0
Parameter (expressed as %)
Sensitivity 80 100 100
Specificity 46 57 76
Positive predictive value 27 38 62
Negative predictive value 90 100 100
Accuracy 52 67 82
Table 9. Comparison ofpreoperative USS , DBCT and IOE scanning in the
assessment ofoperability ofhepatic tumour.
IOE scanning is more accurate than USS (Chi sq = 14.56 ldf, p < 0.001) in
the determination of resectability in patients with hepatic malignancy. DBCT is
also more accurate than USS (Chi sq = 5.07 ldf, p < 0.05). There is no
significant difference between IOE scanning and DBCT scanning in the
determination of resectability (Chi sq = 2.78 ldf, p > 0.1).
IV.F. 1 .b. Relation of duration of symptoms to resection
The period of time between primary resection and presentation with hepatic
metastases in patients with colorectal cancer bore no significant relationship to
the likelihood of the metastases being resectable. The median lag time for
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patients who did not undergo a resection was 312 days and for those who did




Patients in this study were being investigated in a clinical setting and so their
management was altered during the course of their investigation as more
information became available. Patients with pulmonary metastases on CXR
were not subject to angiography or IOE scanning as this would have exposed
them to the risk of investigation-induced morbidity with no possible benefit.
Thus there is a possibility of bias caused by the exclusion of patients from
further investigation on the basis of one of the previous investigations.
Patients undergoing the second and subsequent investigations are selected
groups. The two principle comparisons have been made between the patients
who had both DBCT and IOE scans performed and patients who had DBCT,
IOE and USS performed.
IV.G.2. Chest X ray
When patients are considered for hepatic resection it is important to exclude
dissemination to other sites. In this series, CXR alone detected metastatic
disease in 7% of all referred patients. In the 50 patients who had both
investigations, CT scan of the thorax revealed metastases in 22% of patients
compared to 6% detected by CXR. Overall, 11% of our patients had
pulmonary metastases at the time of referral. In 39 patients, no CXR had
been performed prior to referral, 24 of these were secondary referrals from
other hospitals. The high incidence of pulmonary metastases in patients with
hepatic metastases makes accurate imaging of the lungs as important as hepatic
imaging (Sugarbaker PH, 1990). The PA chest radiograph is not as sensitive
or as accurate as a CT scan of the chest and this has been confirmed by our own
experience.
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IV.G.3. Ultrasonography
Considering the 101 patients who had an USS which detected tumour; the
investigation did not provide reliable information regarding the resectability with
a positive predictive value of only 27% and an overall accuracy of 52%. The
high sensitivity (80%) is to be expected as almost all of the patients in this series
were selected for assessment on the basis of previous ultrasonographic evidence
of hepatic tumour. The low accuracy of USS in determining resectability is
also expexted. The preoperative detection of hepatic tumours by
ultrasonography is extremely variable and shown to range from 42% to 90%
(Machi J, 1991; Clarke MP, 1989). Although smaller metastases are
frequently missed because they are out of the range of resolution of the echo
camera, larger tumours in the superior part of the right lobe may also be missed
because of the lack of a sonolucent window through which to view them.
This problem may be compounded by obesity in some patients.
Taking the series as a whole, ultrasonography has a high negative predictive
value for operability of 90% . By refining the reporting of USS to document
the number of distinct metastases, the involvement of the porta hepatis and the
presence of bilateral disease, USS could be used to exclude patients with
inoperable diseases from further investigation. Although there were 80
patients, with irresectable disease who had a detailed USS report, only 32 of
these contained information relating directly to the exclusion criteria for
resection used in the study. The specificity (33%) and positive predictive value
(35%) of USS in this study are too low identify which patients will ultimately
have resectable disease, this has been shown by others (Sugarbaker PH, 1990;
AdsonMA, 1987).
Ultrasonography is used in a clinical context to screen patients for the presence
of hepatic metastases following surgery for malignant disease, with a view to
curative intervention if possible. Unfortunately hepatic metastases large
enough to be detected by this USS are likely to be irresectable at the time they
are identified, in this series only 28 of 140 patients (20%) eventually had
successful hepatic resection. Patients who are suspected of having metastatic
disease but have no tumour detected by USS should be further investigated.
However Those, who are demonstrated to have irresectable disease by USS
should only be investigated further if there is good reason to suspect the USS
report is inaccurate. Ultrasonography is an excellent screening tool to reduce
the number of patients with irresectable hepatic tumour going on to further
investigation. Its main advantages are high negative predictive value, safety,
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the ease of the investigation, general availability and low cost.
IV.G.4. DBCT scanning
In the 49 patients who had both USS and DBCT, DBCT increased the accuracy
of assessment of resectability of hepatic metastases from 52% to 67% and
reduced the false positive rate to zero. DBCT scanning has been shown by
others to be less accurate than ultrasonography in the detection of hepatic
malignancy (Sheu J-C, 1985; Gozzetti G, 1986;). Castaing showed an equal
accuracy of 68% for ultrasonography and 67% for CT scanning (Castaing
D,1986). Others have shown that CT is more accurate than ultrasonography
(Schreve RH, 1984; Alderson PO, 1983). However, none of these series
have compared the accuracy of the investigations in assessing resectability,
rather than the simple detection of metastases.
DBCT consistently underestimated the number of liver segments involved with
tumour when compared to both laparotomy with contact hepatic
ultrasonography and IOE scanning. If DBCT scanning were the only
investigation used to determine resectability prior to surgery the rate of
laparotomy for irresectable disease would have been 62%, an unacceptably
high figure. Although DBCT scanning is able to detect intrahepatic
malignancy, 11 patients had more extensive irresectable intrahepatic disease
than had been identified by the DBCT scan. This suggests that DBCT
scanning is too insensitive to be used to determine the resectability of tumour.
DBCT scanning however detected tumour in 111 of 116 patients (96%),
correctly diagnosing irresectable disease in 51 with an accuracy of 100% .
This suggests that DBCT scanning is an excellent tool both when screening for
metastases and for excluding patients with extensive disease from further
investigation.
IV.G.5. IOE scanning
IOE scanning is a non-invasive, repeatable and safe technique and was the
most powerful of the preoperative investigations in the assessment of the
resectability of hepatic malignancy. IOE scanning correctly determined
resectability in 74% of the patients who came to laparotomy and had an overall
accuracy in determining resectability of 82%. This improvement was due to
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the increase in the detection of segments involved by tumour. Lewis et al
showed a 38% increase in the number of metastases detected by EOE-13
enhancement over DBCT, comparable to the 43% (61/139) increase in the
number of involved segments in this study (Lewis E, 1982), while Reinig et
al. showed a 41% increase in lesion detection for EOE-CT over unenhanced CT
scans (Reinig JW, 1987). IOE has considerable advantages in that it can be
administered outside the CT room prior to the examination. The enhancement
is predictable and has not failed in this series. The addition of IOE to CT
scanning did not improve the detection of peritoneal spread of tumour. In
particular IOE scanning did not effect the appearance of intra-abdominal lymph
nodes or peritoneal seedlings.
All of the patients in this series were premedicated with hydrocortisone. A
small number of patients experienced mild side effects following the IOE
infusion, these were self limiting in all cases. IOE is phagocytosed from the
circulation by macrophages throughout the body, whilst the largest
concentrations of tissue macrophages are in the liver and spleen, smaller
number are present in the lungs and bone marrow. Tissue macrophages digest
the phagocytosed material, present portions of the phagocytosed material at cell
surface receptors complexed with RNA to aid immunological recognition and
via cell surface receptors cause activation of the complement cascade. It is
likely that the latter of these, the non-specific activation of the complement
cascade, may be responsible for a number of patients feeling "flu like"
following the investigation. The reactions to the infusion have been
documented in Chapter 5. The side effects experienced did not limit the use of
the investigation on patients prior to resection. Previous problems with severe
reactions to the contrast agent in 4% of patients (Miller DL, 1984) have not
been apparent when used in the way described above.
Overall IOE scanning was the most accurate (82%) and specific (76%)
preoperative investigation and had the highest predictive value (62%) for the
resectability of tumour. However, if IOE were the only investigation used
prior to resection, 38% of patients would have been subject to laparotomy for
irresectable disease. IOE scanning and DBCT scanning were not
complementary, there was no advantage in performing both investigations.
Neither investigation can detect small-volume extra hepatic intra-abdominal
disease: inability of CT and IOE scanning to detect this type of disease is a
major and apparently insurmountable limitation of these techniques.
These data were collected before CT portography was popularised in Britain
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(Goulet RJ, 1990; Nelson RC, 1990; Matsui O, 1987). CT portography was
not being performed in Edinburgh at the time of this study. Indirect
comparisons between IOE and CT portography have been published and show
very similar levels of accuracy (Goulet RJ, 1990 ). CT portography however,
has a number of potential disadvantages, the need for arterial cannulation, CT
portography is labour intensive in the placement of the arterial catheter requiring
an experienced vascular radiologist. If there are vascular anomalies the catheter
may have to be repositioned during the scan. Finally portography is a dynamic
investigation and is prone to false positive results because of perfusion defects
and flow anomlies within the liver. Further direct comparisons of these two
techniques within a clinical setting will be required to determine which is the
investigation of choice.
A major advantage of IOE scanning is that it can be performed in any radiology
department with access to a CT scanner. The emulsion in its present stage of
development is stable in storage and has few side effects and the administration
of the emulsion requires a minimum of equipment. The technique is robust and
has been used as an experimental tool in our department without problems.
Utilisation of this technique could allow accurate assessment of liver tumours to
be obtained in District General Hospitals with equipment which is already
available and without the need for particular radiological expertise.
IOUSS
In those patients who were subjected to laparotomy, it appeared that
intraoperative ultrasonography was as accurate as the preoperative
investigations in the assessment of hepatic malignancy. IOUSS detected
tumour in a greater number of hepatic segments but this did not reach
significance. IOUSS also gave information as to the exact vascular
involvement and the precise segmental anatomy of each metastases. Of those
patients who appeared to have resectable metastases on IOE scanning, 33% had
irresectable disease, 28% of whom had an intrahepatic component. This
suggests that IOE scanning, though better than USS, still tends to
underestimate the extent of hepatic involvement. Because of the small numbers
of patients these differences did not reach statistical significance.
Intraoperative ultrasonography has a number of advantages over IOE or DBCT
scanning. The ability to accurately assess the vascular relationships of
tumours, the proposed resection margins and to exclude the presence of even
very small occult metastases makes intraoperative ultrasonography imperative
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before, finally committing the patient to a hepatic resection. The major
limitation of IOUSS in the past has been the prerequisite of laparotomy, this
has been superseded by laparoscopic IOUSS. Laparoscopic IOUSS has all of
the advantages of IOUSS without the need for laparotomy.
IOE scanning is the most accurate preoperative investigation prior to hepatic
resection and so could be considered the "Gold Standard" against which any
other techniques can be compared.
Given the considerable advantage of IOE scanning over DBCT, it appeared that
this investigation could be used to more accurately stage the liver involvement
of patients undergoing curative resection of primary colorectal cancer.
Previous data based on operative ultrasonography and/or CT scanning
following curative resection of colorectal cancer ( Finlay IG, 1986: Machi J,
1987: Olsen AK, 1990; Gunven P, 1985; Davies AH 1990) has suggested
that up to 30% of patients have metastases present at the time of operation.
Only a proportion of these are detectable by palpation and the remainder are
occult. IOE scanning could be used to improve the detection of occult
metastases following colonic resection for cancer.
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Chapter V
IOUSS and 1QE scanning in the screening of patients
undergoing resection of colonic malignancy for hepatic
metastases.
.A. Introduction
Accurate staging of colorectal cancer at the time of surgery is important,
particularly as the presence of hepatic metastases is the most powerful
determinant of outcome in the first two years following curative primary
resection (Cady B, 1970; Wagner JS, 1984; Arnaud JP, 1984.). Hepatic
metastases may not be clinically apparent either by pre-operative hepatic
imaging or palpation at operation. Such occult metastases remain as powerful a
factor in the determination of outcome as detectable lesions (Finlay IG, 1983;
1986). Impalpable (occult) metastases may be detected by DBCT or IOUSS
(Finlay IG, 1983; Charnley RM, 1991). and so it is questionable if more
advanced preoperative staging, requiring prolonged hospital stay and incurring
cost, is of value for patients who in any event require a laparotomy for the
treatment of their primary pathology. Such patients may be candidates for
intraoperative staging by IOUSS alone. Although detecting metastatic disease
at the time of operation will not obviate the need for surgery, it may modify the
planned surgical procedure from high risk, radical primary surgery to palliation
with lower risk but incomplete local resection.
IOUSS has been shown to be of value in hepatobiliary practice (Bismuth
H,1987; Makucchi M,1987; Soyer P, 1992; Sheu J-C, 1985; Castaing D,
1985; 1986; Gozzetti G, 1986; Sigal B, 1982; 1983; Igawa S, 1985),
improving the detection of small tumours and guiding resections. Given its
value in our own patients being staged prior to hepatic resection, it would seem
that its use could be extended to the staging of patients with primary colorectal
cancer. IOUSS has been shown to be a sensitive method for the detection of
colorectal metastases (Charnley RM, 1988; 1989; 1990; 1991; Thomas WM,
1987;MachiJ, 1987; 1991; Boldirini G, 1987; Soyer P, 1992; Sugarbaker
PH, 1990; Davies AH, 1990; Stewart PJ, 1993). There are, however, little
data on the long-term outcome for patients who have been staged by IOUSS
(Machi J, 1991). This particularly applies to the rate of appearance of hepatic
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metastases not detected by IOUSS at operation and the outcome of patients
following the detection of very small metastases by IOUSS. Finally, it may be
possible to identify, by IOUSS at the time of their primary colonic surgery,
patients who have hepatic metastases suitable for resection.
In the previous chapter, IOUSS has been shown to be comparable to both
DBCT and IOE scanning in the detection of known hepatic metastases. This
chapter describes a series of patients presenting with primary colorectal cancer
in whom IOUSS and IOE scanning have been used to detect the presence of
hepatic metastases at the time of potentially curative, primary colorectal
surgery. These patients have been followed up by sequential IOE scans to
detect and monitor the growth of metastases present at the time of primary
surgery and the appearance of metastases occult at the time of operation. In
particular, IOUSS and IOE have been evaluated in comparison to palpation at
the time of operation.
.A.l. Aim
This study aims to answer the following questions:
- Can IOUSS be used as part of the routine of laparotomy for patients
undergoing resection of primary colonic carcinoma without morbidity?
- Does IOUSS at the time of operation detect more hepatic metastases than
visualisation and palpation alone?
- Can IOE scanning at the time of operation be used to confirm the findings of
intraoperative ultrasonography?
- Do occult hepatic metastases exist in patients who have been screened by
intraoperative ultrasonography at the time of surgery?
- Can repeated IOE scanning be used to detect occult hepatic metastases in the
follow up period?
- Can IOE scanning be used to follow the growth of hepatic metastases in
patients who are known to have metastases?
- Can repeated IOE scanning be used in the routine follow-up of colorectal
cancer patients to improve survival by the early detection of resectable hepatic
metastases?
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V.A.2. Design
The study was undertaken as a prospective comparison of the three primary
methods of investigation: visualisation and palpation by the operating surgeon,
IOUSS with visualisation and palpation and IOE scanning.
V.A.3. Patients and method
One hundred and fifty five patients, presenting with a diagnosis of colorectal
cancer to two hospitals in the Edinburgh area between 1st of April 1990 and
31st March 1992, were eligible for entry into the study. Eight consultants in
the Royal Infirmary of Edinburgh and the Eastern General Hospital, agreed to
their patients being followed up within the study protocol. There were 78
males and 77 females with a median age of 70 years ( range 37-93 years ).
V.A.3.a. Consent and recruitment
Each patient was interviewed prior to surgery and given a written description of
the study detailing their involvement. They were then asked to give informed,
written consent to each part of the study. Patients having emergency as well as
elective operations were included. Since the principle investigator (WFAM)
was required to be present at two hospitals, it was not possible to include all
potential patients in the study and some were missed as operations were being
performed simultaneously at the two separate sites.
The only primary exclusion criteria was that of non consent. Patients were able
to withdraw from the study at their own request or at the request of their
consultant. In some emergency cases, the intra-operative ultrasound scan was
performed at the request of the consultant prior to interviewing the patient. The
study protocol, consent forms and information documents were approved by
the local hospital ethical committee and the consultants whose patients were
included in the study.
V.A.3.b. Protocol
Patients presenting with findings on history, clinical examination, double
contrast barium enema or colonoscopy, diagnostic of colorectal cancer, were
interviewed. A further full history and examination was undertaken. Patients
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conseated in writing to all or part of the study and the consultant in charge was
informed. IOUSS was performed at the time of laparotomy for resection of the
primary colorectal cancer following the technique described in chapter 3. The
operative findings and the findings of the intraoperative ultrasonography were
recorded on a database proforma (appendix 5). The patients' postoperative
course was recorded together with their date of discharge. An IOE scan was
undertaken within six weeks of the patients' primary surgery. Patients
continued to be followed up in the regular outpatient clinic of the consultant
who had performed their operation. Repeat IOE scans were undertaken on a 6
monthly basis for 18 months. When the patients had undergone a total of four
IOE scans, they were thanked by letter and discharged from the study (Fig 1.).
After each of the IOE scans, a discharge summary giving the results of the scan
was sent to the consultant in charge and to the patients' general practitioner.









IOE scan at 6 months
IOE scan at 12 months J
IOE scan at 18 months f
V Discharge from follow-up J
Fig I. Algorithm of investigation for patients with colorectal cancer within the
IOE study protocol.
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V.A.3.C. Preoperative investigation
The following investigations were undertaken in the preoperative period: full
blood count, serum urea and electrolytes, bilirubin, alanine aminotransferase,
alkaline phosphatase, gamma gultamyl transferase, carcinoembryonic antigen,
CXR, electrocardiogram, sigmoidoscopy or colonoscopy and biopsy, double
contrast barium enema examination and abdominal ultrasonography, where
appropriate and as arranged by the patients' consultant.
V.A.3.d. Operative data collection
Each operation was witnessed and recorded by the principle investigator
(WFAM). Prior to intra-operative ultrasonography of the liver, the surgeon
was asked to examine the liver, both visually and by bimanual palpation, for
the presence of metastases. He was then asked to describe the size, position
and nature of any masses that he could detect and this information was
recorded. Bimanual palpation and intraoperative ultrasonography were then
undertaken as a combined procedure by WFAM. This examination was carried
out in the manner described previously (chapter III) without extension of the
laparotomy wound. Where possible, and within the constraints of their site,
lesions detected were biopsied. Biopsy was not undertaken within the trial
protocol where it could not be performed without extension of the laparotomy
wound, or mobilisation of the liver. The results were recorded and thermal
image pictures taken of any lesion seen.
In a small number of patients, the consultant in charge of the operation decided
to extend the laparotomy wound or to mobilise the liver in order to obtain
biopsies of lesions detected. WFAM assisted in the biopsy of these lesions
when requested. In cases where there were a number of metastases of similar
appearance, a biopsy was only taken of one lesion and not of every separate
metastasis.
Each metastasis found was identified with relation to its segmental anatomy.
The position and size of a maximum of 10 metastases were noted, after which
only the 10 largest separate lesions were noted. In a number of patients it was
not possible to differentiate discreet metastases as large areas of the liver were
completely replaced with tumour. All cysts and haemangiomas were similarly
documented. In cases where the nature of a cyst was in doubt it was aspirated
and the contents subjected to pathological investigation.
V.A.3.e. Post operative data collection
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The patients post operative course was recorded with regard to their in-hospital
stay, complications and in particular any intra-abdominal collections or
infections related to the liver. A repeat serum CEA was also measured on the
10th post operative day. The patients who had intraoperative ultrasonographic
examination of the liver and an IOE scan of the liver in the immediate post
operative period were offered a further IOE scan every six months for the
subsequent 18 months.
Any patient who declined to undergo a follow up IOE scan was requested to
undergo a single CT scan in the follow up period. Those who did not have any
further scans were followed as far as possible for 18 months after their
operation by telephone interview, review of the case notes and through contact
with their general practitioner.
V.A.3.f. IOE scanning
The patients were monitored by a senior research nurse (JC) during the period
of the IOE infusion and scanning. Pulse, blood pressure and temperature
were measured at 15 minute intervals during the infusion and every thirty
minutes for the following three hours. At each IOE scan appointment, blood
was taken for full blood count, urea and electrolytes, alanine amino
transferase, alkaline phosphatase gamma glutamyl transferase, bilirubin, and
CEA. The data from each examination was entered into the database .
V.A.3.g. Follow up IOE scanning
All of the patients who were followed up had undergone potentially curative
primary surgery. A number of patients were known to have hepatic disease but
this did not exclude them from the study. After the initial IOE scan patients
were called back to the radiology department at 3 monthly intervals for alternate
upper abdominal ultrasonography and IOE scanning (Fig 2 ) noting the size
and site of each metastases.
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Algorithm for IOE
follow up
Admission to the study
Follow up no metastases Follow up with metastases
Repeat I.O.E. scans, USS,






Fig 2 Algorithm for the follow up of patients hy IOE scanning and
ultrasonography.
Patients were excluded from follow up if they failed to attend for follow up or if
they were too unwell to continue in the study.
V.A.3.h. Pathological staging
The colonic tumours, once resected, were sent for pathological assessment and
reported using the Dukes staging technique, as described in chapter I
V.A.3.i. Definition of metastases
The size and site of each lesion identified was recorded, for each investigation,
onto the database. The presence of a metastasis was confirmed if the lesion
was apparent on two independent investigations (palpation, IOUSS, IOE
scanning or by positive pathology). During the follow up period the presence
of metastases was confirmed by the same criteria, or one of the above plus a
rising serum CEA in the absence of local recurrence. In cases where a lesion
was identified on the original examination and then "disappeared" on
subsequent imaging the evidence was examined critically and a decision made
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as to the presence or absence of metastases. This gave an agreed final stage for
each patient. Calculation of the accuracy of each investigation has been made
in comparison to this agreed final stage.
V.A.3.i. Statistical methods
All of the analysis has been performed using 'Statview SE + Graphics' and
dBase III plus programs written by WFAM. Direct comparisons between two
groups of discreet variables have been made using the Chi sq test of
significance. Where appropriate, non parametric methods of analysis have
been used ( Mann-Whitney U test orWilcoxon ranked sign test).
Box and whisker plots have been used to compare groups graphically, with the
whiskers at the 10th and 90th percentile and the box containing the first to third
quartile, the median being marked by a transection of the box. Bar charts and
line graphs have also been used to display data.
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V.B. Results
V.B.I. Preoperative data collection
There were 155 patients who presented between April 1990 and March 1992,
with a median age of 70 years ( range 37 - 93); 79 of these were male. Not all
of the patients were submitted to all of the proposed preoperative investigations
(Table 1).









Total number of patients 155
Table 1. Preoperative investigation of 155 patients having laparotomy prior to
IOUSS and IOE scanning
Elevation of serum CEA was used to confirm the presence of hepatic
metastases. There was only one patient in the series with a single positive IOE
scan in whom the preoperative CEA was normal (indicating tumour which did
not produce CEA). In this patient (number 14), although, the first
postoperative IOE scan was positive, the subsequent three IOE scans were
negative. This patient was confirmed not to have metastases on the outcome of
repeated IOE scans and not on the CEA level which was an unreliable indicator
of disease in this case.
V.B.2. Non consent
Eighty three of 155 patients who had intra-operative ultrasonography performed
did not undergo an IOE scan. Their mean age was 72 years ( range 37- 93
years ), and included 34 men. Of the 83, eight had wide-spread incurable
local and hepatic metastatic disease. These patients were considered too unwell
by their consultant to be subjected to an IOE scan. Four of these patients died
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in the early post operative period. There were a further 34 patients who had
widespread disease without hepatic metastases in whom their consultant felt that
further investigation would be inappropriate. The remaining 41 patients
declined to take part in the study for personal reasons having had the protocol
explained verbally and in writing. The primary reasons varied and included a
desire that they not be submitted to any further intervention, or spend any more
time in hospital. In the case of patients from the Eastern General Hospital,
they did not want to go into another hospital (The Royal Infirmary of
Edinburgh) for their IOE scan. In 13 patients, the medical staff informed the
patients that their cancers had been "cured" and they refused to take part in the
study because they felt the detection of metastases could not apply to them.
With the consent of the consultants, those of the 83 who survived the first post
operative year were offered a single DBCT scan. Only eight patients agreed to
this investigation.
The design of the study required patients to be called in for USS of the liver in
between IOE scans. This part of the study was discontinued after 48 USS
scans had been performed on 38 patients because of lack of resources in the X-
ray department and complaints from the patients that they were being called
back to the hospital too frequently. There were 7 patients with a positive
examination in this small group, 5 of whom had positive IOUSS and IOE
scans. Fourteen patients in the group had final confirmation of metastases (Fig
3, Table 2).
Number of patients having
USS
38
Positive investigation Negative investigation
7 .31
Confirmed positive False positive False negative Confirmed negative
5 2 9 22
Fig 3. 38 patients who had a USS during the follow up period. The result of the
final USS in each patient has been consideredfor the calculation ofstatistics.




Positive predictive value 71%
Negative predictive value 71%
Overall accuracy ■ 1 71%
Table 2. Accuracy of USS in the detection ofmetastases in patients during
follow up after curative resection ofcolorectal cancer.
V.B.2.a. Patients within the study
Only those patients who had both an IOE scan and an IOUSS are considered in
the remainder of this chapter. A full analysis of all patients who had an IOUSS
is undertaken in chapter VI.
.C. Patients having IOUSS and follow up by multiple IOE
scans
Seventy two patients had both an intraoperative ultrasound examination and an
IOE scan. On pathological examination of the resected specimen, the primary
cancer was found to be of gastric origin in one patient and pancreatic in another.
Of the 70 patients remaining to be studied, the median age was 67 years (range
43-88 years) and 46 were men.
V.C.I. IOUSS scanning
IOUSS detected metastases in 16 of the 70 patients whose pathology was
confirmed during follow up (Table 3)
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Patient Ml M2 M3 M4 M5
7 V VI
12 V





64 IV III II
82 VI







Table 3. Metastases detected by Intra-operative ultrasonography in patients
who had evidence ofmetastases on their subsequent IOE scans. The segments
involved are indicated by the roman numerals l-Vlll
Three patients who had metastases present on initial intra-operative ultrasound
scan but not on the initial IOE scan went on to develop metastases detectable by
IOE scanning in the follow up period (patient numbers 12, 111, 113). A
fourth, patient 141, had a negative postoperative IOE scan. At operation this
patient had a palpable mass in segment V the presence of which was confirmed
by IOUSS. The scan also revealed a large number (more than 10) of small
metastases spread throughout the liver. The patient, who was well with no
evidence of recurrence and with a serum CEA level of < 30u/l at the second
IOE scan 12 months after surgery, defaulted from further follow-up within the
study. The patient was subsequently admitted and died with hepatic metastases
36 months after surgery.
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Number of patients having
IOUSS
70
Positive investigation Negative investigation
16 .54
St
Confirmed positive False positive False negative Confirmed negative
16 0 3 51
Fig 4 The results of IOUSS in the detection of metastases at the time of
operation. There were 3 patients who had no evidence ofmetastases on their
IOUSS who went on to develop metastases in the follow up period. These are
false negative investigations for IOUSS.
Of the remaining 56 patients, 3 went on to develop metastases in the follow up
period; these patients were false negative results for IOUSS (Fig 4). A brief
summary of each of these patients is given at the end of the chapter detailing the
site and size of the metastases revealed by palpation, intraoperative
ultrasonography, IOE scanning and the reasoning behind the agreed final
staging. The overall sensitivity and specificity for IOUSS compared to the




Positive predictive value 100%
Negative predictive value 94%
Overall accuracy 96%
Table 4. Accuracy of IOUSS compared to the agreed final stage, in the
detection ofhepatic metastases for 70 patients who had at least one IOE scan
following laparotomy.
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V.C.2. IOE scanning
Each patient had a single IOE scan within 6 weeks of the day of surgery and
subsequent scans every six months until they had a total of 4 scans or defaulted
from the study.
V.C.2.a. IOE Administration
Patients did not display any haemodynamic instability either during the infusion
or during the subsequent scanning. The results of these measurements (Table
5) show no significant change in any of the vital signs. Thirty percent of
patients complained of one or more of the following: metallic taste in the
mouth, nausea, "flu" like feeling and mild rigors. Six patients had a more
marked reaction to the examination consisting of conjunctivitis, rhinorrhoea
and headache. These reactions were all self-limiting and resolved completely
within 24 hours of the infusion. There was no evidence of sensitisation in any
of the patients receiving multiple IOE infusions and the severity of the adverse
reactions of rhinorrhoea etc. did not increase with subsequent infusions.
Two patients had reactions related to the co-administration of Niopam 300
following the infusion of the IOE. The Niopam infusion was not part of the
study protocol and was made under the direction of the radiologist performing
the IOE scan in an attempt to outline the renal tracts. Both of these patients had
moderate angioneurotic oedema of the lips and eyelids associated with
rhinorrhoea and headache. This was terminated by the injection of 10 mg of
chlorpheniramine BP. Neither of these patients had any evidence of
cardiovascular instability. Both were observed overnight and discharged well
the following day. These two patients were excluded from further
investigation as the exact nature of the reaction was unknown. They were not
skin tested for sensitisation.
Parameter Mean Mean Significance
pre-infusion post-infusion
Temp °C 36.5 36.6 NS
Pulse Beats/Minute 72.4 73.6 NS
BP mm/Hg 132 147 NS
Table 5. Pre and post-infusion of IOE . Temp in degrees centigrade Pulse
in beats per minute and BP = mean systolic blood pressure in mm/Hg
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There were no exclusions from the trial because of reaction to the IOE emulsion
in the patients who followed the trial protocol.
V.C.3. Detection of metastases by IOE scanning at the time of
operation
Of the 70 patients, 16 had lesions identified on their initial IOE scan ( Table 6)
Patient LI L2 L3 L4 L5
7 IV V
14 V
16 V VI VIII
17 V VIII II IV
18 VIII
25 VII II VI V VIII
26 II VIII
36 IV V VIII
57 V







Table 6. Lesions detected by the first postoperative IOE scan. These are
identified by a number (LI, L2 ,L5 ) and segment (I, II, ..VIII).
Lesions had been detected in 12 of these patients by IOUSS (Table 3). In 4
patients (patient numbers 14, 16, 36, 85), the lesions identified by IOE
scanning were not confirmed by IOUSS. There was concordance for the
number of metastases per patient in 5 cases and concordance of the site of
metastases for 8 of 37 possible metastases.
Of the patients who had evidence of metastases on their first postoperative 10E
scan and no evidence of metastases on their IOUSS, three went on to have IOE
scans in the follow up period (patient numbers 14, 16, 85). None of these
showed any evidence of metastases after a minimum of 18 months follow up,
confirming these to be false positive investigations. The fourth patient (number
36) who had evidence of cysts on IOUSS, left the study after the first IOE scan
and was alive and well with no overt evidence of hepatic metastases at the close
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of the study.
Three patients who had a negative IOUSS developed metastases during follow
up (patient numbers 3, 99, 106), giving a total of 19 out of 70 patients with
metastases by the end of the follow up period.
There were 11 patients in whom the first IOE scan was negative, and one
subsequent scan, in the follow up period, was positive without confirmation
of metastatic disease. These patients represent false positive investigations for
IOE scanning. In patients 80 and 139, the second IOE scan was positive;
however the CEA remained normal and so the positive scan result was not
confirmed. These two patients had no further scans and remained well at the
close of the study. The second IOE scan for patient 35 was positive but the
third scan was negative. This patient did not have a fourth scan but was alive
and well at the close of the study. Patients 4, 25, 31, 33 had a positive result
for the second IOE scan followed by 2 further negative scans. Patient 137 had
a positive third scan not supported by any other positive investigation and did
not have a fourth scan. Patient 1 l's third scan was positive and the fourth
negative; there was no other evidence of metastases. In patients 24 and 72, the
final IOE scan was positive but not supported by any other investigation. All
of these scan results are false positive investigations for IOE scanning.
V.C.3.a. Accuracy of IOE scanning
As a number of patients had more than one IOE scan, the total number of scans
is greater than the number of patients. In order to gain a true representation of
the accuracy of the investigation the analysis is based on the total number of
scans performed (Fig 5 ). Some patients have had both positive and negative
investigations during their follow up.
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False negative True negative
8 1 145
Fig 5. Breakdown of the results of 195 IOE scans performed in the series.
A total of 195 IOE scans have been performed. Of these there were 27 true
positive scans, 145 true negative, 15 false positive and 8 false negative. The
sensitivity, specificity, positive predictive value, negative predictive value and





Positive predictive value 64%
Negative predictive value 95%
Overall accuracy 88%
Table 7. The accuracy ofIOE scanning overall for 195 investigations .
In Table 8, the specificity and accuracy of IOE scanning has been calculated for
each of the follow up periods. The subsequent scans were reported in
comparison to the earlier scans. However, the level of accuracy of IOE
scanning remained constant throughout the series. In three patients, small
lesions were detected on IOUSS but not on the first IOE scan. These lesions
were all less than 15 mm in diameter and lay in segments V or VI. In each case
there was only one metastasis and its presence was confirmed by subsequent
IOE scans. There was only one patient (number 36 ) who had a positive IOE
scan within 12 weeks of a negative IOUSS and no subsequent follow up. This
Chapter V IOUSS and IOEscanning before resection 123
patient had three cysts on IOUSS and the positive IOE scan reported three
metastases which were spherical and of uniform density. It is very likely that
these 'metastases' were in fact cysts. This patient died before the next IOE
scan with advanced local disease.
Figures expressed as percentages
Parameter IOUSS IOE-1 IOE-2 IOE-3 1 IOE-4 IOE-A11
# of scans 70 70 52 42 31 195
Sensitivity 81 76 82 71 80 77
Specificity 100 93 84 94 92 91
PPV 100 76 56 71 67 64
NPV 93 93 95 94 96 95
Accuracy 94 89 83 91 90 88
Table 8. The accuracy of IOE scanning does not improve with the number of
repeat scans .
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Patient # Palpation Intra-op USS IOE scan
7 V(60), VI( 15) V(60), VI(15) IV(40), V(5)
17 11(20), VI 1(5),
V/VIII(35)










26 11(10) 11(14) 11(10), 11(10)
57 11(10) V(100) V(IOO)





82 0 VI(10) 16 other small
mets
IV(8),VI(8)
89 0 111(6), I V (7),
V(8)
VI1(8)
90 0 VI(35), VIII(40) VI(20), VII(25)
108 0 VII(20) VI(20)
154 0 IV(15) IV(30), V(30)
Patients with metastases on IOUSS and follow up IOE
12 0 V(12) VIII(IO)
111 VI(15) VI(15) 11(10), IV( 13),
IV(4), V(4)
113 0 VI(10) VI(10), VIII(IO)




Table 9. The results ofpalpation , intra-operative ultrasonography and 10E
scanning. Numbers in () represent size ofmetastases in mm, the affected
segment is depicted by roman numerals I VIII.
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V.C.4. Palpation
At operation, the surgeon felt that he could detect metastases by palpation in 15
patients; the presence of metastases was confirmed in 8 (Table 9 ). The
remaining 7 were false positive results for palpation. In 55 patients, the
surgeon could not detect any metastases, 44 of these patients had no evidence
of metastases at the conclusion of the study. The remaining 11 had the









False negative True negative
11 44
Fig 6 Breakdown of the results ofpalpation in 70 patients laparotomised for




Positive predictive value 53%
Negative predictive value 80%
Overall accuracy 74%
Table 10. The overall accuracy ofpalpation ofthe liverfor hepatic metastases
at the time ofcurative primary resection ofcolorectal cancer.
Palpation was less accurate than the initial IOE scan (Chi sq = 2.13 ldf, p >
0.1) and significantly less accurate than IOUSS (Chi sq = 12.67 ldf, p <
0.001) and overall IOE scan (Chi sq = 7.63 ldf, p < 0.01) in the determination
of the presence or absence of hepatic metastases (Chi sq calculated from a four
fold table comparing the total of the true results and the total of the false results
for each investigation).
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V.C.5. Comparison of number, site and size.
There were 12 patients who had metastases on both their intra-operative
ultrasound scan and on their initial IOE scan, and a further 3 who developed
positive IOE scans in the follow up after a positive IOUSS at operation. The
reported site and the size of metastases showed considerable variation (Table
9.).
There were 6 patients with metastases who also had either cysts or












Table 11. The incidence of cysts and haemangiomas in patients who had
hepatic metastases.
These lesions were identified by their appearance on IOUSS alone. The benign
nature of these lesions has been confirmed in the follow up period, in particular
the presence of multiple cysts. Although cysts can mimic metastases on IOE
scanning, their appearance on IOUSS is distinct and quite different from solid
metastases. Malignant cysts were present in one patient (number 25); of seven
lesions present one was recognised as being malignant as it contained multiple
internal septa, debris and a solid component. It is possible that all of the other
lesions present in this patient were also malignant cysts in an earlier stage of
development.
Haemangiomas were identified by their IOUSS appearance alone and were not
confirmed by unenhanced and DBCT scanning.
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V.C.5.a. Follow-up IOE scans
Of the 70 patients who underwent an initial IOE scan, 52 returned for a second,
42 for a third and 31 for the final scan.
Sixteen of the 70 patients entered the study having had hepatic metastases
demonstrated by IOUSS. Ten of these had 2 scans performed, 5 had three
scans and 3 had four scans. IOE scanning was used fo monitor the increase in
size of the metastases with time, and the appearance of new metastases in these
patients.
V.C.5.b. Development of metastases
Three patients developed metastases in the follow up period (numbers 3, 99
and 106). All three IOE scans in the follow up period positive for patient 3.
Patient 99 had the third and fourth scans positive. Patient 106 only had one
scan in the post operative period and this was positive, CEA estimation at this
time was raised at 182 u/1.
V.C.6. Growth of metastases
There were 10 metastases which were monitored over a period of time and from
which growth rates could be calculated. There was consistent rapid growth in
5 of the 10 metastases. In 2 there was no growth or very slow growth and in
the remaining 3 there was static disease or reduction in size of the metastases.
In the patients who showed rapid growth of disease there was no obvious
stabilisation of the rate of growth. (Fig 7 )










IOUSS IOE-1 IOE-2 IOE-3
Fig 7. Growth of 5 metastases in patients who displayed growth of
metastases associated with decline in clinical condition and death. None of
these patients survived to have 4 IOE scans
The rate of growth for the remaining 5 metastases show a mixture of growth
and remission with some lesions disappearing altogether. This was an
unexpected finding in patients who were not receiving any form of adjuvant
therapy. The apparent resolution was complete in 1 patient, the remainder
showed either reduction in size or fluctuations with no real increase over the
period of follow up (Fig 8 Plate 1, 2, 3, 4) .
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Fig 8. The rate ofgrowth ofmetastases in some patients slow or static. All of
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Plate I. Normal IOE scan .
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T.n: 1.25
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Plate 2 . Six months after plate 1 there is a small area of low uptake in
segment VI.
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Plate 3 The area of low attenuation is increasing in size.
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Plate 4. There is now a clearly defined area of low uptake in segment 6. This
was associated with a rise in serum CEA.
V.C.6.a. Resection
Only one patient in this group, with a resectable lesion, was identified. This
46 year old man was found to have a single metastasis in segment V by
intraoperative ultrasonography. He received adjuvant chemotherapy with 5
flurouracil and folinic acid in the postoperative period and had two IOE scans
and a laparoscopic ultrasound examination which confirmed the presence of the
lesion in segment V. Resection of this revealed only nodular hyperplasia with
no evidence of residual tumour cells. This patient died with widespread
metastatic disease 2 years after his hepatic resection.
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• D. Discussion
IOUSS can be performed at the time of laparotomy for primary colorectal cancer
and is a practical method of examining the liver without causing morbidity.
The examination adds little to the operation time (5 mins) and has no recurrent
cost. The equipment available is robust and easy to use.
IOUSS and palpation
IOUSS at the time of primary colorectal surgery detected significantly more
metastases than visualisation and palpation alone. This finding is in
concordance with those of others ( Machi J, 1987; 1991; Charnley RM 1991).
IOUSS correctly determined the presence or absence of metastases in 67 of 70
patients compared to 52 of 70 for visualisation and palpation. IOUSS was also
more accurate than the initial IOE scan: 67 of 70 compared to 59 of 70 (Chi sq =
5.08 ldf, p < 0.05).
Confirmation by IOE scanning
There were 3 patients in whom immediate post operative IOE scanning failed to
detect metastases which were apparent at the time of operation by IOUSS.
These metastases appeared on subsequent IOE scans, suggesting that the
lesions had increased in size or that IOE scan reporting was more accurate when
a number of previous scans could be compared to the current scan. As the
criteria for scan reporting included a number of comparative statements (to
previous scans) it was expected that the accuracy of the scan reports would
increase with the number of scans undertaken, this was not the case. The
accuracy rate remained between 83% and 91% throughout the series. Repeated
IOE scanning in the follow-up period can be used to confirm the results of
IOUSS and in this series eventually detected all of the lesions seen by IOUSS at
operation. There was no significant difference in the accuracy of IOUSS and
the overall accuracy of IOE scanning in the 70 patients (Chi sq 3.28 ldf, p >
0.05)
V.D. 1. Minimum size for detection by IOUSS
There were lesions present at the time of operation which were not detected by
IOUSS. This may have been either because of an error in performing the scan,
or because the lesion was not detectable by virtue of its echogenicity or its size
or both of these factors. The exact minimum size for detection of a metastases
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is unclear. One very small lesion (4mm) was detected and proven by biopsy.
Previous studies using cadaveric material (Charnley 1988) have shown that 2
mm highly echogenic foci, created by injection of gelatine into the hepatic
vasculature, could be detected by a 7.5 MHz probe. Lesions smaller than this
were not detected. IOUSS scanning detected all lesions which were
subsequently detected on the first IOE scan and a number which appeared on
later scans, suggesting that IOUSS could detect metastases at a smaller size
than IOE scanning. There was considerable inconsistency between the size of
lesions reported by both investigations (Table 9). This may account for some
of the smaller lesions being undetected by IOE.
Repeat IOE scanning in follow-up
Technically, repeated IOE scanning can be used in the follow-up of patients
with colorectal cancer. Patients do not become sensitised to repeated infusions
of the contrast agent and the enhancement is maintained in subsequent scans.
There is no evidence of accumulation of IOE in the livers of the subjects
following repeated scanning at 6 monthly intervals and there is no evidence of
any other longer term ill effects of the technique within the study period.
It was however very difficult to recruit patients into this type of follow up and
the refusal rate was high. The principle factors were; a genuine wish to escape
the clinical environment of the hospital, denial of the possibility that the cancer
might return (sometimes fuelled by the attendant medical staff), a wish to avoid
further injections, the side effects of the IOE infusion and finally within the trial
patients from the EGH did not wish to come to the RIE for the IOE scan.
Although the reporting of side effects was low it is possible some of the 56% of
patients who defaulted over the 18 months of the trial did so because of side
effects which they failed to report.
Benign lesions on IOE scan
IOE scanning may not readily detect the differences between cysts and small
metastases. The incorrect diagnosis of cysts as metastases increased the false
positive rate for IOE scanning in the detection of metastases. The presence of a
cyst may be inferred by the lesion having a perfectly smooth outline and an
amorphous centre, however as the lesions become smaller so it becomes more
difficult to make this distinction. It was not possible to differentiate small cysts
from metastases by IOE scanning. There is no published data describing the
detection of cysts by IOE scanning. For the same reasons haemangiomas
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cannot-be differentiated from metastases by IOE scanning. They can however
be demonstrated by bolus injection of contrast during normal CT scanning. A
problem remains how to select patients to have both IOE scanning and DBCT
scanning as there may be no indication from the IOE scan that the lesion in
question is in fact a haemangioma. DBCT scanning may not be performed at
the same time as IOE scanning. When this was performed outside the study
protocol in two patients they both suffered reactions which required hospital
admission and treatment. The accurate detection of both cysts and
haemangiomas is an advantage of IOUSS over IOE scanning.
Growth of metastases
IOE scanning was used to monitor the growth of metastases in patients with
time. This has identified two groups of patients: those who have rapidly
expanding lesions, which behave as expected, and those in whom the
metastases are more indolent. In patients displaying growth, IOE scanning
was able to detect the same metastases on sequential scans and comparisons of
size could be made. This only occurred for 5 individual metastases in the entire
series. In a further 5 metastases, there was sporadic growth and resolution
leading to fluctuation, rather than a steady increase in size. There are a number
of possible explanations for this: the apparent metastases which did not grow
were not in fact metastases but some other lesions or that some tumours were
very slow growing where others were very aggressive, or the suppression of
growth was brought about by the repeated infusion of IOE. Each of the 3
patients with indolent growth had other factors to suggest that the lesions in
question were metastases.
Growth rates for metastases can very greatly ( Finlay IG, 1988). Finlay gives
no detail of the type of enhancement used and the tabulated data had been
subjected to a complex conversion to attempt to estimate the volume of the
tumours assuming that they were ellipsoid and not spherical. Unfortunately
this makes it very difficult to calculate the diameter of the metastases, although
the smallest had a total cell number of 3.8 x 108. A previous paper from the
same author ( Finlay IG, 1983) gave the number of cells / gram of tissue as 1 x
109 Assuming the same conversion factor, this would give a mass of 380 mg
or a volume of 380 mm3 assuming a tissue density of approximately 1 gram /
cm3. A spherical metastases of this volume would have a diameter of
approximately 9 mm. The author has stated that metastases smaller that 1.5 cm
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diameter appeared to be ellipsoid on the scans. Lesions of 1-1.5 cm diameter
are at the limit of resolution for a scanner of the type used in this study. The
columnation used was 13 mm; i.e. the scanner compiled information on the
radio density of tissues from a slice 13 mm thick, at 1.5 cm intervals. Using
this type of setting, small lesions only take up part of the thickness of the scan.
The area of low attenuation is a composite of information from different areas of
the metastasis. In particular the apparent diameter' of the same metastases may
vary considerably depending on where in the plane of scan happens to fall in
relation to its equator. There is little to support the hypothesis that, when less
than 1cm in diameter, metastases are ellipsoids which become spherical when
they reach a diameter of 1.5cm. In papers which have reprints of actual scans,
there is no evidence to show that small lesions are ellipsoids (Alderson PO,
1983; Adson MA, 1984; Rifkin MD,1987; Brower ST,1989; Goulet RJ, 1990;
RavikumarTS, 1987; Olsen AK, 1990; Castaing D, 1986; ParkerGA, 1989;
Bismuth H,1987; Boldrini G,1987; Clarke MP, 1989) Pathological evidence
from resected specimens in the series of patients reported in chapter 4 have
shown small metastases to be spherical or near spherical the appearance of
apparent ellipsoid lesions is likely to represent artefact. This study has reported
the diameter of small lesions on CT and IOE scans using 10 mm columnation at
10 mm intervals to scan the entire liver and with breath holding to eliminate
respiratory movement. The diameter of lesions seen on IOE scanning is an
inevitable approximation which becomes more accurate as the lesion increases
in size. For this reason accurate measurement of metastases is not possible
using these settings when the maximum diameter is approaching 1 cm.
V.D. 1 .a. Partial volume effect
Partial volume effect occurs when the diameter of the metastases is smaller than
the columnation width of the CT scan. As the size of the metastasis approaches
the beam columnation width, only part of the beam crosses the maximum
diameter of the metastasis. The remainder of the beam passes through a section
of the metastasis of smaller diameter or misses the metastasis altogether. This
causes blurring of the margin of the metastasis on the scan (Fig 9). The partial
volume effect can be compensated for to some degree by altering the gate setting
of the CT scanner. Gating allows the range of grey from black to white seen
on the CT image to be adjusted to correspond to a particular level of X-ray
signal attenuation. This has an effect similar to adjusting the contrast on a TV
picture. However, measurement of lesions which approach the columnation
width of the scanner includes a substantial error.
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1.3 cm
Fig 9. As the size ofa metastases approaches the columnation setting of the
CT scanner it becomes more difficult to accurately measure its diameter.
Patients in our series who had large (greater than 1.5 cm) metastases all
displayed growth. The small metastases in patient 113 appeared to decrease in
size and one metastasis disappeared altogether. These were at the lower limit
of resolution for IOE scanning. It is likely that the apparent disappearance of a
lesion and its subsequent reappearance represents a failure of detection rather
than a biological event. Patient 82 was found to have 14 small ( about 1 cm )
metastases on palpation and IOUSS; not all of these were detected by IOE
scanning because they were too small. Furthermore, if there is little or no
normal liver present the technique will fail as IOE uptake only occurs in normal
liver parenchyma. Liver function tests are unfortunately a poor indicator of
the degree of liver replacement and may be normal in patients with more than
80% replacement (McGarrity TJ, 1987).
IOE scanning reduces the partial volume effect to some degree. The greater the
contrast between areas of normal liver and the metastases, the clearer the
margins. However, the measurement of diameter of lesions approaching the
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limit of resolution of the technique will include an unavoidable random error.
This error is magnified by attempting to calculate volumes from the scans.
V.D. 1 ,b. Resectable disease.
From these data it is apparent that the growth of some metastases can be
detected and followed by the use of repeated IOE scanning. In chapter III,
IOE scanning was shown to be more accurate in the detection of metastases than
DBCT and is the investigation of choice. At the time of operation, IOUSS
with palpation was marginally more accurate in the detection of metastases than
IOE scanning, but failed to detect very small and microscopic metastases that
were present. These occult metastases missed by IOUSS were detected in the
follow up period by IOE scanning. In this series these small metastases have
continued to appear throughout the follow up period. Published data shows
that 80 % of hepatic metastases will be apparent within the first 24 months of
surgery (Finlay IG, 1983; Machi J, 1991).
There was no evidence to suggest that scanning in the postoperative period
identified patients with more aggressive disease, although in this series the
appearance of hepatic metastases heralded a rapid decline in clinical condition in
some patients and was associated with rapid and continued growth of the
metastases until death. Others patients were in a more stable state in terms of
growth and survived to the end of the study. This would suggest that patients
with slowly progressive disease might have a survival advantage. Slow
growth of the metastases will also increase the lag time from operation to the
detection of occult metastases (by routine clinical follow-up) in the general
population of patients following colorectal surgery. Might such a delay
indicate a better prognosis? Review of the data in chapter III suggests not and
reveals that the duration of lag time (the time between primary resection of a
colorectal cancer and the appearance of a metastasis, detected by either
abdominal ultrasound or DBCT scanning) was not related to the presence of
resectable disease or therefore prognosis.
The series of patients having repeated IOE scans is small and there were only 2
patients who had resection of their metastases (3%); less than other series
(Coppa GF, 1985; Sugarbaker PH, 1976). There are no published data
relating to the detection rate of hepatic metastases in Scotland or the rate of
referral for resection. It would appear from the crude data (the number of
patients presenting with colorectal cancer per annum in Scotland is 2700) and
the results given in chapter IV, that 81 patients per annum should have
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resectable hepatic metastases, 24 of whom (30%) would expect to have survive
for 5 years if resected. We detected only two patients within the first 2 years
of follow-up, both of whom died with recurrent disease following hepatic
resection. It is possible that other patients in the series may develop resectable
metastases in the future and undergo successful resection.
In order to select patients who would be suitable for hepatic resection, it is
necessary to have 2 IOE scans with a period of 3 months inbetween. Rapid
growth of the metastasis or appearance of more metastases during this time
would prejudice against resection. Patients who display slow growing or
static disease are more likely to undergo resection. Their improved survival
after resection may be a reflection of the more indolent nature of their disease.
To select patients in this manner reduces the number who undergo a technically
successful resection only to succumb to recurrent disease in the following 5
years. Without a prospective trial it is not possible to say if it is the resection or
the selection which improves survival. Historical data, however, supports the
view that patients with hepatic metastases who do not undergo resection have a
negligible 5 year survival (Wagner JS, 1984; Cady B,1970; Arnaud JP, 1984;
Bengmark S,1969; Scheele J,1991)
Computer enhanced tomography has become the mainstay investigation in the
detection and accurate delineation of hepatic tumours in the past decade.
Advances in the technology of image capture and in the processing power of
computers has improved the quality of the images available for reporting. The
need for even greater resolution in hepatic imaging, to detect the small
metastases from colorectal cancers has led to the development of contrast agents
that improve the detection of intrahepatic malignancy. IOE scanning is one of
the few successful techniques that has been developed to enhance hepatic CT
scans looking for hepatic malignancy. Its major advantages are its ease of
preparation, administration, the quality of the images obtained and its
repeatability. This is weighed against the limited side-effects and its cost.
Although 30 % of our patients had some form of mild reaction to the scan it did
not cause distress nor were side effects cited as a reason for refusing further
scans in the follow up period.
At the time of surgery patients response to invitation to further investigations
was dependent to a large degree on the information they had been given and
their perception of their disease. Patients who knew and understood that they
had a malignant disease which could spread, generally agreed to the study on
the grounds that early detection of recurrent disease would be to their benefit.
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In particular patients in whom IOUSS and palpation had suggested metastases,
and who were not too unwell to undergo further investigation, agreed to the
study. Those who did not agree were generally patients who had been told that
their "blockage" had been removed. Some patients did not know that they had
had a cancer and others had been informed that they had been cured. These
patients could not be consented because it was impossible to discuss their
subsequent investigation, which was designed to detect residual, occult
disease, when they had never been accurately informed of the exact nature of
their primary disease.
This series was unable to show that repeat IOE scanning could be used in the
routine follow up of all patients following resection for colorectal cancer as
patients would not tolerate this form of follow-up. Less than half of the
patients who were eligible actually consented to the study.
IOUSS is the gold standard investigation for the detection of hepatic metastases
at operation and matches the accuracy of the IOE scanning, the most accurate
preoperative investigation. IOUSS precludes the need for pre-operative
investigation of the liver in patients who require a laparotomy for relief of their
primary symptoms. A small number of patients (4%) have metastases which
are not detected by IOUSS at the time of operation, these may be detected by
IOE scanning, within 18 months of operation, as they grow. In this series
patients who had hepatic resection of metastases detected by IOUSS / IOE
scanning did not gain any survival benefit.
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Chapter VI
IOUSS at the time of primary resection for colorectal
cancer.
.A. Introduction
The previous chapter has shown that, in a select group, IOUSS is more
accurate than IOE scanning for the detection of hepatic metastases at the time of
primary resection of colorectal cancer. IOUSS in particular is specific and of
high positive predictive value. This information has been used to review the
presentation and operative details of 155 patients who had an IOUSS
performed at the time of primary resection for colorectal cancer. As IOUSS
has been shown to have a PPV of 100% and an accuracy of 94%, the results of
IOUSS in this group of patients are considered to be true without supportive
data.
VI.A.I. Aim
To use IOUSS to stage accurately a group of 155 patients who had colonic
resection for suspected malignancy and to answer the following questions.
- Is IOUSS more accurate than simple palpation at the time of operation?
- Can IOUSS alone be used to improve peroperative staging?
- Does pathological staging of the resected specimen reflect accurately the stage
of disease present in the patient ?
- Could improved staging alter management decisions, and, in particular,
identify patients with resectable hepatic metastases?
VI.A.2. Patients and methods
The patient group has been described (Chapter V) and includes all 155 patients
who had an IOUSS performed at the time of their primary surgery. The
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method used to perform the examination is described in chapter III. Patients
who were followed up by IOE scanning have been described previously.
Details of disease stage and preoperative symptoms and signs were collected at
the time of operation. All of these patients have been followed up via either
their GP or their hospital consultant. The statistical analysis and graphics used
have been described in previous chapters.
VI.A.2.a. Primary diagnosis . (
Of the 155 patients with a preoperative diagnosis of colorectal cancer, a number
of patients were found, at operation, or on subsequent examination of the
resected specimen, to have another primary pathology (Table I).





Table I. The pathological diagnosis in patients undergoing laparotomy for
suspected colonic carcinoma who had an IOUSS
Patients who did not have colorectal cancer have been excluded, leaving 147
patients in the study group
.B. Results
VI.B.I. Pre operative staging
Although 90% of patients had a preoperative chest Xray, only 76% had a
preoperative ultrasonography (USS) of the liver. Visualisation of the colon by
barium enema was undertaken in 72% of patients while 61% underwent flexible
sigmoidoscopy. Complete colonoscopy was performed in 14%. Only 65
patients had a pathological diagnosis before their operation. This led to 8 (5%)
patients having an IOUSS who did not in fact have colorectal cancer. One
patient with gastric cancer and the patient with pancreatic cancer had hepatic
metastases.
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VI.B.2. Pre operative ultrasonography
USS was performed in 119 patients who had colorectal cancer. Eight patients
had a positive investigation which was confirmed by IOUSS, 111 patients had
a negative examination, which was confirmed by IOUSS and by follow-up in
76 and there were 35 false negative examinations and no false positive
examinations. In those patients who had metastases detected by both USS and
IOUSS, USS detected 12 (41%) of the 29 metastases present (Fig I. Table
2.).
Number of patients having
USS
119
Positive investigation Negative investigation
8 Oil
Confirmed positive False positive False negative Confirmed negative
8 0 35 76
Fig I. The results for pre-operative USS in the detection ofpatients with hepatic




Positive predictive value 100%
Negative predictive value 68%
Overall accuracy 71%
Table 2. The accuracy ofpre-operative ultrasonography in the detection of
patients with hepatic metastases from colorectal cancer.
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VI.B.3. Intra-operative ultrasonography
One hundred and forty seven patients with colorectal cancer had intraoperative
ultrasonography performed. There were no complications involved with the
investigation and there was no associated morbidity. The scan was incomplete
and confidence in its findings were low in only 11 patients. The most common
problem was access to the liver being limited by adhesions from previous
surgery .(Table 3 ).
Limiting Factor Number of patients
Adhesions to the liver 9
Adhesions and peritonitis 1
Abnormal hepatic anatomy 1
Total 11
Table 3. Eleven patients had an incomplete scan oftheir liver . The abnormal
hepatic anatomy was a complete congenital absence ofsegments II, III, IV and
abnormal position of segment I. This prevented confident assessment of the
presence ofmetastases.
In two of the 9 patients who had adhesions, access was also limited because the
primary colonic resection was performed through a small transverse incision in
the lower abdomen.
VI.B.3.a. Morbidity
There was no damage caused to the liver by the ultrasound probe or the
surgeons hand in palpating the liver. Neither " Tru-Cut" biopsy nor FNA was
associated with any evidence of bleeding or bile leakage. There were no sub
diaphragmatic or sub hepatic infection related to the manipulation of the liver
during the scanning procedure.
VI.B.3.b. Biopsy
Biopsy was undertaken in 9 patients. The presence of malignancy was
correctly identified in 6 of 9 patients with metastases and in the remaining 3,
the pathology result failed to confirm the presence of clinically apparent
metastases. All 3 of these patients developed gross metastatic disease or died
with hepatic metastases in the follow up period. Biopsy was often difficult to
perform through the low transverse incisions favoured by some of the
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surgeo.ns. With a positive predictive value of only 67%, biopsy was not a
satisfactory standard against which to judge lOUSS.
VI.B.3.C. Equipment failures
There were three equipment failures in the 24 months, and all of which were
related to the handling of the probes during cleaning and connection. In the
first one of the scanning heads was dropped onto a hard floor. In subsequent
use one of the crystals in the probe head failed, giving a loss of a portion of the
scan. This fault could not be repaired and the probe had to be replaced.
In the second instance, the multi connector/sender unit of the probe was
accidentally immersed in 'Cydex' during the sterilisation process. The fault
was recognised when the probe was connected to the echo camera. The probe
was taken directly to the supplier, repaired the same day, and was returned to
operation, without further fault, the following day.
The third failure was related to the design of the multi-pin connector in the
connector / sender unit. A member of staff attempted to connect the unit by
forcing the multi-pin connector into the base unit while it was not correctly
aligned within the socket. This bent one of the pins in the connector so that it
failed to make contact. The fault was recognised on inspection of the unit and
corrected by gently realigning the connector pin to its original position. All
three failures were related to poor treatment of the equipment. There were no
further faults related to the ultrasonographic equipment.
VI.B.3.d. Palpation results
Palpation revealed possible metastases in 38 of the 147 patients and their
presence was confirmed by IOUSS in 27 patients. Of the remaining 109
patients, 16 had metastases confirmed by IOUSS or follow up IOE and 93 had
no evidence of metastases at the end of the study ( Fig 2. Table 4.).
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Positive predictive value 71%
Negative predictive value 85%
Overall accuracy 82%
Table 4 Accuracy ofpalpation at the time of operation compared to the final
agreed stage in 147patients.
Palpation detected less of the patients with metastases than IOUSS ( Chi sq =
11.42 ldfpc 0.001)
Vl.B.3.e. Scanning results





Hepatic metastases from colorectal cancer 120
Hepatic cysts 47
Haemangiomata 4





Table 5. A number ofpathologies other than hepatic metastases were detected
by intraoperative ultrasonography.
Intraoperative ultrasonography revealed a number of pathologies (Table 5 ).
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Thirty- eight patients had lesions which, detected by palpation and / or
inspection of the liver were taken to be metastases by the surgeon at the time of
operation. In 27 of these patients, the diagnosis was confirmed by IOUSS
whilst in the remaining 11 patients, the scan demonstrated cysts which
corresponded to the palpable lesions. A further 13 patients had impalpable
hepatic metastases which were detected by IOUSS alone giving a total of 40
(27% ) of the 147 patients with a diagnosis of colorectal cancer with metastases
detectable at the time of operation (Fig 3. Table 6.). In one patient, the scan
and palpation revealed what appeared to be a metastases in the left lobe of the
liver. This was resected by the surgeon at the time of primary colonic
resection. Pathology revealed the lesion to be a cavernous haemangioma and
not a metastases. This was the only false positive investigations for IOUSS in
the series.
Number of patients having
IOUSS
147
Positive investigation Negative investigation
41 .106
True positive False positive False negative True negative
40 1 3 103





Positive predictive value 98%
Negative predictive value 97%
Overall accuracy 97%
Table 6. The accuracy of IOUSS in the determination of the presence of
hepatic metastases in patients with colorectal cancer.
Both the hepatic cysts and the renal cysts were easily identified by intraoperative
ultrasonography. The haemangiomas were identified by their distinct
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echogenicity within the lesion and posterior acoustic shadowing.
VI.B.3.g. Hepatic anatomy
In all but one patient the internal hepatic anatomy of the portal pedicles
conformed to the recognised pattern . The major hepatic veins were present as
were the portal structures with recognisable primary and secondary
confluences. In the one case, previously described, the left portal pedicle was
absent and the entire - small - left lobe was supplied from the right anterior
portal pedicle. The caudate lobe was supplied by small branches from the porta
hepatis and drained directly into the vena cava.
VI.B.3.h. Metastases.
The smallest colorectal metastasis detected was 4 mm in diameter lying in
segment VI anterior to the right kidney (Plate 1). The most common
appearance was of a "bulls eye" lesion (Plate 2). These metastases were
usually
Plate 1 small metastasis anterior to right kidney.
Chapter VI IOUSS and primary colorectal cancer 149
*
J} Right Hepatic Vein
Metastases
Plate 2 Bulls eye metastasis
easy to identify. The largest metastasis detected was more than 10 cm in
diameter. In one patient, a large iso-echoic conglomeration of several
metastases was only identified because of its derangement of the intrahepatic
anatomy. The tumour deposit could be seen and palpated but could not be
differentiated from normal liver by its echogenic profile, but only by its mass
effect.
VI.B.3.i. Metastases related to stage
The Dukes stage was recorded by the pathologist in 120 patients. These were:
Dukes A in 10, Dukes B in 51, Dukes CI in 46, Dukes C2 in 12 and Dukes D
in l(resected local invasion of the anterior abdominal wall). A number of
these patients had metastases (Table 6). The incidence of metastases increased
with the stage, patients with stage C2 disease having 1.7 times greater risk of
metastases than patients with Dukes A disease.
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A 10 3 (30%) 5 1.6
B 51 9(18%) 22 2.4
CI 46 10 (22%) 29 2.9
C2 12 6 (50%) ■ 22 3.6
D 1 1 (100%) 4 4
Total 120 29 (24%) 82 2.8
Table 6 The number ofmetastases detected per patient increases with more
advanced Dukes stage.
This difference does not reach statistical significance using the Chi Sq. test for
any single Dukes stage when compared against the rest of the series. Using the
results of IOUSS to reassign patients stage corrected for the presence of distant
(hepatic) metastases there were: 7 Dukes A, 42 Dukes B, 36 Dukes CI, 6
Dukes C2, and 29 Dukes D.
VI.B.4. Other factors related to metastases.
Vl.B.4.a. Pre operative weight loss
There were 69 patients who complained of weight loss in the preoperative
period, 20 of whom had hepatic metastases at operation and 49 of whom did
not. Of the remaining 86 patients, 18 had metastases and 68 did not. Using a
two by two contingency table with one degree of freedom, patients with weight
loss were not significantly more likely to have metastases than those who did
not (Chi sq = 0.67 ldf p >0.10).
VI.BAb. Abdominal pain
Out of all 147 patients, when asked, 82 said that they had abdominal pain, of
these 27 had metastases at operation. The remaining 65 patients did not
complain of abdominal pain, 11 had metastases and 54 did not. Significantly
more patients who had abdominal pain had metastases than those who did not
(Chi sq = 4.84, ldf. p < 0.05).
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VI.B.4.C. . Duration of symptoms
The duration of symptoms endured by patients prior to surgery varied greatly.
In this series some patients had a history of more than 13 years. Patients who
had a longer period from their first symptom to diagnosis tended to have fewer
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Fig 4. 155 Patients, grouped by the duration of their symptoms from 3 to
more than 30 months, showed a negative correlation between the duration of
symptoms and the presence ofhepatic metastases.
Younger patients tended to have a longer history than older ones. The median
age at presentation for those with a history of less than 4 months was 72 years
and for those with a history of more than 4 months the median age was 67 years
(p<0.05 Mann-Whitney U test). The median age of patients with metastases
was also 67 and the median age for patients without was 72 years (p<0.05
Mann-Whitney U test) (Fig 5.).











Without metastases With metastases
Fig 5. Patients with metastases were significantly younger at presentation than
those without (p < 0.05 Mann-Whitney U test). The small circles o, represent
values outwith the 10th and 90th percentile ( represented hy the 1, whiskers ).
The box contains the first to the third quartile. The bisection of the box
represents the median value .
VI.BAd. Liver function tests
There was no significant difference in serum bilirubin values (median and
range) in those with (7 mg/1 range 3-34) and those without (8 mg/1 range 2-
41)metastases. The same was true for serum albumin between patients with
(40g/dl range 30-49) and without (38g/dl range 28-58) metastases. There was
a statistical difference in the levels of alanine amino transferase in the two
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Fig 6. Box and whisker plot of alanine amino transferase values in patients
with and without hepatic metastases.
Alkaline phosphatase was also significantly raised in patients with hepatic
metastases (p<0.05 Mann-Whitney U test). The range in the two groups was
large and there was overlap between the patients who did and those who did not
have metastases (Fig 7.).There was no clinically useful cut-off point that could
be used to indicate those patients with and those without metastases.
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Fig 7. Box plot of alkaline phosphatase in patients with and without
metastases (p<0.05 Mann-Whitney U test).
The most powerful predictor of outcome in the 24 months following surgery is
the presence, or absence, of hepatic metastases at the time of operation (Finlay
IG. 1983, 1988). The mean survival for patients with hepatic involvement is
between 10 and 36 months in unselected series (Finan PJ, 1985; Wagner JS
1984) and few, if any, survive to five years without treatment. Survival can
be improved by resection of hepatic metastases, to give five year survival of
25%-30% (Wagner JS, 1984; Coppa GF, 1985; Bengmark S, 1982). Thirty
percent or more of patients may have metastases at the time of surgery, only
15% of which may be detectable by preoperative ultrasonography, or by
palpation at operation (Finlay IG, 1986). During routine follow-up, these
occult metastases will only become apparent when they cause symptoms unless
routine DBCT or IOE scanning is undertaken. The identification of patients
who have hepatic metastases at the time of presentation, may improve survival
by identifying patients who will be suitable for hepatic resection.
VI.c Discussion
Detection may be improved by performing IOUSS at the time of primary
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surgery. This investigation is as accurate as IOE scanning in the detection of
metastases at the time of operation and has high negative predictive value
(97%). The values for sensitivity, specificity, positive predictive value and
accuracy are similarly high at 93%, 99%, 98%, and 97% respectively. To
have values for detection of all metastases of all sizes, as high as this seems to
be unlikely to be true. The very high detection rates attributed to IOUSS are a
reflection of the comparatively poor resolution of the other imaging techniques
used in the routine follow-up of patients with colorectal cancer. If this group
of patients was followed to five years instead of two it is likely that the false
negative rate and the false positive rate for IOUSS would begin to climb and the
overall figures for accuracy would come into line with other published data
(Chapter II, Table 3. )(Charnley RM, 1991; Machi J, 1991). IOUSS did not
interfere with the performance of the primary colonic surgery. Consultants
readily agreed to the procedure and found the scans interesting and informative.
Most were surprised in the early part of the study when the scanner picked up
metastases which they could not detect by palpation. By the end of the study,
the scan added no more than seven minutes to the operation time, although if a
lesion was seen and biopsy attempted, a considerable amount of time could be
added to the procedure depending on the exact site of the lesion. There were
no post operative complications related to the IOUSS; this is in keeping with
other series (above), to date there have been no reports of any morbidity related
to the performance of intraoperative ultrasonography. IOUSS is a sensitive
technique and detected a significantly larger number of the patients with
metastases at the time of operation than palpation alone. This relates primarily
to the ability of IOUSS to detect very small lesions (4 mm in this series) deep in
the hepatic parenchyma. There is an absolute value for the minimum size of
lesion that can be detected by either palpation or IOUSS, although exactly what
this is remains unclear. IOUSS may detect very small lesions if they have an
echogenic structure and a potential limit of 2 mm had been suggested (Charnley
1988). The detection of a 4 mm metastases within the substance of the liver in
this series would appear to be in keeping with the level of resolution found by
others ( Rifkin MD, 1987; Thomas WM, 1987; Machi J, 1987,1991;
Boldirini G, 1987; Makucchi M, 1987; Sheu J-C, 1985; Olsen AK, 1990;
Clarke MP, 1989; Gozzetti G, 1988; Charnley RM, 1988,1989,1991).
The echogenic profile of some metastases is so similar to that of the normal liver
that even when the lesion is palpable and visible to the naked eye it may only be
apparent by its mass effect on ultrasonography. If there are no boundaries of
differing acoustic impedance between a metastases and the liver or within the
metastasis itself, it will not be visible. Most metastases (80%) create a pseudo
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capsule of compressed liver tissue and it is this which creates the anechoic halo
of the classical 'Bulls eye' lesion (Marchal G,1985). This phenomenon is
dependent on the growth pattern of the metastases and the response of the host.
Small, subcapsular metastases were not detected if the scanning head was
placed directly over the lesion. These lesions were detected in two ways,
palpation as part of the routine prior to scanning, and scanning the liver from
both its superior and inferior aspect. Subcapsular lesions can also be detected
by using a stand-off although its use is unwieldy and time consuming in
practice.
Lesions seen on IOUSS were characterised in two ways: firstly by their
appearance and secondly by biopsy. Although the appearance of a lesion is
difficult to quantify there is no doubt that visual lesion recognition was very
accurate. There was only one false positive lesion which was confirmed
pathologically. This gives a false positive rate for the identification of
metastases of 0.7%. In light of this it is reasonable to question the role of
needle biopsy. Biopsy failed to confirm the presence of metastases in 3 of 9
patients. All 3 went on to develop metastases which were detected by IOE
scanning during follow-up. This represented a 30% false negative rate for
biopsy a higher rate than for IOUSS. In the past, biopsy has been seen as the
gold standard for the identification of metastases, however, in this series the
failure rate of targeted biopsy was so high as to make it an unreliable indication
of the true nature of a lesion. The false negatives were caused both by
sampling errors (because of the difficulty in gaining access to the liver through a
low transverse abdominal incision) and reporting errors (interpretation of fine
needle aspiration cytology samples from hepatic metastases may be very
difficult). These factors are not a problem during hepatic resection when the
liver is fully mobilised and a Tru-cut 'needle can be used for sampling
Hepatic anatomy in this series was found to be almost constant with only one
patient displaying a congenital absence of the left portal pedicle. This confirms
that the internal hepatic anatomy provides a very constant map by which areas
of the liver can be identified (Bismuth H, 1982).
The Dukes stage was reported in 82% of the specimens and was shown to
under stage the disease in 23% of these. Because Dukes is a method of
reporting the actual physical appearance of the primary cancer, it can only give
an estimate of stage and thus prognosis, the survival estimate having being
gained from a population of patients who had a similar appearance of primary
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disease.
The identification of patients who actually have metastases at operation
increases the accuracy of the staging. In this series 3 : 10 Dukes A patients
had metastatic disease at the time of operation. The level of metastatic disease
in the Dukes B group was approximately 2 : 10 and for Dukes C over all
approximately 3:10. From these data it would appear the percentage of
patients with hepatic metastases at the time of operation in this small series was
not correlated to the Dukes classification. As expected 3:10 patients had
metastases present at the time of operation (Finlay IG, 1982).
Both pain at presentation and derangement of liver function tests were related to
the presence of metastases but neither of these factors were absolute predictors
of metastases. There was almost complete overlap of the values of liver
function tests between the group with metastases and the group with no
metastases. There was a slight negative correlation between the presence of
metastases and the duration of disease symptoms (opposite to that which might
have been expected). One theory of metastases suggests that with time a
tumour develops its potential to metastasise (Fidler IJ, 1990), this is related to
the number of specific genetic deletions that occur in the cells of the tumour
with successive mitotic cycles (Sanchez J, 1986). The longer a tumour has
been present the more metastases one might expect be present. In this series
the opposite was true, patients who had long periods of symptoms prior to
their operation were slightly less likely to have metastases than those with a
short history. It is possible that within a generally old and frail population that
the presence of the tumour was not related to the duration of abdominal
symptoms. Another explanation would be that those with a long history had
slow growing tumours which, by their nature, were less aggressive and
therefore less likely to metastasise.
Duration of symptoms showed a slightly negative correlation to age at
presentation: the mean age for patients with less than 4 months history was 5
years less than those with a longer history. It would appear from this that
relative youth at presentation and short history are both negative prognostic
factors and carry a higher risk for the presence of hepatic metastases.
Haemangiomas were detected from time to time. At the inception of the study
it had been decided that lesions suspected of being haemangiomas on their
appearance would not be subjected to FNA or Tru-cut' biopsy because of the
possibility of producing intrahepatic haemorrhage. There were 4
Chapter VIIOUSS and primary colorectal cancer 158
haemangiomas correctly diagnosed in 3 patients. One large cavernous
haemangioma was incorrectly diagnosed as a metastasis. This large lesion was
resected and its nature confirmed on pathological section. There was no way
of improving the diagnostic accuracy of IOUSS in the detection of
haemangiomas without the use of ultrasonic contrast enhancement agents
(Mattrey RF, 1982, Matsuda Y, 1986, Carroll BA, 1982).
VI.C.l. Technique
Intraoperative ultrasonography is a simple technique although there is
considerable skill required to correctly interpret the results of the scans. In this
series the principle investigator WFAM was trained by a specialised hepato¬
biliary surgeon (OJG) in the technique of intraoperative ultrasonography and in
the recognition of metastases and other lesions within the liver. That the
accuracy of IOUSS was high and remained so was due to the level of training
prior to the inception of the study and the quality of the images which can be
obtained by IOUSS equipment. Training courses and training manuals are
currently available, as are echo cameras which provide excellent image quality.
Such equipment would allow any general surgeon to perform IOUSS and
achieve acceptable results.
Intraoperative ultrasonography offers an alternative to enhanced CT scanning in
the detection of metastases at the time of operation. Its limitations are that; it
can only be performed at laparotomy and it is a dynamic technique and therefore
operator dependant. It is also difficult to capture the subtle changes of an
infiltrating tumour on a still images. The remaining disadvantage of the
technique is that it is a new skill which must be learned; either by a surgeon in
ultrasonography, or by the radiologist in the interpretation of operative scans.
In British practice it seems likely that the use of ultrasonography by the surgical
community will increase. It is equally unlikely that there will ever be enough
radiologists to support a service of intraoperative ultrasonography for all
patients coming to operation with colorectal cancer. Intra-operative
ultrasonography will remain in the domain of the surgeon.
By using a combination of intraoperative ultrasonography at the time of surgery
and IOE scanning in the follow up period, it is possible increase the detection
of hepatic metastases. There are no data yet available to suggest that early
detection by either intraoperative ultrasonography or by enhanced CT scanning
of resectable hepatic metastases will improve survival. In the past, patients
who have had hepatic resection are those who have survived for at a period of
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time with a small number of hepatic metastases. These patients may represent a
self selected group who already have a better prognosis. The patients in this
series who were found to have hepatic metastases at operation and who were
not pre-selected in the same way did not have a survival benefit from resection.
It seems likely that there is a balance between early detection and surveillance in
that patients who have potentially resectable hepatic metastases at operation
should have a period of surveillance following their surgery to allow other
occult metastases in the liver to declare themselves prior to resection. They
should then be restaged by laparoscopy and laparoscopic ultrasonography prior
to resection.
Of the 155 patients who were operated on for colonic malignancy in this series
8 had other primary pathology. There was marked variation in the level of
preoperative investigation carried out by different clinicians. Up to 29% of
patient with a colonic malignancy have polyps elsewhere in the colon and 4.5%-
9% have synchronous malignancy (Tate JJT, 1988). It is important that these
lesions are detected before operation and removed. Failure to do so may
expose the patient to the risk of further primary tumour as well as the risk of
metastases. There is little to be gained by resecting small volume intrahepatic
metastases in a patient who may have an undetected, synchronous cancer in the
colon.
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Chapter VI1
Carcinoembrvonic antigen: Its relationship to the
presence of hepatic metastases.
VII.A. Introduction
Described by Gold and Freedman in 1965, Carcinoembryonic antigen is a
tumour marker whose elevation, in serum samples drawn from patients with
colorectal malignancy, may be related to the presence of primary or recurrent
carcinoma ( Finlay IG, 1983; Sugarbaker PH, 1976). However, it lacks the
specificity and accuracy required to stand alone as a useful screening test for
primary malignancy of the colon (Go VLW, 1976; Goldenberg DM, 1981;
Tormey DC, 1982; NIC, 1981) and its exact role in this context has,
unfortunately, remained unclear. Serum CEA may be elevated in a number of
benign and malignant conditions (Lowenstein MS, 1978; Stevens DP, 1973)
and may also remain in the normal range in the presence of colorectal cancer
(Neville AM, 1978; Minton JP, 1985; Martin EW, 1976). Repeated assay
of serum CEA following resection for colorectal cancer can give an indication of
recurrent disease (Wanebo HJ, 1978; 1981 Mach JP, 1978; Mackay AM,
1974). Some authors have shown serum CEA elevation to be a late event in
recurrence and therefore an inappropriate criteria for deciding when to initiate
treatment (Sugarbaker PH, 1976; Herrera MA, 1976; Finlay IG, 1983;
Minton JP 1985). Serum CEA is the most commonly used tumour marker in
relation to colorectal cancer (Sikorska, 1988).
Serum CEA estimation is used in a number of contexts: diagnosis of primary
colorectal cancers, immediate assessment of completion of resection and the
detection of recurrence during follow up.
In this chapter three groups of patients are considered. In the first group,
consisting of patients with known hepatic metastases from colorectal cancer,
the relationship of serum CEA to the presence and resectability of hepatic
metastases is defined. In the second group, consisting of patients presenting
with colorectal cancer, the relationship of serum CEA to the presence of hepatic
metastases is defined. The information from groups 1 and 2 is used to identify
a level of serum CEA which indicates the presence of recurrence and this is
tested on a third group of patients in long-term follow up.
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VII.B. Aim
The objective of this chapter is to investigate the relationship of serum levels of
CEA, determined by radio immunoassay, with the presence of primary
colorectal cancer, hepatic metastases from colorectal cancer and the presence of
locally recurrent disease. This has been achieved by evaluating the presence or
absence of hepatic metastases and local recurrence in three groups of patients
following primary resection for colorectal cancer.
VII.C. Patients and Methods
The data from three groups of patients are examined in this chapter;
- Group 1. Patients presenting with hepatic metastases being considered for
hepatic resection (discussed in chapter IV)
- Group 2. Patients who have been staged by IOUSS and / or IOE scanning at
the time of, and following, curative primary resection for colorectal cancer
(discussed in chapter V and VI).
- Group 3. Patients who have been followed up in a dedicated colorectal clinic
following curative resection of colorectal cancers (not previously discussed).
VII.C.l. Group 1
The group consisted of 60 patients, (36 male) average age 61 (28-84 ) with
colorectal hepatic metastases. All of these patients had been extensively
investigated and the exact extent of their recurrent disease recorded. In
particular, the presence of hepatic metastases, pulmonary metastases and local
recurrence was known. The staging of these patients is described in chapter
IV. The results of the investigations related to the serum CEA levels are
described below.
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VII. C.2. Group 2
This group consisted of one hundred and forty seven patients who have had
laparotomy, IOUSS and IOE scanning of the liver at the time of their
presentation with colorectal cancer. Fifty two of these patients had repeated
IOE scans in the follow up period and serum CEA was measured at the time of
each scan. A number of patients continued to have s,erum CEA samples taken
after their last IOE scan as part of their routine follow up and these results have
also been included. The longest follow up in this group of patients is 50
months. These patients have been described in chapters V and VI.
VII.C.3. Group 3
This group consisted of two hundred and sixty five patients admitted to the
Western General Hospital, Edinburgh (WGH), between 1988 and 1990, who
underwent a potentially curative resection of colorectal cancer, identified from
the Lothian Surgical Audit (LSA). The following were excluded from the
series: patients with less than one preoperative and two postoperative CEA
estimations, a palliative primary resection of their primary cancer or incomplete
follow up data. The policy of this unit has been to follow-up all patients who
had a potentially curative resection by repeated serum CEA estimation and
clinical examination. One hundred and twenty five patients remained to be
studied, their median age was 69 years (range 42-91); 65 were male.
Patients in group 3 were followed up in a long-term manner with regular clinical
review (4 visits in the first year, three in the second and annually or better in
the following years). A full history was taken at each clinic visit followed by
physical examination, rectal examination, faecal occult blood testing, rigid
sigmoidoscopy and blood samples were taken for serum CEA estimation.
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VII.C.3.a. Method
The methods for group I and 2 have been discussed and are summarised.
Patients in group 1 were admitted to the Hepatobiliary Unit of the Royal
Infirmary of Edinburgh for consideration of resection of known hepatic
metastases. Each patient underwent a series of investigations to ascertain the
resectability of their disease. These included CT scanning, IOE scanning
angiography and IOUSS (in patients selected for resection). The number of
hepatic segments involved by metastases was known in each patient as was the
presence of local recurrence and the serum CEA.
Patients in group 2 had intraoperative ultrasonography of the liver performed at
the time of primary resection of their colorectal cancer. These patients were
then followed up by sequential IOE scanning, clinical review, sequential
serum CEA estimation and by contact with their GPs.
Group 3. The clinic letters of these patients were interrogated using a standard
format and the information obtained tabulated for analysis. The serum CEA
results for these patients were supplied from the serum CEA database which is
maintained by the Edinburgh University department of clinical chemistry
immunoassay section ( JS, CS).
Comparison and analysis was then performed using Statview SE + Graphics™
(Abacus Inc.).
VII.C.3.b. Serum CEA estimation
All serum CEA estimations were performed by the Department of
Immunochemistry by radio-immunoassay under the direction of JS and CS.
The results of estimations are compared to both internal and national external
controls to ensure continuity of the assay. The upper limit of normal in this
laboratory is 60u/l. In this assay, a level of 100u/l ( using International
Standard IRP 73/601) corresponds to approximately 10^g/l of CEA.
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VII.D. Results
VII.D.l. Group 1
VII.D.l.a. Serum CEA and colorectal liver metastases
Serum CEA was measured in all 60 patients when they presented for restaging.
Patients can be grouped at various cut-off points for CEA; 47 (78%) had a
serum CEA of > 60u/l, 44 (73%) had a serum CEA of > 100u/l, 41 (68%) had
a serum CEA of >160 u/1 and 26 (43%) patients had a serum CEA of > 1000
u/1. The results for serum CEA estimation at the time of presentation for these
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Fig 1. The distribution of serum CEA value in u/l at presentation with
recurrence for patients in group 1 is skewed to the right ( Skewness = 5 ) (This
data is not suitable forparametric analysis).
In order to produce a more normal distribution curve, a logarithmic
transformation was undertaken on the serum CEA values at presentation with
recurrence for the patients in group 1 (Fig 2.)
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Fig 2. Logarithmic transformation of serum CEA u/l at presentation with
hepatic metastases for patients in group 1 (Skewness -0.06). A logarithmic
transformation reduces the skew of the data However, it also reveals an
apparently Bi-modal distribution. This may be expected, as 20 % ofcolorectal
cancers do not produce CEA. The first peak appears in the second column
which includes the value serum CEA of 30u/l. (log = 1.47), 30u/l is the
lowest reported value for serum CEA in our laboratory . Values lower then
30u/l are reported as serum CEA < 30u/l unless an absolute value has been
requested which was not the case in this study, and because of this the left
hand tail of the distribution has been distorted. This distribution of results is
not suitable forparametric analysis..
Because of the lack of normal distribution of the serum CEA values, non-
parametric analysis has been used unless otherwise stated. A parametric
regression analysis was performed on the logarithmic transformation of serum
CEA and age at presentation.
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VII.D.l.b. The relationship of Dukes stage at presentation to serum CEA at
recurrence
The Dukes stage of the primary cancer at presentation was recorded in 45
patients (Table I). Unfortunately the serum CEA at presentation of the primary
cancer was not available for any of the patients in group 1.






Table 1 Serum CEA values at presentation with hepatic metastases for 45
patients in whom the Dukes stage of their original tumour was known. The
serum CEA values do not conform to a normal distribution ( Skewness = 6) and
so nonparametric analysis has been used. There is no significant difference in
the serum CEA value for any ofDukes stages compared to the rest (Kruskal-
Wallis , p = 0.5163)
There was no significant relationship between the level of serum CEA at
recurrence and the Dukes stage of the primary tumour. The site of the primary
cancer was also recorded and this has been related to the serum CEA level at the
time of presentation with hepatic metastases (Fig 3 ). There was no significant
difference in the serum CEA level (at the time of recurrence) between metastases
originating from any one primary site and another, particularly there was no
difference between cancers from the right colon and cancers from the left colon
or rectum.
The level of serum CEA at presentation was significantly lower in those patients
who underwent successful hepatic resection compared to those who did not
(Fig 4.).
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Fig 3. Boxplots ofserum CEA u/l and the anatomical site of the index primary
cancer. There is no significant difference in the levels ofserum CEA found at
recurrence and the original site of the primary cancer . The median value for
each site is above the horizontal transection ( Kruskal - Wallis p-0.27)
The median value for patients with irresectable disease corresponds to the value
at which serum CEA best determines the resectability of disease. A serum
CEA of < 1000 u/l has an accuracy of 58% in determining resectability {Fig 5.)
The number of hepatic segments involved with tumour was also recorded. A
multiple nonparametric analysis of this data revealed no significant difference in
the levels of serum CEA at presentation between those who had one segment
involved and those who had all eight segments involved. There was,
however, a positive correlation between the level of serum CEA and the
number of segments involved with metastases at the time of staging, which did
not reach statistical significance. The number in each of the groups was small
and the variation in serum CEA values is large (Fig 6.). As the number of
segments involved was used as one of the criteria for resection, there was a
positive relationship between more than four segments involved and the
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Fig 4. Box plot ofserum CEA (plotted on a log scale) for patients who did and
did not have a successful hepatic resection for colorectal metastases. Patients
who had a successful resection had a median serum CEA value of 127 u/l,
those who did not had a median value of 1000 u/l (p< 0.05 Mann-Whitnev U
test)

















Fig 5. serum CEA can he used to predict the presence of resectable hepatic
metastases in patients who have had a curative resection of their primary
colorectal cancer. A serum CEA value of < IOOOu/l has a sensitivity of 85%,
specificity of51%, positive predictive value of32%, negative predictive value
of 92% and an overall accuracy of 58% in identifying successful hepatic-
resection as an outcome. Patients with a serum CEA of < lOOOu/l are more
likely to have a successful hepatic resection ( Chi sq = 5.28 Idf p < 0.05)






























Number of involved segments
Fig 6. Box plot of the number of hepatic segments involved by metastases
against the serum CEA u!I {on a logarithmic scale) atpresentation.
There is a trend for the serum CEA to rise with the number of segments
involved by tumour. The value "n" in each box indicates the number of
patients in each group. The median value for each group is printed within (he
box. There is no significant correlation between the serum CEA and the
number of segments involved using the Kendall rank correlation coefficient
(t = 0.2 p = 0.083). It would appear that there is a correlation between the
number of segments involved and the median serum CEA for each group,
except for the patients with 8 segments involved. By removing the data for
patients with 8 segments involved, the value for r increases to 0.3 , p =
0.0027, indicating a stronger and significant relationship. Selective analysis
of this type may be misleading. However common sense would suggest that
the relationship for patients with 1 - 7 involved segments should hold true for
patients with 8 segments involved.
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There is no significant relationship between the log of the serum CEA at
presentation and the age in years of the patient (Fig 7). Because of the normal
distribution of age and patients with colorectal cancer and the near normal
distribution of the log of the serum CEA, the coefficient of regression r is
quoted. This fails to demonstrate a significant correlation. These data were
also analysed using the Kendall rank coefficient, this being a less powerful
test, but more accurate for data which tends not to hhve a normal distribution.
This again shows that there is no significant relationship between age at
presentation with hepatic metastases and serum CEA levels (x = 0.00005 p =
0.5).
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Fig 7. Regression analysis of the age at presentation and the log of the serum
CEA at presentation r = 0.03 p = 0.8 ( Fishers --transformation ) the 95%
confidence intervals are indicated hy thefaint lines.
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Fig 8. Initial examination ofthe lag time from primary resection to detection of
recurrence reveals that the data were skewed to the right.
In fact, logarithmic transformation revealed that there was a bi-modal
distribution. A very early peak corresponding to patients who had their hepatic
metastases detected at the time of primary surgery (mean lag of 1.77 days) and a
second peak corresponding to patients who had been detected during routine
follow-up (mean lag of 562 days). This distribution confirmed that this data
had to be analysed using a non-parametric test. There was no significant
relationship between the number of days from diagnosis to the detection of
recurrence and serum CEA at recurrence (Kendall rank coefficient x = 0.07, p
= 0.4217).
VII.D.2. Group 2
Sixty eight of the 147 patients who had colorectal cancer (46%) had a serum
CEA at presentation greater than 60 u/1. The frequency distribution of the
serum CEA u/1 at presentation did not form a normal distribution and could not






















Fig 9. Frequency distribution of the serum CEA levels at presentation for
patients with colorectal cancer, median 50u/l range < 30 u/l to 4740 u/l .
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Fig 10. A logarithmic transformation of the serum CEA at presentation of
patients for primary resection of colorectal cancer fails to produce a normal
distribution. The histogram remains skewed to the right ( skewness = 1 ).
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Because of the skewed nature of the results of the serum CEA estimations, non-
parametric methods of statistical analysis have again been used for this section.
In a comparison of the level of serum CEA at presentation independent of the
presence of metastases, there was no significant difference in the level of serum
CEA when related to the anatomical site of the primary cancer (Table 2.).
There was a wide range of serum CEA and few significant differences in the
groups (Multiple analysis of significance ANOVA).
Chapter VII CEA and hepatic metastases 174
Site of primary tumour Number of Median serum
tumours CEA(range)
Caecum 25 55 (30-1090)
Ascending colon 7 86 (30-389)
Hepatic flexure 3 30 (30-545)
Transverse colon 9 . 4 30 (30-1200)
Splenic flexure 4 466 (30-4740)
Descending colon 6 36 (30-42)
Sigmoid colon 35 45 (30-2000)
Rectum-Above reflection 5 30 (30-1200)
Rectum-At reflection 6 92 (30-1000)
Rectum-Below reflection 47 55 (30-2150)
Total 147 51 (30-4740)
Table 2. The site ofpritnary cancers in 147 patients having resection for
colorectal cancer. The mean and range ofserum CEA values were calculated
for each of these groups. These have been compared using the ANOVA
multiple comparison ofsignificance. The serum CEA levels for cancers ofthe
splenic flexure were significantly higher than all of the other sites ( p - 0.05
Fishers PLDS) , there is no significant difference in any of the other groups
The sample size is probably too smallfor this test to be reliable.
Dividing the groups into right sided and left sided cancers (the point of division
being splenic flexure cancers to the right, and descending colon cancers to the
left), there was no significant difference in the serum CEA values with respect
to site (p = 0.94 Mann-Whitney U test).
In this series (group 2), there was no significant difference between the serum
CEA levels for Dukes A, B, C (p= 0.47 - 0.85 multiple Mann-Whitney U
tests).
There were 10 patients who had a serum CEA of greater than 1000 u/1; 6 of
these had hepatic metastases. Of the remaining 4, 2 had carciomatosis
peritonei, one had locally advanced but resectable disease and one had a
curative resection of a Dukes 'B' colonic cancer.
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All patients were staged and the presence or absence of hepatic metastases was
determined at the time of primary resection by 10USS and during the follow up
period by IOE scanning. Patients were grouped into those who had metastases
(43 patients) and those who did not (104 patients) (Fig 11). The serum CEA
was significantly higher at presentation for patients with metastases than for
those without (p < 0.05 Mann-Whitney U test) . The range in the two groups









Fig 11. Log serum CEA u/l at presentation for 43 patients with and 104
without hepatic metastases, prior to resection of the primary tumour. Patients
with hepatic metastases had a significantly higher serum CEA at presentation
than those without.
Of the 43 patients with metastases, 18 (42%) had a serum CEA at presentation
of greater than 100 u/l; 26 (25%) of the 104 patients without metastases had a
serum CEA of greater than 100u/l ( Fig 12 . Table 3).
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Fig 12. Algorithm for the detection of hepatic metastases at the time of
presentation hy determination of the plasma CEA. A cut offpoint of 100 u/l




Positive predictive value 41%
Negative predictive value 78%
Overall accuracy 67%
Table 3. Accuracy ofCEA >100 u/l in predicting the presence of hepatic
metastases in patients presenting with colorectal cancer.
Patients with a serum CEA level of more than 100 u/l are significantly more
likely to have hepatic metastases (Chi sq. = 5.29 ldf p < 0.05).
To determine if the absolute level of which serum CEA is likely to indicate the
presence of hepatic metastases in patients presenting with colorectal cancer
multiple calculations were performed with cut off levels above and below 100
u/l (Table 4. and Fig 13.). An analysis was carried out using four fold
contingency tables to calculate a value for x2 for each of the combinations of
true positive, false positive, true negative, false negative for a given value of
serum CEA in determining the presence of hepatic metastases. Yates correction
was not applied. This gives the following results.
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Calculation of Chi sq for various
values of CEA in the
determination of the presence of
hepatic metastases.
Hepatic metastases No hepatic metastases
CEA > X TP FP, TP+FP
CEA < X FN TN FN+TN
TP+FN FP+TN TP+FP+FN+TN
True positive = TP
True negative = TN
False positive = FP
False negative = FN
(TPxTN - FPxFN)2 (TP+FP+FN+TN)
Sq ~ (TP+FP) (FN+TN) (FP+TN) (TP+FN)
Fig 13 . Multiple calculations of Chi sq were made using this formula.
Serum CEA > level in u/1
60 80 100 120 140 160 200 250 500 750 1000
Sensitivity 59 54 44 41 41 41 37 32 22 17 15
Specificity 58 69 75 80 81 83 85 87 92 93 96
PPV 35 40 41 45 46 49 48 48 50 50 60
NPV 78 79 78 78 78 79 78 77 75 74 74
Accuracy 59 65 67 69 70 71 71 71 72 72 73
X2 3.5 6.4 5.3 7.2 8.0 9.8 8.2 6.8 4.9 3.8 5.5
Table 4. Multiple estimations of the accuracy of serum CEA in the
determination of patients with hepatic metastases from colorectal cancer.
Accuracy continues to increase as the serum CEA level is increased, at the
expense ofsensitivity. The highest value for yf (9.77) occurs at a serum CEA
level >l60u/l. This is the optimum level ofserum CEA at which to determine
patients who have and have not got hepatic metastases, prior to colonic
resection.
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A serum CEA value of >160u/l is an accurate indicator of patients who have
hepatic metastases at the time of primary resection (Fig 14) ( Chi sq 9.8 ldf, p
< 0.01)












Fig 14. Serum CEA at a level of 160 u/l is an accurate and sensitive indicator
of patients with colorectal liver metastases.
There were 52 patients who had more than one estimation of serum CEA in the
follow-up period. Twelve of the 52 had metastases, 2 of the 12 had no
elevation of serum CEA above 30 u/l at any time, 6 had no elevation above
100u/l at any time and 6 had elevation of serum CEA > 100 u/l associated with
the appearance of hepatic metastases. There were 5 patients with a serum CEA
of more than 160u/l in follow-up all of whom had metastases. There were 40
patients who did not have metastases of whom 1 had a serum CEA of greater
than 160 in the follow up period. The plots for the patients who had and those
who did not have hepatic metastases are drawn below (Fig 15, 16,) to show
the difference in trend of serum CEA in the two groups.
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Time after operation in months
Fig 15. Patients following operation in whom there was evidence of
metastases on IOE scanning. The serum CEA is plotted on a log scale with the
cut off levels of 100 u/1 and 160 u/1 indicated hy faint horizontal lines. There
is very little difference in the accuracy ofserum CEA at the 100 u/l and 160 u/l
in the determination ofwhich patient have and have not got metastases during
follow up .
There were 40 of the 52 in whom there was no evidence of hepatic metastases.
Four had a serum CEA of greater than 100 u/l in the follow up period. Only
one patient showed a rapid rise in serum CEA to 204 u/l. This was the final
estimation in this patient and was associated with a normal IOE scan.
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Fig 16. Patients following operation in whom there was no evidence on IOE
scanning ofhepatic metastases.
The accuracy of serum CEA in determining the presence of hepatic metastases
in these patients is calculated at the 100 u/1 and 160 u/1 levels ( Fig 17, Fig 18 ,
Table 5. ).
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Fig 17. Serum CEA at 100 u/l in the determination ofmetastases in the follow
up period.














Fig 18. Serum CEA at 160 u/l in the determination ofmetastases in the follow
up period.









Table 5. Serum CEA at the 100 u/l and 160 u/l in the determination of the
presence ofhepatic metastases in 52 patients . The 160 u/l level gives a 7%
improvement in specificity, a 23% improvement in PPV and a 4% increase in
accuracy, at the expense ofa 8%fall in sensitivity and a I % fall in NPV.
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The elevation of serum CEA to > 160 u/1 is 85% accurate (Chi sq = 13.87 ldf,
p < 0.001) in the identification of patients who have hepatic metastases.
Analysis of patients in group 1 has shown that patients with a serum CEA of
<1000 u/1 are more likely to have resectable disease, so patients who have a
serum CEA of between 160 u/1 and 1000 u/1 are more likely to have resectable
hepatic metastases than patients with results outside this range.
Vll.D.3. Group 3
There were 125 patients in this group. The median duration of follow up was
28 months (3 - 60). Dukes stage at presentation was recorded in 97 patients as
follows: A - 10, B - 27, C - 38, D - 22.
Various levels of cut-off for CEA have been considered in this group of
patients. There were 60 patients in whom the serum CEA rose to more than a
cut-off of 60 u/1 on at least one occasion. Forty eight of these patients had
evidence of recurrent disease, 27 had evidence of hepatic metastases. Of the
remaining 65 patients, 5 (two with hepatic metastases) who developed
recurrence with no elevation of serum CEA above 60u/l. Serum CEA level
rose to greater than a cut-off of 100 u/1 on at least one occasion in 54 patients,
46 of whom developed recurrent disease of the remaining 71 patients 7
developed recurrent disease. A rise in the serum CEA to 100 u/1 was a
significant indicator of recurrent disease ( Chi sq = 71.26 ldf, p < 0.001 ).
serum CEA rose to a level of greater than a cut-off of 160 u/1 on at least one
occasion in 40 patients, 34 of whom had evidence of recurrent disease. Serum
CEA did not rise to more than 160 u/1 in 85 patients, 19 of whom had recurrent
disease. Six of the 7 patients who had no post operative elevation in their CEA
had no elevation of serum CEA prior to their primary colonic resection. In 38
patients, serum CEA elevation preceded, clinically apparent, recurrent disease.
In 16 patients, staging investigations were instigated on the basis of a single,
high serum CEA result alone.
There were 29 patients with evidence of hepatic metastases by clinical
examination supported by abdominal ultrasonography, abdominal CT scanning
or operative findings. Twenty seven of these patients had a serum CEA of
>100 u/1 and 23 had a serum CEA of > 160 u/1. The results for sensitivity,
specificity, PPV, NPV, and accuracy have been calculated for the detection of
recurrence and specifically for the detection of hepatic metastases for serum
Chapter VII CEA and hepatic metastases 183
CEA a.t both 100 u/1 and 160 u/1. In order to compare the significance of the
two levels of serum CEA in determining recurrence, x2 values have been
calculated and compared (Table 6).
Recurrence Hepatic recurrence
60 u/1 100 u/1 160 u/1 60'u/l 100 u/1 160 u/1
Sensitivity 89 87 64 93 93 85
Specificity 82 89 92 65 72 83
PPV 79 85 85 44 50 57
NPV 91 90 78 97 97 95
Accuracy 85 88 80 77 77 83
X2 64.2 71.26 43.71 42.16 38.3 44.7
Table 6. The accuracy ofserum CEA estimation in determining the presence of
recurrent disease and the presence ofhepatic metastases in patients in routine
follow-up after curative resection of colorectal cancer. The value ofyf has
been calculatedfor each column from the values ofTP, TN, FP, FN. (see Fig
13.) The higher the value ofChi sq, the more likely it is that patients have been
divided into those with and those without recurrence on the basis of the serum
CEA value. All ofthese results reach significance atp < 0.001 level.
VII.E. Discussion
Serum CEA elevation may be related to a number of primary pathologies
(Kalvins JV, 1985). Elevation of serum CEA, in conjunction with suspicious
lesions on either barium enema examination or colonoscopy, supports the
diagnosis of colonic malignancy. A rise in serum CEA may be related to the
presence of local recurrence or hepatic metastases (Finlay IG, 1983;
Sugarbaker PH, 1976; Wood CB, 1980) in patients who have undergone
resection of a primary colorectal cancer. In group 1, 78% of patients had
elevation of serum CEA above 60 u/1 associated with the presence of hepatic
metastases. Twenty two percent of the colon cancers in this group did not
produce CEA. It has been shown by others (Mackay AM, 1974; Minton JP,
1985) that around 20% of colorectal recurrence do not produce an elevation of
serum CEA. Sixty eight percent of patients with hepatic metastases had a
serum CEA of > 160u/l. Elevation of serum CEA was loosely related to
volume of liver involved by metastases. This suggests that the larger the
Chapter VII CEA and hepatic metastases 184
volume of metastases the greater the serum CEA for those cancers which
produce CEA. The level of serum CEA at the time of staging was significantly
higher in patients with irresectable disease (p<0.05 Mann-Whitney test
corrected for paired results), although the range of values for serum CEA was
so wide that the two groups overlapped entirely. This data confirms that
elevation of serum CEA is an indicator of recurrent disease but is too inaccurate
(accuracy of 58% for serum CEA > 1000 u/1) to indicate irresectable, recurrent
hepatic disease. Elevation of CEA may be caused be other tumour burden apart
from that in the liver. Although this would also be an indication that the patient
was not suitable for resection.
At presentation, 44% of patients (in group 2) with a diagnosis of colon cancer
had a serum CEA level of > 60 u/1. This is fewer patients than expected and at
the lower end of the reported range (Sikorska H, 1988). Group 2 represents a
selected group of patients who had undergone an lOUSS. There are fewer
stage D cancers than expected (Hardcastle JD, 1986) in group 2, this may be
explained by some unrecognised selection of patients prior to operation. It is
possible the GPs referring patients with advanced disease may have had a
preference for the Western General Hospital (WGH)(not included in this part of
the study), as the regional oncology centre is on that site. This is supported by
a higher than expected number of Dukes 'D' patients in group 3 which was
drawn from the WGH.
Very high levels of serum CEA are an indication of poor prognosis (NIH
Consensus statement 1981) and so serum CEA may be used as an adjunct to
pathological staging (CEA and prognosis is explored in a subsequent chapter).
There was a significant relationship between elevation of serum CEA and the
presence of hepatic metastases. The median for patients with no metastases
was 48 u/1 compared to 91 u/1 for those with metastases (p < 0.05 Mann-
Whitney U test). Dividing the group at a CEA level of 160 u/1 gave the most
significant difference, in the groups of patients with a x2 value of 9.77.
Previous studies have also noted the relationship between CEA and hepatic
metastases (Finlay IG, 1983; Herrera MA, 1976; Sugarbaker PH, 1976 ).
However, the upper limit of normal in these studies was 25 //g/1 or 250 u/1
using our standard, which is much higher than our upper limit of normal (60
u/1). Elevation of CEA was related to the presence of recurrence and to poor
prognosis in all of these studies.
During the follow up period, we were unable to show that the appearance of
metastases on IOE scanning preceded elevation of serum CEA or vice versa.
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The two events were coincident in those patients whose cancers produced CEA.
This was to be expected, as the serum CEA estimations were made at the same
time as the IOE scans and were used to confirm the findings of the scans . It
has been suggested that serum CEA estimations must be made with a much
higher frequency (monthly) to provide early detection of recurrent disease
(Martin EW, 1977; Sugarbaker PH, 1976). Finlay has suggested that serum
CEA elevation lags behind detection of hepatic metastases by CT scanning (
Finlay IG, 1983). Again the upper limit of normal for CEA in Finlay's study
was 250 u/1, more than four times the upper limit of normal in our laboratory
and 90 u/1 higher than the most accurate level for the detection of metastases in
our series. It is impossible to say from these data that the elevation of serum
CEA in patients in group 1 preceded the presence of detectable recurrent
disease, as this data was not recorded. Patients in group 3 had regular out¬
patient follow-up and estimation of serum CEA at each clinic visit. Serum
CEA elevation preceded clinical evidence of disease in 38 (72%) of 53 patients
with recurrence undergoing classical out-patients' review. This is similar to
previously reported series (Mackay AM, 1974; Mach JP, 1978)
The data from group 2 show that palpation at operation had an accuracy of
81%, and 97% when combined with IOUSS in the detection of hepatic
metastases. A serum CEA of > 160 u/1 indicated hepatic involvement in 23%
of patients with 71% accuracy and a level of 100 u/1 indicated involvement in
28% of patients with 67% accuracy. This compares favourably to preoperative
ultrasonography which indicated hepatic metastases in 21% of patients with an
accuracy of 69%. In patients being followed-up after resection of colorectal
cancers, a single serum CEA estimation of >100 u/1 indicated recurrent disease
with a positive predictive value (PPV) of 85% in 43% of the population and a
value of 160 u/1 will indicate hepatic recurrence with a PPV of 57% in 32% of
the population. It is not possible to compare the accuracy of IOE scanning and
serum CEA estimation in the detection of hepatic metastases from these data as
the results of one of the investigations were used to confirm the finding of the
other.
These data show a significant relationship between serum CEA and the presence
of colorectal cancer metastases (group 1). They also show a significant
relationship between elevation of serum CEA above 160u/l and the presence of
hepatic metastases at the time of presentation with colorectal cancer (group 2)
which is independent of Dukes stage. Elevation of serum CEA in the follow-
up period was significantly related to the presence of recurrent disease overall
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and at a higher level to the presence of hepatic metastases (group 3). The level
of CEA of >160 u/1 was found to be the most significant in determining the
presence of hepatic metastases at the time of primary resection and during
follow up. There were no data collected from the patients in group 3 to define
which patients found to have hepatic metastases following a serum CEA rise to
160 u/1 then went on to successful hepatic resection. From group 1,
successful hepatic resection was significantly related to levels of serum CEA<
1000 u/1.
Two of the major advantages of serum CEA testing is that it is cheap, and
easily repeatable. These data shows that serum CEA estimation is more
accurate than clinical examination in determining which patients have recurrent
disease. These data have not clarified the temporal relationship of serum CEA
elevation and appearance of metastases on plain CT scan or abdominal
ultrasound. However, data from Group 1 suggests a relationship between
lower levels of serum CEA and fewer hepatic segments being involved by
tumour and data from Group 2 suggests that serum CEA increases with time in
patients with hepatic metastases. Detection of serum CEA elevation of >160 u/1
will indicate patients who have hepatic recurrence with 83% accuracy in the
follow up period. If the serum CEA elevation is below 1000 u/1 the hepatic
recurrence is more likely to be resectable. We have shown ( chapter V) that
patients will not accept repeated IOE scans as a form of follow up for their
colorectal cancer. No studies to date report the use of enhanced CT scanning
in the routine follow up of patients with colorectal cancer, outwith prospective
clinical trials. Repeated CEA estimation is a realistic adjunct to clinical follow
up which is inexpensive and non-invasive. Its lack of accuracy is more than
compensated for by it availability and ease of use. This study has confirmed
the clinical value of CEA as a marker of recurrence and the presence of hepatic
metastases following curative resection of colorectal cancer.
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Chapter VIII
Initial development and use of laparoscopic
ultrasonography in the detection of hepatic metastases
VIII.A. Introduction
Chapters V and VI have shown as have others that IOUSS is the most accurate
method of detecting metastases at the time of operation (Machi J, 1987; 1991;
Boldirini G, 1987; Bismuth H, 1987; Makucchi M, 1987; Sheu J-C, 1985;
OlsenAK, 1990; Clarke MP, 1989; Gozzetti G, 1986; Charnley RM, 1991).
The major drawback of the technique is the need for laparotomy. Recent
advances in the field of laparoscopy have led to a resurgence of its use by the
surgeon. Laparoscopic staging of malignant disease is not new but has always
been limited to a visual assessment and biopsy (Cuschieri A, 1978; Warshaw
AC, 1990). As examination of the liver is limited to the surface of the organ,
the internal mass cannot be examined (Watt I, 1989). Previous development
of laparoscopic ultrasonography was limited by the technical performance of
small transducers but in particular the lack of a suitable linear array which could
be passed through a laparoscope port (Okita K, 1984). Confirmation of the
accuracy of IOUSS in the detection of hepatic metastases and a recognition of
the limitations of pre-operative investigations, including IOE scanning, in the
accurate assessment of patients prior to laparotomy for resection of hepatic
metastases has led to the development of laparoscopic ultrasonography.
Expertise gained in the field of IOUSS has led to successful outcome for a pilot
study. Further development of laparoscopic surgery and in particular surgery
for colorectal cancer may require surgeons to perform laparoscopic examination
of the liver as a matter of routine at the time of laparoscopic resection.
VIII. B. Aim
To develop a practical method of performing contact ultrasonography of the
liver by laparoscopic access to the abdominal cavity. To perform a pilot,
feasibility study, using this technique and compare its performance to IOUSS
and IOE scanning in the detection of known hepatic metastases.
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VIII.C. Patients and methods
There were 147 patients who were being assessed for resection of known
hepatic metastases (discussed in chapter III). Of these, 23 gave informed
consent to laparoscopy and laparoscopic ultrasonography, prior to laparotomy
and IOUSS. The equipment to perform laparoscopic ultrasonography was
available from April 1991. Patients were not" suitable for laparoscopic
ultrasonography if it was not possible to perform laparoscopy for any reason.
Patients had already undergone CXR, preoperative USS and IOE scanning of
the liver. A number of patients had also had CT scans of the chest. In the
initial series all patients were planned to go on to laparotomy.
VIII.C. 1. Equipment.
There were no commercially available laparoscopic ultrasound probes at the
inception of this study. There were, however, linear array 5 and 7.5 MHz
endo-anal probes. These are used for the imaging and accurate biopsy of
prostate cancer and mapping of anal sphincters prior to anal canal surgery. The
Aloka endo-anal ultrasound probe has both a suitable scanning array and a long
enough shaft to allow access to the abdominal cavity. The probe has an
external diameter of 18 mm and is too large to fit down an ordinary laparoscope
port. WFAM designed and built a custom port with the help of a local medical
engineering company (Oxyliter, Edinburgh). The design criteria were that the
port could replace an ordinary laparoscope port without loss of
pneumoperitoneum, allow the endo-anal ultrasound probe to be inserted and
manipulated without damage to the patient or the probe and that at the end of the
procedure the large port could be used to pass an ordinary 10 mm laparoscope.
All of these criterion were met by the first design (Plate 1 ). The large bore
laparoscope port consisted of four main parts: an obturator rod, a dilator, the
port, and a downsizer. The port and the downsizer both contained replaceable
silastic seals to maintain pneumoperitoneum. The entire device was
constructed from surgical steel and medical grade silastic.
The probe was connected to the Aloka 610 echo camera; the images obtained
were stored on video tape and as still prints.
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Plate 1. The large bore port assembly with obturator, dilator, large bore port,
and downsizer. The entire assembly was constructed using an original design
from surgical steel andmedical grade silastic.
VIII.C.2. Operation
Pneumoperitoneum is obtained by Veress needle puncture in the supra-umbilical
position to an intra-abdominal pressure of 14 cm of water. A 10 mm
disposable laparoscope port is introduced in the supra umbilical position and
routine laparoscopy performed. A second 10 mm port is introduced in the
epigastric position and the laparoscope transferred to this position. The
obturator rod of the large port is introduced through the epigastric port and the
port removed, leaving the rod in place. The large port and dilator assembly is
placed over the rod and pushed into the abdominal cavity under direct vision.
The dilator and rod are removed and the endo anal probe inserted through the
large port.
VIII.C.3. Scanning
The crystal array is manipulated onto the upper surface of the liver under direct
vision. The scan of the liver can then take place. Because of the altered
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orientation of the scanning probe to the liver and the limitations of movement of
the probe, the actual examination technique is quite different to that performed at
open operation.
VIII.C.4. Position 1
With the probe head lying immediately to the right of the falciform ligament,
and with the proximal edge of the scanning face at the inferior border of the
liver and the scanning face pointing in a posterior direction, the probe is gently
and slowly rotated in a clockwise and anti-clockwise direction through and arc
of 5-10°. Whilst the probe is being slowly rotated it is advanced, both the
primary divisions of the intrahepatic portal vein and the origin of the hepatic
veins are seen (Fig 1). This is the basic starting point of the scan and the point
of reference when defining the intra-hepatic anatomy. The probe is then
advanced over the anterior surface of the liver to its maximum extent.
Fig 1 Position 1 The probe is advanced until both the primary confluence ofthe
portal vein and the origin of the hepatic veins have been seen.
VIII.C.5. Position 2
At the start of each scan, the most superior part of the liver is viewed. By
advancing the probe until either the head of the probe loses contact with the
surface of the liver, because of its natural curve, or the tip of the probe is
pushed hard up against the under surface of the diaphragm, the most superior
part of the vena cava can be viewed. By sweeping the probe to the right and
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pushing in; the sub diaphragmatic part of the right lobe of the liver is
demonstrated (Fig 2 .).
Fig 2. Multiple sweeps of the right lobe of the liver are made pushing the
probe in and sweeping to the right. Small rotatory movements ofthe probe are
made as it is swept slowly to the right.
Once this has been done the probe is returned to position 2 and swept in an arc
to the right across the right lobe of the liver. This is repeated in successive arcs
across the surface of the liver with, on each occasion, the probe starting a little
nearer to the inferior border of the liver. The lateral extent of each scan is the
point at which either the under surface of the liver is encountered or the face of
the probe loses contact with the surface of the liver because of its natural
curvature. The right lobe having been scanned, the left lobe is dealt with in a
similar manner.
VIII.C.6. Position 3
With the probe lying to the left of the falciform ligament, the tip is swept to the
left and pushed in. This demonstrates the most superior part of the left lobe.
Successive sweeps across the left lobe are then made until the entire lobe has
been visualised.
VIII.C.7. Interrogation
At open intraoperative ultrasonography, small movements of the fingers are
used to gently tilt the scanning head through a few degrees of an arc. This
causes the plane of the scan to pass through the region of interest over and over
again. The same effect can be obtained with the laparoscopic probe by gently
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rolling the probe between the fingers of the examining hand causing the shaft to
rotate by a few degrees. This small movement causes the plane of the scan to
sweep back and forth through the area of interest giving an impression of three
dimensions (Fig 3).
Fig 3 By making small rotational movements of the shaft of the probe regions
of interest can be viewed again and again giving the impression of three
dimensions.
VIII.C.8. Biopsy
Once a lesion has been identified, it is possible to biopsy it under ultrasound
control by inserting a 'Tru-cut' biopsy needle through the anterior abdominal
wall and into the surface of the liver. The biopsy needle is prepared by
scratching its tip to improve its echo signal. The tip of the needle can then be
placed directly into the lesion to be biopsied under ultrasonic control and the
sample obtained. Biopsy of surface lesions are obtained by using forceps
inserted through a separate 5 mm port in the infra-costal area.
VIII. D. Results.
All 23 patients had IOE scans which suggested resectable hepatic metastases, 2
went on to successful resection of their hepatic metastases following
laparoscopic ultrasonography. Of the remaining 21 patients, 2 had no
evidence of any malignant disease. Eleven patients had widespread intra-
5-10 degree Arc
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abdominal disease on laparoscopy; 2 of these also had irresectable multiple
hepatic metastases. In 7 patients, laparoscopic ultrasonography revealed
widespread intrahepatic disease not seen on IOE scanning. In one of these
patients tumour thrombus from a hepatoma was identified in the left portal vein
(Plate 2).
Plate 2 Tumour thrombus in the left portal vein on Laparoscopic
ultrasonography.
In one patient laparoscopy was impossible because of adhesions. There were
no complications related to the investigation and there were no equipment
failures.
VIII.E. Discussion
The use of laparoscopy as a staging investigation is not new, (Cuschieri A,
1978; Watt I, 1989; Warshaw AC, 1990; Cuesta MA, 1992) but its use in
malignancy of the liver has been restricted by the inability to "see" into the solid
organ. This limitation is removed by laparoscopic ultrasonography. Previous
attempts at laparoscopic ultrasonography have failed because of the technical
limitations of the small array probes used (Ohta Y, 1981: Oda M, 1982; Okita
K, 1984) . These limitations have now been removed (Asher SM, 1992;
Murugiah M, 1993; Windsor JA, 1993).
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This series is not randomised and represents patients in whom the feasibility
and general performance of the technique of laparoscopic ultrasonography has
been assessed. Indirect comparison may be made to the group of patients
considered chapter IV from which this subgroup of patients was drawn. The
successful resection rate was much higher (66%) in patients who had open
staging than those who were staged laparoscopy and laparoscopic
ultrasonography (8%). Patients with irresectable iritra-hepatic disease made up
69% of the inoperable cases in the open group and only 38% of the inoperable
cases in the laparoscopy group. All 23 patients in the laparoscopy group
would have had a staging laparotomy including intraoperative ultrasonography
before resection of their liver metastases had they not undergone laparoscopy.
It is worthy of note that both patients who had resectable disease defined by
laparoscopic staging went on to successful resection where as 13% of the
patients who went directly to laparotomy had irresectable disease.
These data suggest that laparoscopic ultrasonography may obviate the need for
IOE scanning prior to laparotomy and hepatic mobilisation. What then is the
role of IOE scanning in these patients? In the patients discussed in chapter IV
the IOE scan was used to identify those with potentially resectable metastases.
All of the data from chapter IV, V and VI suggest that contact hepatic
ultrasonography is more accurate than IOE scanning in the detection of
intrahepatic malignancy at the time of operation. The data in this series shows
that laparoscopy can detect the peritoneal spread of disease, which IOE
scanning cannot, and that laparoscopic ultrasonography is more sensitive that
IOE scanning in the detection of intrahepatic disease. A rationalisation of the
pre-operative staging of patients with hepatic malignancy would suggest the
following investigations; preoperative chest Xray or thoracic CT scan, pre¬
operative USS of the abdomen and serum CEA to exclude gross disease.
Patients who have had colorectal malignancy should undergo visualisation of
their remaining colon prior to laparoscopy. These patients should then have
laparoscopy and laparoscopic ultrasonography as the staging investigation of
choice and should only go on to IOE scanning or another form of enhanced CT
scan if the results of the laparoscopic investigations are in any way ambiguous
or laparoscopy is not possible.
These results are very encouraging and suggest laparoscopic ultrasonography is
an important technique in the assessment of patients prior to resection of hepatic
malignancy. Laparoscopic ultrasonography can significantly reduce the
number of patients undergoing negative staging laparotomy for hepatic
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malignancy and so reduce both the length of hospital stay and morbidity in these
patients.
Laparoscopic colectomy is now a practical procedure (Schlinkert RT, 1991;
Wexner SD, 1992; Monson JR. 1993) and has been performed in patients
with both benign and malignant disease (Fugger R, 1993). Initial fears that it
may be impossible to perform a radical cancer operation, with a satisfactory
lymph node harvest appear to be unfounded (Falk PM, 1993). It is however
clear that it is impossible for the surgeon to palpate the liver during laparoscopic
colon resection. Laparoscopic ultrasonography provides a means whereby the
disadvantage of being unable to perform hepatic palpation can be negated.
There is no doubt that examination of the liver is an important part of the
laparotomy for colorectal cancer, laparoscopic ultrasonography allows the
laparoscopic surgeon to examine the liver with as much if not more accuracy
than a surgeon, at open operation, performing palpation alone.
It is likely that in the future laparoscopic ultrasonography will become a
standard investigation performed at staging laparoscopy for patients prior to
resectional surgery for intra-abdominal malignancy. Commercial interest has
boomed since 1991, with a number of companies now producing sophisticated
laparoscopic ultrasound probes which incorporate colour Doppler imaging
within variable frequency, variable focus linear array scanning heads. This
type of equipment will greatly enhance the development of laparoscopic
ultrasonography.




In chapter I, the importance of staging in the treatment of colorectal cancer
was discussed. Staging systems have been developed by relating known
outcome to factors which can be assessed at presentation and operation for
colorectal cancer. In this chapter, the presence of a number of factors are
related to the survival of a group of patients with colorectal cancer.
All of the patient who had IOUSS performed at the time of curative colorectal
surgery have been followed up for a minimum of 2 years. Patients who
agreed to IOE scanning in the follow up period have had extensive
investigation, those who refused have been followed up via their general
practitioners. Details of survival or the date of death have been collected for
all patients.
IX.A.l. Aim
This chapter correlates survival to the presence of risk factors detectable at the
time of presentation with colorectal cancer. The aim is to find which factors
have independent prognostic significance and which do not. This information
can then be used to suggest a rational protocol of investigation at the time of
primary resection for colorectal cancer.
IX.A.2. Method
The follow up and details including date of death are contained in the
colorectal cancer database. The database has been used to link known
outcome to potential risk factors. Patients have been grouped according to
these factors into a new database entitled SURVIVAL.dbf (Appendix 3).
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IX.A.2.a. Patients
Patients from the colorectal cancer database are discussed (Chapter VI); all
patients who had, undergone an intraoperative ultrasound scan and in whom
the diagnosis of colorectal cancer had been confirmed were included in this
analysis (147 patients). These patients have been'discussed in chapter VI.
IX.A.2.b. Life table calculation
Life table calculations have been carried out with the assistance of the
Department of Medical Statistics (RAE) using SPSS. Cox proportional
hazards regression was used to test the association between factors recorded at
the time of operation and subsequent mortality. Each factor was tested
separately (univariate analysis), and then a forward stepwise procedure was
used to identify factors that gave independent prognosis.
IX.A.3. Results
Life tables were calculated for the following: Dukes stage A, B and C, the
presence of hepatic metastases, the presence of a preoperative CEA of >160
u/1, the presence or absence of weight loss and the grade of surgeon
performing the primary colorectal resection. The longest follow up was for
50 months median 39 months range 24 to 50 months. Seventy patients died
(48%) during this time. Thirty eight men and 32 women died, representing
48% and 42% of the populations of each sex respectively
IX.A.3.a. Cox proportional hazards regression analysis
Univariate and multivariate analysis were used. The multivariate analysis
was calculated for all patients (n = 147) and for patients who in whom the
primary cancer had been assigned a Dukes stage (n = 121) (Table 1).
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Factor Univariate
Significance
Multivariate 1 Multivariate 2
Age at diagnosis NS p < 0.05 p<0.01
CEA>160 p< 0.001 p< 0.001 p < 0.05
Cure p < 0.01 NS NS
IOUSS mets p< 0.001 p< 0.001 p< 0.001
Grade of surgeon p < 0.05 p < 0.05 p < 0.05
Weight loss NS NS NS
Dukes stage p< 0.001 - p< 0.001
Table I. Cox proportional hazards regression of 7 prognostic factors for
patients having primary resection of colorectal cancers. Multivariate
analysis 1 includes all patients (n - 147) and excludes Dukes stage from the
calculation. Multivariate 2 includes the Dukes stage in the calculation and
excludes the 26 patients for whom there was no Dukes stage.
IX.AJ.b. Life tables
These have been calculated and drawn by SPSS (RAE) and are presented on
the following pages.
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Fig 1 Life table for survival related to Dukes stage at presentation. There
were 121 patients in whom the Dukes stage ofdisease was known. Of these
there were 10 Dukes A\ 51 Dukes 'B' 59 Dukes 'C' and 1 Dukes 'D\ Dukes
C and D have been grouped together. FU - follow up in years. NCODE I
= Dukes A, 2 - Dukes B, 3 = Dukes C and D.
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IX.A.3.d. Survival by surgical "cure"
FU
Fig 2 Life table ofsurvival for patients in whom the surgeon thought he had
performed a curative resection and those in whom he felt he had not. FU =
follow up in years. CURE = T, those patients who had a curative resection,
and F, those who did not. Patients in whom the surgeon thought he could
palpate metastases are in the F group whether or not they actually had
metastases.
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Fig 3. Life table for patients in whom the serum CEA at presentation was
>160 u/l and those in whom it was not. CEA160 ( 1.00 ) = CEA >160 all,
CEA160 ( .00) = CEA < 160 u/l. FU = Follow up in years.
IX.A.3.f.
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Fig 4. Life table ofsurvival by the presence/absence ofmetastases by IOUSS
at operation. NMET 1- metastases present on IOUSS. NMET 2 = no
metastases present on IOUSS. FU = Follow up in years.
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IX.A.3.S. Survival by grade of the principle surgeon performing the operation
Fig 5. Survival by the grade ofprinciple surgeon performing the primary
surgery. SURGGRAD; CONS = Consultant, SR. = Senior Registrar,
REG. = Registrar. FU = follow up in years.
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•B. Discussion
Both the univariate analysis and plots of the life tables (Fig 1-5) have shown
that the Dukes stage, the presence of metastases at operation by IOUSS,
elevation of serum CEA to >160u/l, the grade'of surgeon performing the
operation and whether or not the surgeon felt he had performed a curative
resection are significantly related to survival (Table 1). The forward stepwise
procedure has identified which of these factors are independent variables.
This analysis has been performed on two groups of patients: those in whom
the Dukes stage was known and the whole group independent of Dukes stage.
This shows that; age at diagnosis, CEA at presentation of > 160u/l, the
presence of metastases detected by IOUSS, the grade of the surgeon
performing the operation and the Dukes stage of the primary tumour all have
independent significance. These, then, are the factors that should be
assessed at the time of resection in order to more accurately predict the
outcome for any individual patient.
Duke and others have shown that the primary tumour's local, vascular and
lymphatic spread is an indicator of prognosis and also that metastatic spread
outside the field of resection is a negative factor. (Miles EW, 1925;
Michelassi F, 1991; Murray D, 1975; Dukes CE, 1932; 1958: Jass JR, 1987;
Rankin FW, 1928; Brown CE, 1938; Sunderland DA, 1949; Collier FA,
1940). The site and presentation of the cancer in the colon or rectum had
been given significance (Jeekel J, 1987), as had its genetic makeup, in
particular the presence or absence of tumour related genes (Monnat M, 1987).
In this series, both the Dukes stage and the presence or absence of metastases
on IOUSS are powerful independent prognostic indicators. Dukes staging
has been discussed in chapter I. It is the most commonly used staging
classification in Great Britain and widely quoted in the literature. The
prognostic importance of occult metastases detected during follow up has
been described by Finlay (1983). The ability to detect these small metastases
at the time of surgery by IOUSS has been described ( Charnley RM, 1991;
Machi J, 1991; Clarke MP, 1989: Boldirini G, 1987; Olsen AK, 1990;
Soyer P, 1992; Stewart PJ, 1993; Knol JA, 1993; Boutkan H, 1991)
however the independent prognostic significance of metastases detected by
IOUSS at the time of primary surgery has not been reported. As previously
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reported by Finlay, the presence of impalpable metastases is independent of
Dukes stage.
Although elevation of CEA has a significant relationship to the presence of
metastases (Wanebo HJ, 1978; 1981; 1994; Minton JP, 1985; Herrera MA,
1976; Norton JA 1991; Sikorska H, 1988; Schneebaum S, 1993; Seregani E,
1994), it also remains an independent prognostic indicator on multivariate
analysis. This suggests, as would be expected, that CEA is an indicator of
the presence of disease in general and not just of hepatic metastases. That
elevation of CEA is related to the presence of hepatic metastases reflects that
the liver is the most common site of metastasis for colorectal cancer.
In this series, the seniority of the surgeon who performed the primary
operation was a significant predictor of outcome on univariate analysis. This
might have been expected if there was case selection of patients more complex
or difficult case were operated on by the more senior surgeon. However the
significance of grade of surgeon remains in both groups of multivariate
analysis. This is an unexpected finding as the operations performed by
juniors are supervised and controlled by their seniors. Such a profound
difference in outcome related to the grade of surgeon performing the operation
has not been previously reported.
The age of the patients at diagnosis is not of prognostic significance on
univariate analysis. However, on multivariate analysis it becomes a
significant independent factor and, as expected, the older patients have a
poorer outcome than younger patients.
IX.C. Conclusion
Current clinical practice in Edinburgh is for the operating surgeon to make an
assessment, at operation, as to whether the operation has achieved a curative
resection. The resected specimen is then examined by the pathologists and
staged by Dukes method. This level of staging is inadequate. The surgeons
assessment of cure at the end of the operation is not an independent prognostic
indicator of survival and does not add to the accuracy of prognosis when the
Dukes stage is known. This data has shown that the important prognostic
factors for any individual surgeon performing an operation are; Dukes stage,
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the presence of metastases on IOUSS, a preoperative serum CEA of > 160 u/1
and the age of the patient. For the group as a whole the grade of surgeon
performing the operation is also significant.




The conclusions drawn from this thesis will be considered in four parts:
1. The use of IOE scanning for the detection of hepatic metastases at the time
of primary resection of colorectal cancer.
2. The use of IOUSS for the detection of hepatic metastases at the time of
primary resection of colorectal cancer.
3. The role of serum CEA estimation in patients with colorectal cancer.
4. The accurate staging of patients with colorectal cancer at the time of
surgery and their subsequent follow up.
X.A.I. IOE scanning
IOE scanning is an accurate, safe, and above all, clinically applicable
technique for the enhancement of CT scans to improve the detection of
hepatic metastases. Anxiety because of toxic side effects published by Reinig
and Sugarbaker (Reinig JW, 1987) and lack of commercial production has
meant that IOE scanning has remained a research tool.
CT portography (CTAP) has become a popular technique for the investigation
of hepatic metastases. It is both accurate (90%) and sensitive (91%) (Soyer P,
1992; Lindberg CG, 1993). The techniques of arteriography are well
developed and the contrast agents have a documented safety record. As yet
there have been no reports of adverse reactions or morbidity associated with
CTAP scanning. This technique has become the pre-operative investigation
of choice for imaging hepatic malignancy prior to resectional surgery. There
have been reports of false positive investigations with CTAP, with up to 42%
of round defects being perfusion or flow anomalies, and a false positive rate of
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up to 23% in the detection of segments involved by tumour (Paterson MS,
1992; Llauger J, 1992; Lindberg CG, 1993). CTAP compares favourably
with MRI and IOUSS ( Soyer P, 1992, 1993) in terms of both sensitivity and
accuracy, but has a higher false positive rate than either. 10E scanning in
this study has a similar accuracy to that of CTAP and a very much lower false
positive rate of only 15 out of 195 investigations (7,7%). The lower limit of
resolution of CTAP is also similar to IOE scanning at around 1 cm
(Mclaughlin RF, 1993)
The comparison of IOE scanning to DBCT in this study shows IOE scanning
to give superior results in terms of the number of hepatic segments shown to
be involved by tumour and in the determination of resectability of hepatic
tumour.
IOE scanning fails to detect very small intra-hepatic tumour deposits. For
patients undergoing resection of primary colorectal cancer, the false negative
rate in the detection of small hepatic metastases was low (4.5%). In these
patients, IOE scanning was used only to detect tumour within the liver, and
not to determined resectability. IOE scanning cannot detect the presence of
small peritoneal metastases as it has no advantage over palpation and
visualisation in this regard.
IOE scanning is a repeatable investigation: there has been no evidence of
either sensitisation or tachyphalaxsis to the contrast agent. However,
patients are unwilling to have repeated IOE scans during their follow-up.
This limited the recruitment to the study and would limit the use of IOE
scanning in a clinical context.
X.A.I .a. IOUSS
Intraoperative ultrasonography is the gold standard for the premortem
detection of intra-hepatic malignancy. This investigation has an accuracy of
more than 90% in the detection of intrahepatic malignancy in two groups of
patients studied in this thesis. The investigation has a negligible false
positive rate and is more accurate than attempted biopsy in the correct
identification of malignant lesions. Others have obtained similar results for
IOUSS (Stewart PJ, 1993: Machi J, 1991), recently Soyer has found CTAP
and IOUSS to have similar sensitivity in the detection of small metastases but
IOUSS was more specific (Soyer P, 1992). IOUSS can be used at the time
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of surgery for patients with colorectal cancer to improve the detection of
hepatic metastases in these patients. The information gained by IOUSS is of
independent significance in the determination of survival following cureative
resection of colorectal cancer.
There are no practical limitations to the use of'IOUSS, the equipment is
inexpensive, the technique is simple and may be learned over a short period
of time by general surgeons. IOUSS is the method of choice for the detection
of hepatic metastases at the time of resection for colorectal cancer.
Laparoscopic ultrasonography offers the same accuracy of hepatic staging
during laparoscopic surgery as may be attained at laparotomy.
X.A. 1 .b. Hepatic resection
Two patients in this series were suitable for, and underwent hepatic resection
for colorectal metastases detected at the time of their primary surgery by
IOUSS and IOE scanning. Unfortunately both of these patients died of
recurrent disease within 2 years of their hepatic resection. Early detection of
hepatic metastases, at the time of curative resection of colorectal cancer, and
their subsequent resection, has not been shown to improve patients survival
in this small series.
X.A. I.e. CEA
It is becoming clear that, with the advent of IRMA test kits for serum CEA
estimation, the accuracy of this investigation in the determination of
prognosis and recurrence has improved.
In patients with known recurrence of colorectal cancer being staged for
hepatic resection, the level of serum CEA at presentation with recurrence has
a negative correlation to the resectability of the tumour. Although significant,
this relationship is unfortunately of little clinical value as the spread of CEA
values is so wide. A serum CEA of >1000 u/1 at presentation with recurrence,
however, gives predictive value of 92% for irresectable disease. The overall
accuracy for CEA in the determination of resectability is low at 58%.
In patients presenting with colorectal cancer, elevation of serum CEA is
positively correlated to the presence of hepatic metastases. In this series,
preoperative CEA of 160u/l was found to have a 71% accuracy in determining
the presence of metastases. Not only may the preoperative CEA give an
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absolute indication of the risk of recurrence, but postoperative measurement
of CEA values may also give an indication of the timing of recurrence.
Elevation of CEA to > lOOu/1 in the postoperative period is an indicator of
recurrent disease in 83% of patients.
CEA is an indicator of prognosis and timing of recurrence in 70% - 80% of
the population of patients with colorectal cancer. When correctly interpreted,
a rising CEA may be the only indicator of recurrence of colorectal
malignancy. As such, this test represents a cost-effective and practical
method indicating prognosis and of screening for recurrence.
X.A.2. Laparoscopic ultrasonography
Initially using modified endo-anal equipment and latterly custom built probes
(Aloka), laparoscopic hepatic ultrasonography has been performed
(Jakimowicz JJ, 1993). This small series has shown that laparoscopic
ultrasonography can be performed and can provide an image quality similar to
that obtained with IOUSS at laparotomy. The use of laparoscopic
ultrasonography is the subject of a further investigation currently underway in
the University Department of Surgery. It is likely that laparoscopic
ultrasonography will become the mainstay investigation prior to laparotomy
for hepatic resection and may replace all other preoperative imaging
investigations. Laparoscopic ultrasonography will become a vital part of the
staging laparoscopy prior to laparoscopic colonic resection for malignant
disease.
X.A.3. Staging ofcolorectal cancer
There is no doubt that the presence of hepatic metastases from colorectal
cancer is an indicator of poor prognosis. The presence of hepatic metastases
is associated with a mean survival of 18 months and a negligible 5 year
survival. We have used IOUSS to detect very small volume intrahepatic
tumours which are at an early stage of their development. Early detection
may explain the better than expected survival of patients with hepatic
metastases in this series.
Survival analysis has shown that the presence of hepatic metastases detected
by IOUSS at the time of operation is a prognostic indicator which is
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independent of Dukes stage and preoperative serum CEA, each of which
have independent prognostic value. The assessment of curative resection,
including the detection of metastases by palpation, by the surgeon at
operation, is not an independent indicator of prognosis. Accurate staging and
follow-up of patients in this series has also revealed a significant association
between junior grade of principle surgeon and poor prognosis, which also
remains an independent factor after multivariate analysis.
The four factors identified in this series (Dukes stage, age, hepatic metastases
and serum CEA) could be used, with appropriate weighting, to construct a
perioperative staging system which, by taking into account all four
independent variables, would give a more accurate estimate of prognosis than
any of the variables considered singly. The number of patients in this series
is too small to allow accurate weighting, a larger series will be required.
However, the relevant factors have been identified and potential for
improved staging recognised.
This thesis has shown that intraoperative ultrasound scanning at the time of
curative resection for colorectal cancer is a practical procedure that provides
independent prognostic information. This technique should be used to
improve the staging of colorectal cancer at the time of operation so that both
the results of surgery and adjuvant therapies can be assessed in groups of
patients for whom the stage of disease has been accurately documented.
Accurate matching for stage will allow the effects of different treatments on
similar groups of patients to be compared. Failure to assess the presence of
hepatic metastases introduces a powerful, random effect on outcome which
may mask more subtle effects brought about by adjuvant treatment regimens.
It is only through improving our knowledge of malignant disease that we can
hope to improve treatment and so, survival. To this end, this thesis has
shown that surgeons who are treating patients with colorectal cancer, and in
particular coloproctologists who may be treating large numbers of patients
with malignant disease, should undertake intraoperative ultrasound scanning
of the liver as a part of their operative routine.
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Appendix 1 Summaries of patients with positive scans.
Introduction
These are short summaries of patients who had either a positive IOE scan and
a negative IOUSS at the time of operation or a negative IOE scan and a
positive IOUSS. They are included to give an indication of the reasoning in
each case as to the final confirmation of the presence or absence of metastases.
The details of each patient with confirmed metastases
1. Patient number 3. 65 year old woman, curative resection of a Dukes B
carcinoma of the caecum. No palpable metastases, IOUSS normal,
developed metastases on the second IOE scan confirmed by the two following
scans. Final CEA was 37 u/1. Status: confirmed hepatic metastases.
2. Patient number 7. 61 year old man. A low rectal carcinoma, Dukes B
resected by abdomino perineal resection. Hepatic metastases detected by
palpation and IOUSS at the time of operation and confirmed by follow up IOE
scanning. CEA at final scan 6350 u/1. Status: confirmed hepatic metastases.
3. Patient number 12. 62 year old man. Sigmoid colectomy for a Dukes A
adenocarcinoma of the descending colon. Palpation of the liver was normal.
IOUSS detected a 12 mm metastases in segment V. The first three IOE scans
were normal; however, the final IOE scan detected a single metastasis in
segment VIII. The patients' CEA was 97 u/l prior to resection, fell to normal
during his early follow up and had risen gradually to 61 at the time of re¬
presentation of the metastases. Status: confirmed hepatic metastases.
4. Patient number 17. 88 year old woman. Right hemicolectomy for a
Dukes B carcinoma of the transverse colon. Three hepatic metastases were
palpable at the time of operation and confirmed by IOUSS. The first IOE
scan detected all three metastases. CEA at the time of the IOE scan was 101
u/1. Status: confirmed hepatic metastases, died.
5. Patient number 18. 78 year old man. Anterior resection for a Dukes CI
carcinoma of the rectum. This was tethered to bowel and bladder at operation
but all of the tumour was resected. There were no palpable hepatic
metastases. IOUSS revealed a single 14 mm metastasis in segment VI. A
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metastasis was confirmed on the first IOE scan but placed in segment VIII.
On the third scan the metastasis was correctly sited in segment VI and was 10
cm in diameter. CEA was 30 u/1 before primary resection. The CEA at the
time of the last IOE scan was 30 u/1. Status: confirmed hepatic metastasis.
6. Patient number 25. 56 year old woman. Anterior resection and
hysterectomy for a locally extensive mucinous Dukes CI carcinoma of the
upper rectum. Palpation at operation revealed three metastases, one each in
segment II, VI and VIII, these were 20, 10 and 20 mm in diameter
respectively. On IOUSS, these were found to be cysts, the largest of which
(in segment VI) contained internal septa and debris. This was defined as a
cystic metastasis at the time of the scan. The presence of multiple complex
cysts was confirmed on the first IOE scan. The patient died before the second
scan. CEA at the time of the IOE scan was 92 u/1. Status: confirmed
hepatic metastases.
7. Patient number 26. 82 year old woman. Right hemicolectomy for
Dukes B adenocarcinoma of the transverse colon. The tumour was tethered
to bowel and a single hepatic metastasis was detected by palpation. IOUSS
detected the same 14 mm metastasis in segment II. IOE scan was reported as
showing two 1 cm metastasis one in segment II and the other in segment VIII.
The patient died before the second IOE scan. CEA at the time of death was
<30 u/1. Status: confirmed hepatic metastases.
8. Patient number 57. 60 year old man. Right hemicolectomy for a Dukes
B carcinoma of the ceacum. Palpation at operation revealed a single 10 mm
metastasis in segment II. IOUSS detected a large 10 cm ill-defined mass in
segment V. Biopsy of this confirmed the presence of metastatic
adenocarcinoma. IOE scan confirmed the same metastasis. The patient died
before the second IOE scan was performed. CEA at presentation was 84 u/1.
Status: confirmed hepatic metastases.
9. Patient number 64. 78 year old woman. Sigmoid resection for a Dukes
A adenocarcinoma of the recto sigmoid junction. Palpation at operation
revealed a 10 cm metastasis in segment IV. This was confirmed on IOUSS
and the presence of two more metastases in segments II and III was
confirmed. The largest metastasis was confirmed by biopsy. IOE scanning
suggested five metastases all in segment IV. The patient died before the
second IOE scan. CEA at the time of the first scan was 194 u/1. Status:
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confirmed hepatic metastases.
10. Patient number 82. 62 year old man. Abdomino perineal resection for
a Dukes CI carcinoma of the rectum. There were no palpable metastases,
although IOUSS detected more than 10 small metastases through both lobes of
the liver, two of which were confirmed on the first 10E scan. Subsequent
scans revealed one of the metastasis to be of increasing size. The final IOE
scan failed to detect any metastases and is a false negative. Status:
confirmed hepatic metastases.
11. Patient number 89. 70 year old woman. Right hemicolectomy for
Dukes C2 carcinoma of the colon. There were no palpable metastases.
IOUSS detected 4 metastases in segments III, IV and V. A single metastasis,
8 mm in segment VII, was also detected by the first IOE scan. CEA at the
time of the IOE scan was 500u/l. The patient died before the second scan.
Status: confirmed hepatic metastases.
12. Patient number 90. 61 year old man. Anterior resection for a Dukes
CI adenocarcinoma of the rectum. Palpation revealed two metastases
confirmed by IOUSS, in segments VI and VIII, 35 and 40 mm in diameter.
These were identified by IOE scanning as being in segments VI and VII.
This patient underwent hepatic resection and the two lesions were confirmed.
The IOE scans of the remaining liver in the follow up period were normal.
Status: confirmed hepatic metastases.
13. Patient number 99. 77 year old man. Abdomino perineal resection for a
Dukes CI mucinous carcinoma of the rectum. IOUSS and palpation of the
liver at the time of operation were normal, as were the first and second IOE
scans. The third scan revealed three metastases, each 2 cm in diameter, in
segments IV, VI and VII. The fourth scan revealed 7 metastases of various
sizes scattered throughout the liver. CEA at the time of the last scan was
>1000 u/1. Status: confirmed hepatic metastases.
14. Patient number 106. 62 year old man. Reversal of a Hartmanns
operation for carcinoma of the transverse colon. The original tumour was
Dukes CI. Palpation of the liver at reversal was normal, as was IOUSS.
The first IOE scan was also normal, the second detected a 30 mm metastasis
in segment V. CEA at the time of the second IOE scan was 182 u/1. Status:
confirmed hepatic metastases.
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15. Patient number 108. 43 year old man. Sigmoid resection for a Dukes
CI carcinoma of the colon. Palpation of the liver failed to detect any
metastases. IOUSS detected a single 20 mm mass in segment VII. This was
also apparent on the first IOE scan. The patient underwent a course of
chemotherapy and resection of the right lobe of the liver. On pathological
sectioning, the lesion had decreased in size. Tfyere was no evidence of
carcinoma, only an area of fibronodular hyperplasia. The patient was re¬
admitted with local and hepatic recurrence in Feb. 1994 and died. Status:
confirmed hepatic metastases.
16. Patient number 111. 68 year old woman. Subtotal colectomy for a
Dukes CI carcinoma of the rectum. Palpation at the time of operation
detected a 15 mm metastasis in segment VI. This was confirmed by IOUSS,
as was the presence of several cysts. The first IOE scan failed to detect any
lesions. The second IOE scan detected 4 metastases. CEA at the time of the
second IOE scan was 101 u/1. Status: confirmed hepatic metastases.
17. Patient number 113. 76 year old male, curative resection of a Dukes C2
carcinoma of the transverse colon. No palpable metastases, single 10 mm
metastases in segment VI on IOUSS confirmed on the second and fourth IOE
scan, with 2 metastases on the second IOE scan, in segments VI and VIII and
only one metastases on the final scan in segment VIII. Follow up CEA at 24
months was 1630 u/1. Status: confirmed hepatic metastases.
18. Patient number 141. 58 year old man. Right hemicolectomy for a
Dukes B adenocarcinoma of the ceacum. Palpation at operation revealed the
presence of a single 12 mm metastasis in a subcapsular position in segment V.
This was confirmed on IOUSS which showed the liver to be largely replaced
by metastases. Three IOE scans failed to detect any lesion. CEA at the time
of the last IOE scan was < 30 u/1. The patient, who failed to attend for his
fourth IOE scan, was admitted more than three years after the original
resection with hepatic metastases and local recurrent disease. Although there
was no biopsy taken at the time of operation, there was no doubt that the liver
was full of metastases. There was no evidence of cirrhosis or cysts. Status:
confirmed hepatic metastases.
19. Patient number 154. 43 year old man. Anterior resection for a Dukes
B adenocarcinoma of the upper rectum. Palpation of the liver at operation
was normal. IOUSS revealed a 15 mm metastasis in segment IV. The first
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IOE scan detected a metastasis in segment IV and also a metastasis in segment
V. CEA at the time of scanning was 74 u/1. The patient died before the
second IOE scan. Status: confirmed hepatic metastasis.
Patients who have had a positive IOE scan in whom metastases have not been
confirmed.
1. Patient number 4. 57 year old woman. Sigmoid resection for a Dukes
C2 adenocarcinoma of the colon. A single small nodule on the liver was
biopsied after detection by palpation alone. No metastases on IOUSS. The
biopsy was negative, The first, third and fourth IOE scans were negative, the
second was a false positive. CEA at the time of the second IOE scan was 3 1.
CEA at the time of the last scan was 204 u/1, indicating the possibility of local
recurrence. Status: no hepatic metastases. This represents a false positive
IOE scan.
2. Patient number 11. 79 year old woman. Right hemicolectomy for a
Dukes B carcinoma of the caecum. Palpation of the liver at the time of
operation was normal, as was IOUSS. The first, second and fourth IOE
scans were normal, the third suggested a 10 mm metastasis in segment VI.
CEA at the time of presentation was 545 u/1 and remained below 50 for the
duration of the follow up. Status: confirmed no hepatic metastases.
3. Patient number 14. A 77 year old woman with a pre-operative CEA of
30 u/1, at operation was found to have a mobile cancer of the upper rectum
above the peritoneal reflection. Curative resection was undertaken with a
restorative stapled anastomosis. There was no evidence of metastases at
operation either by palpation or by intraoperative ultrasonography.
Pathological examination revealed a 2 cm protuberant adenocarcinoma, 6 cm
from the distal resection margin of the rectum (Dukes B). The first post
operative IOE scan suggested the presence of a single small metastasis in
segment V. This did not appear on subsequent IOE scans over the 18 month
period of follow up. Status: no hepatic metastases. This represents a false
positive IOE scan.
4. Patient number 15. 76 year old man. Abdominoperineal resection for a
Dukes B adenocarcinoma of the rectum. Palpation of the liver at operation,
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IOUSS and the first IOE scan were all normal. The second IOE scan
suggested three metastases in segments II, III and V. This was supported by
a rise in CEA to 100 u/1. However, the third and fourth IOE scans did not
show any evidence of metastases and the CEA fell to 67 u/1 over a period of
12 months. Preoperative CEA was 93 u/1. Status: confirmed no hepatic
metastases. The patient died 1186 days after his operation. There was no
evidence of hepatic metastases at the time of death.
5. Patient number 16. An 80 year old woman with a pre-operative CEA of
66u/l. At operation she was found to have a mobile carcinoma of the caecum.
Curative resection was undertaken with a restorative single-layer anastomosis
with absorbable suture material. There was no evidence of metastases at
operation either by palpation or by intraoperative ultrasonography.
Pathological examination revealed a 2.5 cm protuberant tumour of the
caecum, 17 cm from the proximal resection margin (Dukes B). The first
preoperative IOE scan suggested three metastases in segments V, VI and VIII
of the liver, and measuring 8 mm, 8 mm and 6 mm in diameter respectively.
Preoperative ultrasonography had not detected any abnormality and
subsequent IOE scans over the period of the study failed to detect any
abnormality. This represents a false positive IOE scan. Status: no hepatic
metastaes.
6. Patient number 24. 46 year old woman. Sigmoid resection for a Dukes
CI carcinoma of the colon. There were no palpable metastases, IOUSS was
clear as were the first three IOE scans. The final IOE scan suggested a single
small metastasis in segment VII. CEA at the time of the last scan was 30 u/1.
CEA at the time of primary resection was also 30 u/1. The presence of
metastases in this patient was not confirmed. Status: no hepatic metastases.
7. Patient number 31. 80 year old woman. Right hemicolectomy for a
Dukes B carcinoma of the ceacum. Palpation of the liver at operation was
normal as was IOUSS. The first, third and fourth IOE scans were normal,
the second showed a 22 mm metastasis in segment II. The CEA prior to
operation was 30 u/1 and remained at that level through out her follow up.
Status: no hepatic metastases.
8. Patient number 33. 70 year old man. Total colectomy for a stenosing
carcinoma of the caecum. Palpation at operation revealed two lesions on the
surface of segment V and VIII. These were shown to be cysts on IOUSS:
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there were no other lesions. The first, third and fourth IOE scans were
normal, the second scan showed a 5 mm lesion in segment 8 in a subcapsular
position. CEA at the time of the last IOE scan was 30 u/1. Status: confirmed
no hepatic metastases.
9. Patient number 35. 76 year old man. Anterior resection for a Dukes CI
adenocarcinoma of the rectum. Palpation and IOUSS at the time of operation
were normal as were the first and third IOE scans. The second scan
suggested a metastasis in segment II. CEA at operation was 131 u/1. Three
months after surgery it was 135 u/1 then 76 u/1, 30 u/1, 93 u/1, 73 u/1 . The
patient failed to attend for his final scan because of recurrence of local disease.
Status: no hepatic metastases.
10. Patient number 36. An 80 year old man with a pre-operative CEA of
30u/l, who had an emergency subtotal colectomy for an obstructing
carcinoma of the sigmoid colon. The primary tumour was mobile and a
restorative single layer anastomosis was made with interrupted absorbable
sutures. Palpation of the liver by the surgeon revealed apparent metastases in
segments, II, IV, V and VI. These were 22 mm, 10 mm, 10 mm and 10
mm in diameter respectively. Intra-operative ultrasonography revealed three
cysts in segments IV, V and VI. The lesion in segment II was not seen. A
single IOE scan in the post-operative period suggested metastases in segments
VI, V, and VIII, each 10 mm in diameter. Pathological examination of the
specimen showed a 3.3 cm stenosing Dukes CI carcinoma 5 cm from the
distal resection margin. There were also 9 adenomas in the resected
specimen. Preoperative hepatic ultrasonography failed to detect any
abnormality . This patient did not enter the IOE follow up phase of the study
and when last seen at a clinic 6 months after surgery was well with a CEA of
55u/l. This represents a false positive IOE scan. Status: no hepatic
metastases.
11. Patient number 72. 66 year old woman. Right hemicolectomy for a
Dukes CI carcinoma of the caecum. Palpation of the liver at the time of
operation was normal as was IOUSS. The first, second and third IOE scans
were also normal. The final IOE scan suggested three metastases of 20 mmCO
each, in segments IV, VI and VIII. CEA prior to surgery was 44 u/1 and at
the time of the last scan was 30 u/1. Although the lesions seen on the last IOE
scan may have been metastases this was not confirmed by any other
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investigation. The patient died 677 days after surgery. Unfortunately the
presence of hepatic metastases was not confirmed at the time of death.
Status: possible hepatic metastases not confirmed
12. Patient number 80. 69 year old man. Anterior resection for a Dukes
CI adenocarcinoma of the colon. Two small lesions were detected at
operation by palpation on the surface of segments V and VI. These were not
detected by IOUSS which identified subcapsular cysts in the same position.
They were detected by the second IOE scan and reported as metastases in a
subcapsular position in segments VI and VIII, each now 2 cm in diameter.
CEA at the time of the final IOE scan was 60 u/1. The patient became
symptomatic and no further scans were performed. These lesions were not
confirmed as metastases within the criteria of the study and so this represents
a false positive IOE scan. Status: no hepatic metastases.
13. Patient number 85. A 69 year old man with a pre-operative CEA of 65
u/1, at operation had potentially curative anterior resection of a Dukes CI
carcinoma at the peritoneal reflection of the rectum. The tumour was locally
invasive being fixed to the left pelvic side wall, the dome of the bladder and
the left ureter. There was no evidence of trans-celomic spread or of hepatic
metastases either on palpation or intra-operative ultrasonography. The first
post-operative IOE scan revealed two apparent metastases in segments IV and
VII each of 8 mm diameter. Three subsequent scans over the 18 month
period of the study failed to confirm the presence of any abnormality in the
liver. This represents a false positive IOE scan. Status: no hepatic
metastases.
14. Patient number 137. 46 year old man. Anterior resection and resection
of bladder for a Dukes C2 carcinoma of the rectum. Palpation of the liver at
the time of the operation was normal as was IOUSS. The first and second
IOE scans were also normal. CEA prior to surgery was 30 u/1. The third
IOE scan suggested a 7 mm metastasis in segment VII. This patient had a
local recurrence of his disease and a fourth scan was not performed. Status:
possible hepatic metastases not confirmed.
15. Patient number 139. 44 year old man, curative resection of a Dukes B
carcinoma of the right colon, preoperative CEA was 54 u/1. There were no
palpable metastasis, no metastases on IOUSS. The second IOE scan showed
a single 10 mm metastasis in segment III. The CEA was 58 u/1 (within the
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normal range). He became clinically unwell and had no further imaging.
This represents a false positive IOE scan. Status: no hepatic metastses.
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Appendix 2
Computerised storeage of data.
A.2.A. Introduction
It was obvious from the inception of this project that there would be a large
amount of data collected. The most efficient way to store the data in a
manageable form was in a computerised database. The database and the
software to run the database was developed within dBase III plus, a
commercially available database package ( Ashton Tate Corp. ). There were a
number of advantages to this system and some disadvantages. All of the
database design, construction and programming was done by the author,
WFAM. The aim was to produce databases which would contain all of the
information from each patient in such a way that the various parameters could
be compared and the patients could be sorted on the basis of any parameter.
All of the patients' details were stored and, although a duplicate paper copy
was kept, this was only as a safe guard against data loss. The programming
feature of dBase III plus allowed the author to produce a customised package
which, when installed, would allow the collection and indexing of patient data
by any operator without previous knowledge of dBase III plus.
A.2.B. Equipment
All of the database construction and programming was performed using dBase
III plus and "dBase III plus" Administrator. The computer used was an IBM
PS/2 286 AT. Information concerning the use of "dBase III plus" and
programming was obtained from "dBase III plus made easy", Miriam Liskin,
Osborne, McGraw-Hill, Berkley, California and from "dBase III plus,
Programmers Reference Guide" Edward Jones, Howard W. Sams &
Company, 4300 West 62nd St, Indianapolis, Indiana. Both of these texts
were considerably more useful than the manuals supplied with the program.
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A.2.C. Design
The database was designed on paper in the first instance. A list of the data to
be collected was made and used to construct a data collection sheet. The data
files for each patient were constructed by converting the outline structure of the
sheet into screens in the computer program. Each screen matched one of the
data collection sheets, not only in appearance but in the type of information in
each field.
Each file in the database can contain a maximum of 127 fields. As the data
entry sheets contained many times that number of fields (580 in total) it was
necessary to construct a number of files for each patient, each file being a
separate database in its own right. These separate databases each contained
identical key fields which allowed the separate databases to be linked (related)
together for data input and analysis.
There were eight separate files, each containing information on a different
aspect of the patients' history, examination or investigation. Each file
contained four identical key fields, these were for the patients' first name, last
name and their date of birth. These three strings; "LASTNAME",
"FIRSTNAME" and "DOB" were joined in a fourth field called "LINK" .
Every patient file in each of the databases used in this thesis contain this
"LINK" field. Because of the highly individual nature of these three fields,
the identifier "LINK" could be considered as unique for each patient.
A.2.D. Data files.
There are 8 data files of various length and complexity for each patient. Each
of these is linked to a screen construction file. The construction of these
screens is such that they are identical to the paper 'Patient Data' sheets and so
transfer of data is as straight forward as possible. The screens contain
information regarding how information should be put into the computer, its
format, and where required codes that are used to identify various stages of
disease or clinical findings. The screens are designed to ensure that data is put
into the computer in a consistent manner. Failures of consistency have made
data analysis more difficult.
Within "dBase III plus", data can exist in a number different formats. The
data is stored in a field and each field must have a format. Data can only be
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entered if it conforms to the format of the field. If an attempt is made to enter
data which does not conform it will be rejected. The formats are: character,
date, numeric, logical and memo.
A.2.E. Basic design
The database is designed so that patient data could be put in by anyone with
basic computer skills and no special knowledge of "dBase III plus". Apart
from the commands required to gain access to the database and the codes to
access the protected files all of the basic functions of the program are menu
driven.
A.2.E.I. Protection
To gain access to the database the operator must use a code word followed by
their name and an individual code number. This gives three levels of protection
to the program and the data within it. All of the database information is
encrypted so that the data files can not be read without first going through the
codes at the beginning of the program.
A.2.E.2. Data entry
Once access has been gained to the program the operator is given a menu of the
facilities within the program (Fig I).





WHICH INPUT SCREEN WOULD YOU LIKE?
A. INPUT A PATIENT INFORMATION
B. PRINT PATIENTS IN DATABASE
C. MARK A FILE FOR DELETION
D. LIST APPOINTMENT DATES
E. DATABASE UTILITIES
X. TO EXIT PROGRAM
MAKE A CHOICE FROM THE LIST
Fig 1 opening menu from the colorectal cancer database.
Choice " A " initiates access to the patients' files menu. In order to gain
access to the files, it is necessary to input the patients' first name, last name
and date of birth. The program will then search the database for a match. If
none existed it will then search for an inexact match on the last name alone. If
there is no match for the last name, the program will display all the patients
with a last name whose opening string of letters matches those of the input data.
For instance if the operator inputs "Charles Smith" and date of birth "22/01/27",
this will match patient 106 exactly and this patients' records will be accessed.
Just typing "Smith" will bring up the two patients in the database with the last
name Smith. If only the letter S is supplied a list of the 17 patients with a last
name beginning with 'S' will appear. The operator will then be asked to
choose one of the records to view, or to create a new set of files based on the
information used for the patient search, in this case the letter 'S'. Every time a
patient is put into the database the same procedure is used, this prevents
patients having two or more sets of files produced. If it is indeed a new
patient, the search information (last name, firstname, and data of birth) would
V J
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then be used to initiate and add to the index a blank set of files for that patient.
These files could then be opened and filled ( Fig 2 ).
During the two years of data input, this system only failed twice. Once the
computer hard disc cross linked one of the "dBase 111 plus" files to a file in
"Reference manager", another database program on the hard disc and this had
to be corrected manually. On the second occasion, unauthorised access to the
computer resulted in reallocation of one of the keys on the keyboard. This
allowed a non-alphanumeric character to be typed into an index field corrupting
the index. This was corrected by rebuilding the database from backup. The
software has never failed and there was no duplication of notes and no
inadvertent addition of the wrong information into the wrong patients' files.
Each patient's file can be accessed as often as required to add and edit data as
they became available.
The follow up fdes are accessed from the second level menu and are indexed in
a similar manner. Patients can only have follow up files if they already exist in
the patient identification database. Once accessed, the follow up menu will
allow a choice of all of that patient's follow up files in chronological order. If
no file existed, a new one could be generated and then filled. Again the
system will search for all similar patients prior to the initiation of a new set of
files. When completed, the files are automatically saved as they were closed.
A.2.F. Storage
All of the data was stored on the hard disc of the computer and on floppy discs.
The floppy disc information was encrypted, the discs were divided into sets,
one set for daily backup, one for weekly and one (stored at a different location)
for a monthly backup. As mentioned the backups were required on two
occasions to reconstruct the database when it failed.

















Fig 2 Program flow for the input of information into the colorectal cancer
database.
A.2.G. Analysis
Once all of the data had been collected and prior to analysis, it was necessary to
check the database for "rubbish". There were a number of fields which were
completed in an inconsistent manner, either because the questions were
ambiguous or because the nature of the data was not exact. The major
problems occurred with fields which required a Yes / No answer but were not
logical fields. These were then filled in as ether Y for Yes or T for True, and
N or F for the negative response. Unfortunately, "dBase III plus" can only
search for exact matches of characters or for characters within a string of
characters. The use of either YorT for a response meant that either inexact
search parameters had to be used or all of the fields containing this type of data
had to be corrected to contain either T,F or Y,N responses. The latter approach
was chosen and all of the fields of this type were "cleaned" to contain only one
type of response. A number of short programs were written for this purpose.
Once all of the data had been cleaned and checked, analysis was performed.
As the central question was the comparison of the results of one investigation
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against another, most of the analysis was comparative. In order to compare
two databases it is necessary to link them so the same patients in each database
can be compared. "dBase III plus" allows databases to be "related", provided
they contain a field which is the same in each database and on which the
database is indexed. The "link" field was used for this. As all of the patients
were entered into each of the databases in the same order, it was also possible
to use the unique number allocated to each patient by "dBase III plus" called
RECNO(). This is a chronological record of the order in which files are
entered into the database. As all the files for one patient were created at the
same time, it was a second unique identifier for each patient. RECNOQ could
not be used for the follow-up files as they were not all created at the same time
and so had different record numbers for records belonging to one patient.
Once two or more databases had been related, then a search for patients
fulfilling any number of criteria from any number of the databases could be
constructed. For instance, by relating the blood result database COLONCAB
to the intraoperative ultrasound result database COLONCAI, it was possible to
list the CEA result for each patient with hepatic metastases at operation. This
type of search can be carried out with any combination of scope of patients or
criteria for the search.
A.2.H. Discussion
With hindsight, there are a number of features of this database which were
unnecessary. The eight separate databases containing a total of 548 fields was
more comprehensive than was required. A number of the fields related to data
which was not collected or not available from the majority of the patients.
These fields were discussed at the design stage and included because of the
general feeling thst it was better to include too much rather than let data go
unrecorded. This was an error: these largely empty fields have cluttered up the
databases and slowed down data entry and recovery. The ideal database
should contain fields for available and important information. The maintenance
of a database in clinical projects is difficult and is made more so by having
larger numbers of fields to fill. Failure to complete each patient's record leads
to a dilution of the number of patients that can be used for analysis. In order to
complete all of the data, a full time research nurse, JC, was employed to
record the details of the IOE scans and to search for the data that was missing.
In all cases all of the data that was available for each patient was recorded
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prospectivly. For most patients there were a number of fields left blank for
investigations which were not performed.
Further development of this data base would have allowed all of the patients to
be called for their investigations directly from the database and all of the clinic
appointments and letters to have been arranged from the computer. This was
not done for a number of reasons but principally because the programming of
the database was ongoing and by the time a clinic appointment program had
been written and checked most of the patients had already been documented in a
follow up diary and their scans arranged. The number of patients entered into
the database was much lower than had been envisaged. The diary system
worked perfectly for the numbers involved and was both simple and reliable.
If larger numbers of patients had been involved then computerisation may have
held some advantages, particularly in booking and sending for the patients to
come in for follow up scans.
The "dBase III plus" software was robust and reliable. The program itself did
not cause any problems and worked faultlessly throughout. Programming in
"dBase III plus" was also straight forward and allowed the development of a
set of databases to collect a large amount of data on a moderate number of
patients. It is undoubtedly a powerful tool which can allow inexperienced
programmers to produce useful software with the minimum of difficulty.
Computerisation of data should not be seen as the answer to all problems in data
collection and storage. In particular, the ability to store large amounts of data
should not be used as an excuse to collect more data. Data should only be
collected if it is of relevance to the question being asked and if it will provide or
help to provide an answer. Unfortunately this was not the case with all of the
data collected in this database. More critical planning of the content could have
led to a much slimmer database with fewer empty spaces. The only advantage
to collecting large amounts of data is that some unexpected relationship may
turn up during the analysis. However, the likelihood of completely
unexpected relationships being discovered are remote. The only data which
has proved to be of worth was that which was collected with the express intent
of providing an answer to a specific question.
A.2.1. Programs
A number of the key programs for the colon cancer database have been included
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in appendix 3. All of the programs were written by the author without the
assistance of any other programmer. In total 116 programs were written for
the LIVERCA database and the COLONCA database. This does not include
the construction of the actual databases and the screens for data input. A small
number of programs have been written not directly related to the management of
the databases. These perform basic statistical analysis of the data. One such
program calculates Chi Squared while another calculates sensitivity, specificity,
and accuracy.
Further development of the COLONCA database had not been undertaken.
However, it will be possible to use this program as the basis for a
computerised colorectal clinic with regulated follow up of all patients and
automatic recall to the out-patient clinic and for colonoscopy. By using the
database to run a clinic, all of the data from patients' follow up would be
collected prospectivly and subsequent analysis would be both rapid and straight
forward.
There is no doubt that in the future, patients' clinical details will be collected
onto databases as part of the daily routine of admission. The course of the
patients' admission will be prospectivly recorded as will the results of their
investigations and their outcome. This will result in large databases from
which data can be drawn and analysed. It will be possible to insert key fields
to record particular information in response to relevant questions. In this way,
large patient databases will speed up data collection for research projects such as
this. Both the LIVERCA database and the COLONCA database are prototypes





These are a sample of the 117 programs that have been written to allow the
data collected on patients within this study to be correlated. The file
structures for two of the databases used for the COLONCA database are also
listed, as is a summary of the contents of the Survival.dbf file.
Programme titles
COLOPEN3
This is the first of the opening programs. It checks that all of the databases
are available and that their indexes are also present.
COLOPEN2
This is the second of the opening programs. It welcomes the user to the
database and displays the various options from this programme. To add
patients to the database or to add information to a patient who already exists,
the user must choose "A" from the menu.
OPEN
This is the last of the opening screens. It requires the user to input patient
details in order to select the appropriate patient from the database or to initiate
a new set of screens for a new patient if required.
NOTECHEK
The data gained by OPEN is used in NOTECHEK to check all of the patients
in the database for a match. If no match exists, then all of the patients with the
same last name will be presented. If there is no match for the last name in full,
then any patients with a last name which has an identical string of letters
beginning with the first letter of the last name will be presented.
COLINIT
If no match is found by NOTECHEK, then the user is asked if a new set of
files should be created for the data which had been used for the search.
These are just a sample of the programmes that have been written during this
thesis. In total 117 programmes have been written, all of them by WFAM.
There has been no external programming advice.
* PROGRAM.: COLOPEN3.PRG
* Author..: Tony Miles
* Begun on October I, 1990
* Notice..: Copyright to University Of Edinburgh
* Notes...: Opens the files and the indexes for colon study
* Master Program
CLEAR












STORE SPACE(1) TO m_ans
STORE SPACE(1) TO mansw
STORE SPACE(1) TO m_ansn
* SET UP ALL OF THE INDEX FILES TO USE IN THE PROGRAM
USE COLONCA.DBF INDEX CA.NDX
USE COLONCAP.DBF INDEX CAP.NDX
USE COLONCAO.DBF INDEX CAO.NDX
USE COLONCAU.DBF INDEX CAU.NDX
USE COLONCAI.DBF INDEX CAI.NDX
USE COLONCAR.DBF INDEX CAR.NDX
USE COLONCAB.DBF INDEX CAB.NDX
USE COLONCAC.DBF INDEX CAC.NDX
CLOSE DATABASES
DO COLOPEN2.PRG













* Author...: Tony Miles
* Date : October 23, 1990
* Notice...: Copyright University of Edinburgh
* Notes....: Opens the screens for Colon Cancer Database
* called from COLOPEN.PRG
DO WHILE .T.
* Writes the opening screen
m_ans = 1 1
@ 2,32 SAY "WELCOME TO THE"
@3,26 SAY "COLORECTAL CANCER DATABASE"
@ 1,23 TO 4,54 DOUBLE
@ 6,34 SAY "DATA INPUT"
@ 7,34 TO 7,43
@ 9,22 SAY "WHICH INPUT SCREEN WOULD YOU LIKE?"
@ 12,23 SAY "A. INPUT A PATIENT INFORMATION"
@ 13,23 SAY "B. PRINT PATIENTS IN DATABASE"
@ 14,23 SAY "C. MARK A FILE FOR DELETION"
@ 15,23 SAY "D. LIST APPOINTMENT DATES"
@ 16,23 SAY "E. DATABASE UTILITIES"
@ 18,23 SAY "X. TO EXIT PROGRAM"
@ 11,16 TO 19,61 DOUBLE
* THIS IS THE END OF SCREEN CONSTRUCTION
choice = space(l) && Initiates the memory variable
@ 20,24 SAY "MAKE A CHOICE FROM THE LIST" GET choice PICTURE '!'
@ 19,22 TO 21,54
READ
* to find out if answer is in range of reply
DO WHILE .NOT. choice $ "ABCDEX"
choice = " "
@ 22, 0
@ 22,10 SAY "YOU MUST CHOOSE FROM THE LIST ABOVE" GET choice PICTT
READ
ENDDO
* Print choice and ask for verification
@ 22,0
@ 20,24 SAY "YOUR CHOICE IS " + choice
@ 23,0
answer = " "
@ 22,23 SAY " ENTER. OR N. TO RE-ENTER " GET answer PICTURE "!"
@ 21,22 TO 23,54
READ
IF answer = "N"
LOOP
END IF
answer = ' '
* NOW GOES ON TO THE DO CASE BELOW
* TO FIND OUT WHICH SUB PROGRAM TO DO
DO CASE
CASE choice = "A"
DO OPEN.PRG





CASE choice = "B"
DO COLLIST.PRG
CASE choice = "C"
DO ERASE.PRG
CASE choice = "D"
DO LISTFILE.PRG
CASE choice = "E"
DO UTILITY.PRG















Copyright to the University of Edinburgh
Program for the identifiiication of
patients
called from COLOPEN2.PRG
THIS IS THE KEY FILE IN THE DATABASE IT OPENS THE
FIELDS ON EACH NEW PATIENT AND WILL STOP DATA GETTING MIXED UP






@5,28 SAY "PATIENT IDENTIFICATION"
@ 4,25 TO 6,53 DOUBLE
@ 8,17 SAY "ACCURATE PATIENT IDENTIFICATION IS VITAL TO THE"
@ 9,17 SAY "RUNNING OF THIS PROGRAM"
@ 10,17 SAY "IF THE INFORMATION IS INACCURATE YOU WILL "
@ 11,17 SAY "LOSE YOUR DATA FOREVER"
@ 7,15 TO 12,65 DOUBLE
@ 14,20 SAY "LASTNAME"
@ 16,18 SAY "FIRST NAME"
@ 18,15 SAY "DATE OF BIRTH"
@ 13,13 TO 19,67 DOUBLE
m_ans = ' 1
@ 20,30 SAY "TO GO ON PRESS ANY KEY
@ 21,20 SAY "TO GET TO THE OPENING MENU PRESS X" ;
GET m_ans PICTURE '!'
@ 19,18 TO 22,62
READ
IF m_ans = 'X'
RETURN
END IF
mans = 1 '
* The next section initiates the public momory variables
* for the identification of the patients
PUBLIC m_last, m_first, m_dob, mednum, m__link, m_date
m_ednum = 0
m_last = SPACE(25)
@ 14,30 GET m last PICTURE "!!!!! I !!!!!! 1 !!!!!!!!!!!! "
READ
STORE LTRIM(TRIM(m_last)) TO m_last
m_first = SPACE (25)
@ 16,30 GET m first PICTURE "!!!!!!!!!!!!!!!!!!!!!!!!!"
READ
STORE LTRIM(TRIM(m_first)) TO m_first
m_dob = CTOD (' /' / 1)
@ 18,30 GET m dob
READ




m_ans = " "
@ 20,20 SAY' "IF CORRECT PRESS ENTER. "
@ 21,20 SAY "PRESS N TO RE-ENTER X TO EXIT" GET mans PICTURE "!"
@ 19,18 TO 22,62
READ
DO CASE
CASE m_ans = "N"
LOOP







IF m_goback && THIS SENDS YOU BACK TO PTID SCREEN
LOOP
ENDIF
* This ends the identification of the patients and the check to
* make sure that they are not already in the database
* The next section initiates a new set of screens for patients
* not already in the database
IF m_initgo
m_ans = ' 1









* Author...: Tony Miles
* Date ....: October 23, 1990
* Notice ..: Copyright University Of Edinburgh
* Notes....: Checks to see if a patient is already in the
* database
* Open the data base, index, and screen to use
mans = ' 1
CLEAR
DO WHILE .T.
* Find out if there is a match in the file
USE COLONCA.DBF INDEX CA.NDX
SEEK mlast
IF .NOT. FOUND() && IF THERE IS NO MATCH THEN EXITS THE PROGRAM




* This section lists all of the duplications in the database file
DO WHILE LTRIM(TRIM(LASTNAME)) = m_last .AND. .NOT. EOF()
IF TRIM(FIRSTNAME) = m_first .AND. DOB = m_dob
@1,10 SAY ' YOUR PATIENT IS ALREADY IN THE DATABASE'
m_ednum = RECNO()






@ 1,10 SAY ' THERE IS NO EXACT MATCH BUT HOW ABOUT..'
LIST WHILE TRIM(LASTNAME) = m_last ;
LASTNAME, FIRSTNAME, DOB
@22,5 SAY ' CHOOSE THE RECORD NUMBER OF THE FILE TO EDIT'
@ 23,5 SAY ' OR ZERO (0), TO EXIT.' GET m_ednum PICTURE '99999'
READ
CLEAR




@ 10,10 SAY ' YOU ARE GOING TO EDIT THE FILES FOR '
@ 11,10 SAY TRIM(LASTNAME) + ', ' + TRIM(FIRSTNAME) + ;







ENDDO && THIS ENDS THE READ OUT OF THE PATIENTS DUPLICATED






@ 13,10 SAY ' PRESS ANY KEY TO GO ON, X, TO EXIT' GET m_ans
READ











NOTE : INITIATES THE SCREENS FOR THE FILES
CALLED FROM OPEN.PRG
The next section initiates a new set of screens for patients
not already in the database
Say a warning message to prevent initiation of unwanted screens
@ 5,31 SAY 1 WARNING1
@ 4,29 TO 6,39 DOUBLE
@ 13,10 SAY ' YOU ARE ABOUT TO INITIATE A NEW SET OF SCREENS'
@ 14,10 SAY ' THE SCREENS WILL BE FOR *
Say the name of the patient who's screens you are about to make
@ 16,10 SAY m_last+', '+m_first+'. '+DTOC(m_dob)
@ 15,8 TO 17,65 DOUBLE
@ 18,10 SAY ' IT IS IMPOSSIBLE REMOVE THIS INFORMATION'
@ 19,10 SAY ' IF YOU ARE NOT SURE GET OUT BY PRESSING X,'
@ 20,10 SAY ' IF YOU ARE SURE YOU WANT TO GO ON PRESS Y,'
m_ans = " "
@ 22,40 GET m ans PICTURE "!"
READ
DO WHILE .NOT. m_ans $ 'XY'
@ 22,0
m_ans = " "









this section initiates the actual files for the database
USE COLONCA.DBF INDEX CA.NDX
GO BOTTOM




REPLACE LASTNAME WITH m_last
REPLACE FIRSTNAME WITH m_first
REPLACE DOB WITH m_dob
REPLACE LINK WITH m_link
m_ednum = RECNO()
USE COLONCAP.DBF INDEX CAP.NDX
GO BOTTOM




REPLACE LASTNAME WITH m_last
REPLACE FIRSTNAME WITH m first
REPLACE DOB WITH m dob
REPLACE LINK WITH m_link
USE COLONCAO.DBF INDEX CAO.NDX
GO BOTTOM




REPLACE LASTNAME WITH m_last
REPLACE FIRSTNAME WITH m_first
REPLACE DOB WITH m_dob
REPLACE LINK WITH m link
USE COLONCAU.DBF INDEX CAU.NDX
GO BOTTOM




REPLACE LASTNAME WITH m_last
REPLACE FIRSTNAME WITH m__first
REPLACE DOB WITH m_dob
REPLACE LINK WITH m_link
USE COLONCAI.DBF INDEX CAI.NDX
GO BOTTOM




REPLACE LASTNAME WITH m_last
REPLACE FIRSTNAME WITH m_first
REPLACE DOB WITH m_dob
REPLACE LINK WITH m_link
USE COLONCAR.DBF INDEX CAR.NDX
GO BOTTOM




REPLACE LASTNAME WITH m_last
REPLACE FIRSTNAME WITH m_first
REPLACE DOB WITH m_dob
REPLACE LINK WITH m_link
USE COLONCAB.DBF INDEX CAB.NDX
GO BOTTOM




REPLACE LASTNAME WITH m last
REPLACE FIRSTNAME WITH m_first
REPLACE DOB WITH mdob
REPLACE LINK WITH m_link
USE COLONCAC.DBF INDEX CAC.NDX
GO BOTTOM




REPLACE LASTNAME WITH mlast
REPLACE FIRSTNAME WITH mfirst
REPLACE DOB WITH m_dob




** THIS IS A PROGRAM TO DO CHISQ


















INPUT "ENTER A" TO m_A
INPUT "ENTER B" TO m_B
INPUT "ENTER C" TO m_C


















Structure for database: C:survival.dbf
Number of data records: 149
Date of last update : 10/11/94
Field Field Name Type Width
1 LINK Character 40
2 DATERX Date 8
3 AGEDIG Numeric 3
4 WTLOSS Logical 1
5 CEA Numeric 4
6 SURGGRADE Character 4
7 CURE Logical 1
8 DATEOFDEAT Date 8
9 DEAD Logical 1
10 METFINAL Logical 1
11 IOEYN Logical 1
12 CODE Character 3
** Total ** 76
Command Line ;<C :> .'SURVIVAL :Rec: EOF/149 :1ns
Enter a dBASE III PLUS command.
Record# daterx agedig cea surggrade dateofdeat metfina1 code wt1os:
1 10/10/90 43 30 CONS / / .F. CI .T.
2 04/22/90 74 738 SR 05/02/90 .T. C2 .T.
3 02/08/90 65 40 SR / / .T. B .F.
4 10/22/90 57 30 CONS / / .F. C2 .F.
5 11/17/90 62 30 SR / / .F. CI • F.
6 10/23/90 61 1040 CONS 01/31/93 .T. C .F.
7 04/24/90 76 339 CONS 05/03/90 .T. .T .
8 06/04/90 63 78 CONS 05/09/91 .F. B .F.
9 12/24/90 65 0 SR 12/27/90 .F. C .F.
10 10/11/90 79 545 SR 02/18/94 .F. B • T.
11 05/10/90 62 97 CONS / / .T. A .F.
12 09/26/90 69 102 CONS / / .F. B .T.
13 08/21/90 77 30 CONS / / .F. B .F.
14 07/31/90 76 93 CONS 10/29/93 .F. B • F.
15 11/12/90 80 66 CONS / / .F. B .T.
16 09/28/90 88 101 CONS / / .T. B .T.
17 01/01/91 78 30 CONS 04/04/92 .T. CI .F.
18 05/09/90 61 56 PROF / / .F. A .T.
19 07/16/90 75 30 CONS / / .F. CI .F.
20 10/24/90 50 39 CONS / / .F. B .F.
21 10/29/90 70 115 CONS / / .F. C .T.
22 11/05/90 78 55 SR / / .F. B .F.
23 08/03/90 46 30 SR / / .F. CI .F.
24 09/12/90 56 92 CONS 12/28/91 .T. CI .T.
25 03/29/90 82 30 CONS 04/25/90 • T. B .F.
26 05/18/90 75 49 CONS / / .F. B .F.
27 11/27/90 61 30 SR / / .F. B .F .
28 10/03/90 66 30 CONS 08/29/92 • F. C .F.
29 10/04/90 67 194 CONS 06/13/92 .F. CI .T.
30 11/27/90 80 30 CONS / / .F. B .F.
31 11/29/90 61 787 CONS 10/28/92 .F. CI .F.
32 08/23/90 70 30 CONS / / .F. B .T.
33 10/24/90 83 30 REG / / .F. B • F.
34 03/22/90 76 131 CONS 01/20/92 .F. CI .F.
35 12/11/90 80 30 SR / / .F. CI • F.
36 07/19/90 74 306 CONS 07/25/92 .F. CI .F.
37 08/02/90 55 30 CONS / / .T. C2 .T.
38 09/05/90 55 30 CONS / / .F. .F.
39 11/28/90 71 51 CONS / / .F. A .F.
40 09/05/90 76 45 CONS / / .F. .F.
41 08/27/90 83 30 CONS / / .F. • F.
42 07/30/90 76 41 SR / / .F. • T.
43 08/20/90 81 0 REG 09/06/90 .F. .F.
44 05/16/90 86 67 CONS / / .F. A .F.
45 10/26/90 93 356 SR 10/17/92 .F. C2 .F.
46 05/30/90 67 425 CONS 10/10/90 .F. .T.
47 10/10/90 66 58 SR / / .F. B .F.
48 11/28/90 79 30 CONS / / • F. .F.
49 05/16/90 76 30 CONS 06/20/90 .F. .T.
50 07/16/90 84 30 CONS / / .F. .T.
51 07/04/90 66 1000 CONS 09/24/90 .T. .T.
52 04/05/90 82 374 CONS 04/30/91 .T. C2 .T.
53 08/08/90 75 1280 CONS 03/27/94 .F. C2 .T.
54 10/17/85 60 84 CONS / / .T. B .T.
55 05/15/90 66 913 REG 10/04/91 .F. B .F.
56 09/05/90 86 46 CONS / / .F. B .F.
57 11/26/90 77 149 REG 12/30/90 .F. B .T.
58 08/22/90 53 4740 SR / / .F. .T.
59 03/15/90 69 340 SR 05/01/91 .F. B .T.
60 08/02/90 78 194 SR 11/21/91 .T. A .T.
61 12/19/90 78 32 SR 04/06/91 .F. CI .T
62 12/04/90 63 117 SR 03/15/93 .F. CI .T
63 12/19/90 80 119 CONS / / .F. CI .F
64 01/10/90 77 504 CONS 06/05/91 .F. CI .F
65 11/16/90 59 919 SR / / .F. B .T
66 12/05/90 83 35 SR 02/24/93 .F. CI .F
67 01/09/91 67 77 CONS / / .F. • T
68 01/29/91 66 44 CONS 12/06/92 .F. CI .F
69 02/19/91 83 44 CONS / / • F. A .F
70 01/29/91 72 159 SR 07/01/93 .F. CI .T
71 02/13/91 69 86 CONS /' / .F. .T
72 02/14/91 78 36 CONS / . '/ .F. CI .F
73 02/14/91 60 53 CONS / / .F. B .F
74 02/18/91 53 69 SR / / .F. B .F
75 01/14/91 81 2000 SR 06/01/91 .T. .F
76 01/28/91 69 105 SR 07/19/93 .F. CI .F
77 10/22/90 74 30 CONS / / .F. B .F
78 01/14/91 62 500 CONS / / .T. CI .T
79 02/14/91 78 32 CONS 01/29/92 .F. B .F
80 02/21/91 72 36 CONS 05/01/91 .F. B .T
81 02/21/91 69 65 CONS / / .F. CI .T
82 04/09/90 76 30 CONS / / .F. B .T
83 02/04/91 55 167 REG 04/18/93 • T. CI .F
84 02/25/91 83 73 CONS / / .F. A .T
85 07/09/90 70 500 CONS 01/21/91 .T. C2 .T
86 06/28/90 61 1600 CONS 10/17/92 .T. .F
87 03/12/91 81 93 CONS 08/19/91 .F. CI .F
88 04/10/91 86 40 SR / / .F. .T
89 04/16/91 67 30 CONS 08/13/91 .T. CI .F
90 03/04/91 68 85 PROF 10/31/91 .F. CI .F
91 02/27/91 76 30 SR 05/28/91 .F. B .T
92 04/22/91 54 33 SR 10/25/91 .T. .T
93 05/22/91 51 60 SR / / .F. B .F
94 12/13/90 62 49 CONS / / .F. CI .F
95 04/18/91 77 34 CONS / / • T. CI .F
96 11/21/90 62 39 CONS / / .F. B .F
97 06/17/91 63 96 CONS / / .F. B • T
98 01/18/91 79 65 SR 07/06/91 .F. .F
99 05/02/91 71 30 CONS / / • F. B .T
100 06/27/91 74 68 SR / / • F. B • T
101 05/27/91 71 172 CONS / / .F. CI • F
102 05/04/91 62 30 SR 08/23/93 .T. CI .T
103 06/27/91 86 213 SR 10/06/92 .F. B .T
104 05/02/91 43 49 CONS 11/30/93 .T. CI .F
105 10/21/91 59 30 SR 02/04/94 .F. C2 .T
106 10/01/91 78 91 CONS / / .F. B .F
107 10/10/91 68 645 CONS 07/09/92 .T. CI .T
108 09/10/91 76 47 CONS / / .F. A .T
109 06/26/91 76 1200 CONS 11/01/93 .T. C2 .F
110 10/21/91 82 74 CONS / / .F. .F
111 05/02/91 71 205 CONS 02/10/93 .F. C2 .F
112 11/04/91 77 62 SR 01/28/94 • T. B • F
113 03/07/91 71 55 CONS / / .F. .F
114 09/04/91 75 30 SR 10/24/92 .F. CI .T
115 06/27/90 71 70 REG / / • F. .T
116 02/12/91 68 389 SR / / .F. B .T
117 08/13/91 76 248 SR 01/27/92 .T. CI .T
118 07/18/91 64 30 CONS / / • F. .F
119 09/09/91 72 45 SR / / .F. B .T
120 08/05/91 85 88 SR / / .F. B • F
121 05/01/91 68 48 SR / / .F. CI . T
122 10/11/91 73 35 CONS / / .F. A .F
123 03/14/91 52 249 CONS 05/12/93 • T. .F
124 04/17/91 70 2000 CONS 12/22/91 .T. D .T
125 02/12/91 74 34 CONS / / .F. B .F
126 10/22/90 66 0 CONS / / .T. .F
127 02/18/91 65 30 CONS / / .F. CI .F
128 04/22/91 57 36 SR 10/09/91 .T. C .F
129 10/29/91 84 90 CONS 07/22/92 .T. B .T
130 10/10/91 78 31 SR / / .T. A .F
131 10/30/91 74 0 SR / / • F. .F
132 09/18/91 46 30 CONS / / .F. C2 .T
133 12/04/91 84 55 CONS /■ / .F. C .F
134 12/04/91 44 54 SR / 7 .F. B .T
135 12/09/91 58 30 REG / / .F. CI .F
136 12/12/91 58 0 REG 12/28/93 .T. B .T
137 12/11/91 84 50 CONS / / .F. CI .F
138 11/06/91 58 38 CONS 05/14/92 • T. C2 .F
139 01/09/92 65 43 CONS / / .F. B .F
140 01/10/92 63 1090 REG 02/25/92 .T. C .F
141 02/05/92 78 0 REG 02/12/92 .T. .T
142 02/06/92 69 55 CONS / / .F. B .T
143 01/29/92 37 0 CONS / / .T. C .T
144 02/25/92 76 1600 CONS / / .F. B .T
145 11/11/91 73 0 CONS / / .T. B .F
146 02/20/92 68 30 CONS / / .F. C .T
147 03/13/92 59 37 SR / / .T. B .T
148 03/05/92 43 74 REG / / .T. B • F
149 11/18/91 72 30 SR 01/09/93 .F. .T
Structure for database: C:colonca.dbf
Number of data records: 155
Date of last update : 07/09/94
Field Field Name Type Width
1 CIS Character 1
2 LINK Character 40
3 OTHERFIND Memo 10
4 MEMFIELD Logical 1
5 MALAISE Logical 1
6 CONSTIPAT Logical 1
7 OTHER Memo 10
8 TELNO Character 12
9 LASTNAME Character 25
10 FIRSTNAME Character 25
11 ADDRESS Character 60
12 PCODE Character 10
13 DOB Date 8
14 SEX Character 2
15 CONS Character 25
16 WEIGHT Numeric 3
17 HEIGHT Numeric 4
18 AGEDIG Numeric 3
19 ETHNIC Character 3
20 GPNAME Character 25
21 GPADDRESS Character 60
22 GPCODE Character 10
23 OCC Character 20
24 DATESS Date 8
25 DATEGP Date 8
26 DATEHC Date 8
27 DATED Date 8
28 DATERX Date 8
29 GICA Logical 1
30 GICAD Date 8
31 GICAF Character 10
32 GICAFD Numeric 3
33 FAP Logical 1
34 FAPD Date 8
35 FAPF Character 10
36 FAPFD Numeric 3
37 LBA Logical 1
38 LBAD Date 8
39 LBAF Character 10
40 LBAFD Numeric 3
41 UC Logical 1
42 UCD Date 8
43 UCF Character 10
44 UCFD Numeric 3
45 CD Logical 1
46 CDD Date 8
47 CDF Character 10
48 CDFD Numeric 3
49 OC Logical 1
50 OCD Date 8
51 OCSITE Character 20
52 OCF Character 10
53 OCFD Numeric 3
54 OCFSITE Character 20
55 MI Logical 1
56 MID Date 8
57 MIF Character 10
58 MIFD Date 8
59 CHOLE . Logical 1
60 CHOLEDATE Date 8
61 ULCERSURG Logical 1
62 ULCERSURGD Date 8
63 GUTSURG Logical 1
64 GUTSURGD Date 8
65 DURG1 Character 40
66 DRUG 2 Character 40
67 DRUG 3 Character 40
68 DRUG4 Character 40
69 DRUG 5 Character 40
70 DRUG6 Character 40
71 DURG7 Character 40
72 DRUG 8 Character 40






























103 SIGOUT Numeric 3
** Total ** 985
Structure for database: C:co1oncab.dbf
Number of data records: 155
Date of last update : 03/20/94
Field Field Name Type Width Dec
1 CIS Character 1
2 LINK Character 40
3 LASTNAME Character 25
4 FIRSTNAME Character 25
5 DOB Date 8
6 CXR Character 1
7 BAENEMA Character 2
8 SIGRF Character 1
9 SIGPATH Character 2
10 COLONOSC Character 2
11 BX Character 2
12 BXPATH Character 2
13 FNACL Character 2
14 FNACT Character 2
15 WBB Numeric 5 2
16 RBC Numeric 5 2
17 HB Numeric 5 2
18 HCT Numeric 5 2
19 MCV Numeric 6 2
20 MCH Numeric 4 1
21 MCHC Numeric 4 1
22 PLATS Numeric 4
23 GRAN Numeric 5 2
24 LYMPH Numeric 5 2
25 MONO Numeric 5 2
26 EOS IN Numeric 5 2
27 BASO Numeric 5 2
28 ESR Numeric 3
29 NA Numeric 4
30 K Numeric 5 2
31 CL Numeric 4
32 C02 Numeric 3
33 U Numeric 5 2
34 LD Numeric 4
35 ALT Numeric 4
36 ALKPHOS Numeric 4
37 BIL Numeric 4
38 GGT Numeric 4
39 TOTPROT Numeric 3
40 ALB Numeric 3
41 CEA Numeric 4
42 CA 19 9 Numeric 3
43 TNF Numeric 4
44 FERITIN Numeric 4
** Total ** 244
Structure for database: C:co1oncao.dbf
Number of data' records: 155
Date of last update : 08/23/94
Field Field Name Type Width
1 CIS Character 1
2 LINK Character 40
3 OP 3 Character 25
4 OP2 Character 25
5 OP1 Character 25
6 PRIMARY Character 3
7 WOUNDINF Character 2
e CONSTUCT Character 2
9 DOUGHNUT Logical 1
10 GUN Character 3
n OTHERINV Memo 10
12 LOCALINV3 Character 2
13 LOCALINV2 Character 2
14 ASSTGRADE Character 4
15 SURGGRADE Character 4
16 LASTNAME Character 25
17 FIRSTNAME Character 25
18 DOB Date 8
19 CA1SITE Character 2
20 CA2SITE Character 2
21 OPCODE1 Character 7
22 OPCODE2 Character 7
23 OPCODE3 Character 7
24 COLOSTOMY Logical 1
25 EMERG Character 2
26 SURG Character 25
27 ASSIST Character 25
28 METS Character 1
29 METIS Character 3
30 MET2S Character 3
31 MET3S Character 3
32 MET4S Character 3
33 MET5S Character 3
34 MET6S Character 3
35 MET7S Character 3
36 MET8S Character 3
37 MET9S Character 3
38 MET10S Character 3
39 MET ID Numeric 3
40 MET2D Numeric 3
41 MET3D Numeric 3
42 MET4D Numeric 3
43 MET5D Numeric 3
44 MET6D Numeric 3
45 MET7D Numeric 3
46 MET8D Numeric 3
47 MET9D Numeric 3
48 MET10D Numeric 3
49 MET IB Character 1
50 MET2B Character 1
51 MET3B Character 1
52 MET4B Character 1
53 MET5B Character 1
54 MET6B Character 1
55 MET7B Character 1
56 MET8B Character 1
57 MET9B Character 1
58 MET10B Character 1
59 MET1P Character 1
60 MET2P Character 1
61 MET3P Character 1
62 MET4P Character 1
63 MET5P Character 1
64 MET6P Character 1
65 MET7P Character 1
66 MET8P Character 1
67 MET9P Character 1
68 MET10P Character 1
69 LOCALINV Character
70 MOBILITY Character 1
71 CURE Logical 1
72 BXOTHER Character 1
73 AMASTAMO Character 1
74 LI Character 1
75 L2 Character 1
76 STAPLED Character 10
77 DBCLOSE Character 1
78 SIGINF Logical 1
79 COLOSHIELD Logical 1
80 BOWELLEV Logical 1
81 TETRACYCLI Logical 1
82 DRAINS Character 2
83 BLOODTX Character 2
84 ANASLEAK Character 2
85 CHESTINF Character 2
86 ABDOCOLLEC Character 2
87 WOUNDHAEM Character 2
88 WOUNDBURST Character 2
89 INTBLEED Character 2
90 STOMA Character 2
91 HOSPDAYS Numeric 3
92 ABXDAYS Numeric 3
93 DEATH Logical 1
94 DEATHDAYS Numeric 3
95 CAUSE Character 25
96 CERT1 Character 25
97 CERT2 Character 25
98 CERT3 Character 25
99 ICD CODE Character 10
Total ** 528
Structure for database: C:co1oncai.dbf
Number of data records: 155
Date of last update : 10/11/94
Field Field Name Type Width
1 SCANNUM Character 1
2 CIS Character 1
3 LINK Character 40
4 HAEMANUM Numeric 2
5 CYSTNUM Numeric 2
6 EXCLUDED Character 2
7 LASTNAME Character 25
8 FIRSTNAME Character 25
9 DOB Date 8
10 CTRUNNUM Numeric 12
11 METS Character 1
12 METIS Character 3
13 MET2S Character 3
14 MET3S Character 3
15 MET4S Character 3
16 MET5S Character 3
17 MET6S Character 3
18 MRT7S Character 3
19 MET8S Character 3
20 MET9S Character 3
21 MET1OS Character 3
22 MET ID Numeric 4
23 MTS2D Numeric 4
24 MET 3D Numeric 4
25 MET4D Numeric 4
26 MET5D Numeric 4
27 MET6D Numeric 4
28 MET7D Numeric 4
29 MET8D Numeric 4
30 MET9D Numeric 4
31 MET10D Numeric 4
32 MET IV Numeric 4
33 MET2V Numeric 4
34 MET3V Numeric 4
35 MET4V Numeric 4
36 MET5V Numeric 4
37 MET6V Numeric 4
38 MET7V Numeric 4
39 MET8V Numeric 4
40 MET9V Numeric 4
41 MET10V Numeric 4
42 TOTVOL Numeric 4
43 TOTLIVVOL Numeric 4
44 PERCENTCA Numeric 3
45 RTEMP Numeric 4
46 RPULSE Numeric 3
47 RBP Character 8
48 HTEMP Numeric 4
49 HPULSE Numeric 3
50 HBP Character 8
51 LOWTEMP Numeric 4
52 LOWPULSE Numeric 3
53 LOWBP Character 8
54 RIGORS Logical 1
55 HEADACHE Logical 1
56 METALTASTE Logical 1
57 ANOEDEMA Logical 1
Dec
58 OTHERREACT Memo 10
























START OF TREATMENT /OPERATION
PREVIOUS MEDICAL HISTORY
GI CANCER Y N_ NK_
FAP Y N NK_
LARGE BOWEL ADENOMA Y__ N_ NK_
ULCERATIVE COLITIS Y_ N_ NK_
CROHN'S DISEASE Y_ N_ NK_
OTHER CANCER Y N_ NK_
ni Y N NK_
OTHER
CHOLECYSTECTOMY Y_ N__ NK_
PEPTIC ULCER SURGERY Y__ N___ NK_


























































































normal / susp / pos
normal / susp / pos / polyps / sync ca / fail
normal / pos / polyps / sync ca / fail ./ n.d.
normal / pos / polyps / sync ca / fail /n.d.
BIOPSY
r'sig / f'sig / colonos' / fnac
normal / susp / cancer / polyp
neg / susp / pos / other / nd





































SCANNER ALOKA OTHER .
SURGEON GRADE
ANATOMICAL LANDMARKS CLEAR? CONFIDENCE HIGH ■ LOW
FINDINGS
CYSTS HAEMANGIOMA
DESCRIPTION OF METASTASES RANKED BY SIZE















SITE IS BY SEGMENT NUMBER







CEACUM / ASC COLON / HEP FLEX / TRANS
SPL FLEX / DESC / SIGMOID
ABOVE / STRADDLING / BELOW REFLECTION
CEACUM / ASC COLON / HEP FLEX / TRANS
SPL FLEX / DESC / SIGMOID




























LOCAL INVASION ABDO MUSCLE / PELVIC WALL MUSCLE / BLADDER
URETER / OTHER BOWEL / OVARY / UTERUS





MOBILE / TETHERED / FIXED
YES / NO
NODES / SEEDLINGS / TUMOUR BED
OPERATIVE TECHNIQUE
ANASTOMOSIS ' NONE / STAPLED / SUTURED(ONE OR TWO LAYER)
LAYER ONE ABSORBABLE / NONABSORBABLE
LAYER TWO ABSORBABLE / NONABSORBABLE
STAPLED EEA / PROXIMATE(SIZE cm) / GIA / PLC
DOUGHNUT OK YES/NO
END/END END/SIDE SIDE/END SIDE/SIDE
DISTAL BOWEL CLOSURE PURSE STRING / STAPLED
SIGMOIDOSCOPE INFLATION CHECK YES / NO
COLOSHIELD YES / NO
ON TABLE BOWEL LAVAGE YES / NO
TETRACYCLINE LAVAGE YES / NO
DRAINS NONE / NONE SUCTION / SUCTION / SUCTION IRRIGATION
BLOOD TRANSFUSION NONE / PRE OP / PER OP / POST OP
POST OPERATION COMPLICATIONS
ANASTAMOTIC LEAK NONE / SUSP / PROVEN / RE OPERATION
CHEST INFECTION NONE / SUSP / PROVEN / TREATED
INTRA ABDOMINAL COLLECTION NONE / SUSP / PROVEN / DRAINED
WOUND HAEMATOMA NONE / OBSERVED / TREATED
WOUND INFECTION NONE / OBSERVED / ABX / DRAINED
WOUND DEHISCENCE NONE / SUPERFICIAL / DEEP (RE OP)
INTRAPERITONEAL BLEED NONE / MINOR / MAJOR / RE OP
STOMA RETRACTION / NECROSIS / REVISION
DAYS IN HOSPITAL DAYS
DAYS OF ANTIBIOTICS DAYS
■ DEATH YES / NO
CAUSE INFECTION / MI / CVA / PE / HAEMORRHAGE/OTHER






PATHOLOGIST • PATH #
FIXED / FRESH
LENGTH OF SPECIMEN cm LENGTH OF TUMOUR cm
CIRCUMFERENCE cm WIDTH OF TUMOUR cm
PROXIMAL CLEARANCE cm DISTAL CLEARANCE cm
APPEARANCE ULCERATING / PROTUBERANT / DIFFUSELY INFILTRATING
RELATION TO PERITONEAL REFLECTION ABOVE / STRADDLING / BELOW
LOCAL SPREAD
DYSPLASIA ONLY / SUBMUCOSA / MUSC PROPRIA / BEYOND MUSC PROP
THROUGH PERITONEUM / INTO OTHER ORGANS
DEPTH BEYOND MUSC PROP mm BX OF TUMOUR BED POS / NEG / N. A.
MINIMUM CUMFERENTIAL MARGIN mm
CONFIRMED HISTOLOGICALLY YES / NO LOCAL EXCISION YES / NO / ?
LYMPHATIC SPREAD
NODES EXAMINED # NODES POSITIVE #
APICAL NODE POS / NEG / N.A.
INVASION OF LYMPHATIC SPACES YES / NO
INVASION OF PERINURAL SPACES YES / NO
EXTRAMURAL DEPOSITS NOT IN NODES YES / NO
INVASION OF EXTRAMURAL VEINS YES / NO
LIVER METS CONFIRMED YES / NO
PERITONEAL METS CONFIRMED YES / NO
PARA AORTIC NODES CONFIRMED YES / NO
PATH OF TUMOUR
ADENO CA / MUCINIOUS CA / SIGNET RING CA / OTHER_
DIFFERENTIATION BY WORST AREA POOR / OTHER
DIFFRERNTIATION BY PREDOMINANT AREA POOR / OTHER
INVASIVE MARGIN EXPANDING / INFILTRATING
LYMPHOCYTES AT MARGIN CONSPICUOUS YES / NO
ADENOMAS YES / NO # SYNCHRONOUS CA YES / NO
ULCERATIVE COLITIS YES / NO F.A.P. YES / NO
CURATIVE / NONCURATIVE LOCAL SPREAD / NONCURATIVE DISTANT SPREAD
CODE A / B / CI / C2
RADIOLOGY REPORT
RECTAL TUMOURS
HEIGHT OF LOWER BORDER FROM SPHINCTER cm
CIRCUMFERENTIAL INVOLVEMENT ANT / RIGHT / POST / LEFT QUADRANTS
LENGTH cm
RADIAL EXTENT OF TUMOUR
CONFINED TO BOWEL WALL
THROUGH WALL INTO PERI-RECTAL SPACE
THROUGH PERI-RECTAL FASCIA
COLONIC TUMOURS
SITE CEACUM / ASCENDING / TRANSVERSE / DESCENDING / SIGMOID
RADIAL EXTENT OF TUMOUR
CONFINED TO BOWEL WALL
THROUGH BOWEL WALL
DISTAL SPREAD
SACRUM / COCCYX / BLADDER / PROSTATE / SEMINAL VESICALS / UTERUS













C.T. UNENHANCED AND WITH WATER SOLUBLE CONTRAST
METASTATIC DEPOSITS YES / NO
NUMBER SEGMENT INVOLVED DIAMETER mm



























IF MORE THAN 10 METS SPECIFY SITE ( BY SEGMENT ) OF LARGEST DEFINABLE MASS OR
GROUP OF METS.
TOTAL VOLUME OF METASTATIC DEPOSITS
TOTAL VOLUME OF NORMAL LIVER









RIGORS YES / NO














CHEST XRAY NORMAL YES / NO
METASTASES YES / NO
NUMBER
MAX DIAMETER OF LARGEST MET cm
MEDIASTINUM NORMAL YES / NO
C.T.
MEDIASTINAL NODES YES / NO
SIZE OF LARGEST NODE IN mm <5 / 5-10 / 10-15 / >15
PULMONARY METASTASES YES / NO
NUMBER




NEGATIVE / MUCOSAL / MUSCLE / FULL THICKNESS / BEYOND
QUADRANT ANT / RIGHT / POST / LEFT
ABDOMINAL ULTRASOUND
INVOLVEMENT OF OTHER ABDOMINAL STRUCTURES YES / NO'
i
IF YES BLADDER / PROSTATE / SEMINAL VESICLES / VAGINA / UTERUS / PELVIC SIDE
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